{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2023/07/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia ISSN: 0214-3429 Volumen 36 N\u00famero 4 Agosto 2023 P\u00e1ginas: 334-443SPANISH JOURNAL OF CHEMOTHERAPYQuimioterapiaREVISTA ESPA\u00d1OLA DE Revista Espa\u00f1ola de Quimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas Fundada en 1988 por la Sociedad Espa\u00f1ola de Quimioterapia Indexada en Science Citation Index Expanded (SCI), Index Medicus (MEDLINE), Excerpta Medica/EMBASE, \u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1fico en Ciencias de la Salud (IBECS) Secretar\u00eda t\u00e9cnica Dpto. de Microbiolog\u00eda Facultad de Medicina Avda. Complutense, s/n 28040 Madrid revista@seq.es Disponible en Internet: www.seq.esPublicidad y Suscripciones Sociedad Espa\u00f1ola de Quimioterapia Dpto. de Microbiolog\u00eda Facultad de Medicina Avda. Complutense, s/n 28040 Madrid Atenci\u00f3n al cliente Tel\u00e9fono 91 394 15 12 Correo electr\u00f3nico info@seq.es Consulte nuestra p\u00e1gina web www.seq.es \u00a9 Copyright 2023 Sociedad Espa\u00f1ola de Quimioterapia Reservados todos los derechos. Queda rigurosamente prohibida, sin la autorizaci\u00f3n escrita del editor, la reproducci\u00f3n parcial o total de esta publicaci\u00f3n por cualquier medio o procedimiento, comprendidos la reprograf\u00eda y el tratamiento inform\u00e1tico, y la distribuci\u00f3n de ejemplares mediante alquiler o pr\u00e9stamo p\u00fablicos, bajo las sanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia Publicaci\u00f3n que cumple los requisitos de soporte v\u00e1lido ISSN 0214-3429 e-ISSN 1988-9518 Dep\u00f3sito Legal M-32320-2012 Maquetaci\u00f3n Vic+DreamStudio Impresi\u00f3n Espa\u00f1a Esta publicaci\u00f3n se imprime en papel no \u00e1cido. This publication is printed in acid free paper. LOPD Informamos a los lectores que, seg\u00fan lo previsto en el Reglamento General de Protecci\u00f3n de Datos (RGPD) 2016/679 del Parlamento Europeo, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio) Si desea realizar cualquier rectificaci\u00f3n o cancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por e-mail a la Sociedad Espa\u00f1ola de Quimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE Director J. Barber\u00e1n L\u00f3pez Comit\u00e9 Editorial F. \u00c1lvarez Lerma (Barcelona) V. Asensi (Oviedo) E. Bouza (Madrid) R. Cant\u00f3n (Madrid) X. Guirao (Barcelona) J. Gonz\u00e1lez del Castillo (Madrid) S. Grau (Barcelona) E. Maseda (Madrid) Consejo Editorial L. Aguilar (Madrid) J. I. Al\u00f3s (Madrid) J. R. Azanza (Pamplona) J. Arag\u00f3n (Las Palmas de Gran Canaria) A. Artero (Valencia) G. Barbeito (Santiago de Compostela) J. M. Barbero (Madrid) J. Campos (Madrid) F.J. Candel (Madrid) E. Cant\u00f3n (Valencia) J. A. Capdevila Morell (Barcelona) M. Casal (C\u00f3rdoba) J. Castillo (Zaragoza) F. Cobo (Granada) J. Cobo Reinoso (Madrid) N. Cobos (Madrid) J. L. del Pozo (Navarra) R. De la C\u00e1mara (Madrid) C. De la Calle (Barcelona) M. Dominguez-Gil (Valladolid) J. Eiros (Valladolid) P. Escribano (Madrid) A. Estella (C\u00e1diz) M. C. Fari\u00f1as \u00c1lvarez (Santander)J. Fort\u00fan (Madrid) J. J. Gamazo (Vizcaya) E. Garc\u00eda S\u00e1nchez (Salamanca) I. Garc\u00eda Garc\u00eda (Salamanca) J. E. Garc\u00eda S\u00e1nchez (Salamanca) E. Garc\u00eda V\u00e1zquez (Murcia) J. G\u00f3mez G\u00f3mez (Murcia) M. L. G\u00f3mez-Lus (Madrid) J. Gonz\u00e1lez del Castillo (Madrid) F. Gonz\u00e1lez Romo (Madrid) J. J. Granizo (Madrid) J.M. Guardiola (Barcelona) J. Guinea (Madrid) J. Guti\u00e9rrez (Granada) J. B. Guti\u00e9rrez (C\u00f3rdoba) B. Isidoro (Madrid) P. Llinares (La Coru\u00f1a) J. E. Losa Garcia (Madrid) J. R. Maestre Vera (Madrid) L. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba) R. Men\u00e9ndez (Valencia) P. Merino (Madrid)) P. Mu\u00f1oz (Madrid) J. L. Mu\u00f1oz Bellido (Salamanca) V. Navarro (Alicante)M. Ortega (Barcelona) J. Oteo (Madrid) J. A. Oteo (Logro\u00f1o) E. Palencia Herrej\u00f3n (Madrid) A. Pascual Hern\u00e1ndez (Sevilla) J. Pasquau (Sevilla) J. Pem\u00e1n (Valencia) J. L P\u00e9rez-Arellano (Las Palmas) B. P\u00e9rez-Gorricho (Madrid) A. Ramos (Madrid) J. Reina (Palma de Mallorca) M. A. Ripoll (\u00c1vila) I. Rodriguez-Avial (Madrid) M. Ruiz (Alicante) M. Sabri\u00e1 (Barcelona) B. S\u00e1nchez Artola (Madrid) M. Segovia (Murcia) R. Serrano (Madrid) D. Sevillano (Madrid) A. Su\u00e1rez (Madrid) A. Tenorio (Huelva) A. Torres (Murcia) C. Vallejo (Oviedo) J. Vila (Barcelona) J. Yuste (Madrid)J. Mensa (Barcelona) J. M. Ramos (Alicante) J. Reina (Palma de Mallorca) M. Salavert (Valencia) A. Soriano (Barcelona) A. Torres (Barcelona) C. Fari\u00f1as(Santander)Secretario de Redacci\u00f3n Luis Alou CerveraSumario Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n 334 de 65 o m\u00e1s a\u00f1os de edad Mar\u00eda Pilar Arrazola Mart\u00ednez, Jos\u00e9 Mar\u00eda Eiros Bouza, Pere Plans Rubi\u00f3, Joan Puig-Barber\u00e0, Jes\u00fas Ruiz Arag\u00f3n, \u00c1lvaro Torres Lana Control de la infecci\u00f3n en residencias de ancianos: Documento de reflexi\u00f3n 346 sobre la situaci\u00f3n en Espa\u00f1a Emilio Bouza, Jos\u00e9 Augusto Garc\u00eda Navarro, Sergio Alonso, Juan Carlos Duran Alonso, Carina Escobar, Benito J. Fontecha G\u00f3mez , Mar\u00eda Isabel Galv\u00e1 Borr\u00e1s, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Francisco Javier G\u00f3mez Pav\u00f3n, Diego Gracia, Jos\u00e9 Guti\u00e9rrez Rodr\u00edguez, Martha Kestler, Fernando Mart\u00ednez Cuervo, Francisco Javier Mart\u00edn S\u00e1nchez, Carlos Melero, Rosario Men\u00e9ndez Villanueva, Patricia Mu\u00f1oz, Esteban Palomo, Juan Manuel P\u00e9rez-Castej\u00f3n Garrote, Jos\u00e9 Antonio Serra Rexach, Sebasti\u00e1n Jos\u00e9 Santaeugenia, Francisco Jos\u00e9 Tarazona Santabalbina, Mar\u00eda Teresa Vid\u00e1n Astiz Reducci\u00f3n del riesgo de progresi\u00f3n en receptores de trasplantes infectados 380 por SARS-CoV-2 tratados con anticuerpos monoclonales Francisco Javier Candel, Miguel Salavert, David Lorite Mingot, Marta Manzano Crespo, Paula P\u00e9rez Portero, Rafael Cuervo Pinto Influencia de factores epidemiol\u00f3gicos y cl\u00ednicos en la reactogenicidad a la 392 vacuna Comirnaty\u00ae en trabajadores sanitarios de un hospital universitario espa\u00f1ol (estudio COVIVAC) Carlos Risco-Risco, Diego Mart\u00ednez-Urbistondo, Rafael Su\u00e1rez Del Villar, Luis Ayerbe Garc\u00eda- Monz\u00f3n, Alberto P\u00e9rez-Rubio, Jos\u00e9 Barber\u00e1n-L\u00f3pez, David Andaluz-Ojeda, Paula Villares Fern\u00e1ndez Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en 400 dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempo David S\u00e1nchez Fabra, Tina Herrero Jord\u00e1n, Alicia Alda Lozano, Victoria Duro Su\u00e1rez, Nuria Saura Blasco, Isabel Torres Courchoud Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los 408 pacientes atendidos por infecci\u00f3n en urgencias Agust\u00edn Juli\u00e1n-Jim\u00e9nez, Rafael Rubio-D\u00edaz, Juan Gonz\u00e1lez Del Castillo, Eric Jorge Garc\u00eda- Lamberechts, Itziar Huarte Sanz, Carmen Navarro Bustos, Francisco Javier Candel, Pedro \u00c1ngel De Santos, Ra\u00fal Alonso Avil\u00e9s En Nombre Del Grupo Infurg-Semes Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en 416 Mycoplasma genitalium en el \u00e1rea sur de Tenerife Cristian Mateo Le\u00f3n, Diego Garc\u00eda Mart\u00ednez De Artola, Berta Pino-CalmOriginales Original BreveQuimioterapiaREVISTA ESPA\u00d1OLA DE Revisi\u00f3nVolumen 36 N\u00famero 4 Agosto 2023Sumario Nocardiosis pulmonar despu\u00e9s de infecci\u00f3n por COVID-19: caso cl\u00ednico y revisi\u00f3n 421 de la literatura Jos\u00e9 Ortiz, Francisco Jover, Victoria Ortiz De La Tabla, Elisabet Delgado Alba Bell\u00e9s Bell\u00e9s, Iv\u00e1n Prats S\u00e1nchez, Eric L\u00f3pez Gonz\u00e1lez, Jes\u00fas Aramburu Arnuelos, Albert Bernet S\u00e1nchez, Merc\u00e8 Garc\u00eda Gonz\u00e1lez Concordancia entre el GeneXpert y el Life Real Detection Kit en el diagn\u00f3stico de 427 las infecciones respiratorias agudas Celia Garc\u00eda-Rivera, Isabel Escribano, Esperanza Merino, Juan Carlos Rodriguez Enfermedad de Kikuchi-Fujimoto: una rara linfadenopat\u00eda y su relaci\u00f3n plausible 429 con las vacunas del virus del papiloma humano Adri\u00e1n Rodr\u00edguez-Ferreras, Ivan Vielba Postigo, I\u00f1igo Perez Abraguin, Laura Redondo Farias, Mar\u00eda Jos\u00e9 Lopez De Goikoetxea Uso de ceftarolina en infecciones complejas del sistema nervioso central 434 Alicia Alonso \u00c1lvarez, Efr\u00e9n S\u00e1nchez Vidal, Luc\u00eda Ramos Merino, Dolores Sousa Regueiro, Joaqu\u00edn Serrano Areba, Enrique M\u00edguez Rey, Pedro Llinares Mod\u00e9jar Ajuste posol\u00f3gico de linezolid por Aaron Pupl\u00e0 Bartoll, M\u00aa Dolores Bell\u00e9s Medall, Catal\u00e1n, Celia Roig Mart\u00ed, Julia Bodega Azuara, Mayte Gil Candel, Vicent Esteve L\u00f3pez, Ra\u00fal Ferrando Piqueres Dos casos de Prevotella oris causando infecciones pleuropulmonares graves 439 Domingo Fern\u00e1ndez Vecilla, Mary Paz Roche Matheus, Gotzon Iglesias Hidalgo, Est\u00edbaliz Ugalde Z\u00e1rraga, Miren Josebe Unzaga Bara\u00f1ano, Jos\u00e9 Luis D\u00edaz De Tuesta Del Arco Diagn\u00f3stico v\u00edrico alternativo en las sospechas de viruela del mono 442 Jordi Reina, Elisa Gonz\u00e1lez De HerreroQuimioterapiaREVISTA ESPA\u00d1OLA DE Volumen 36 N\u00famero 4 Agosto 2023 Cartas al DirectorContents QuimioterapiaREVISTA ESPA\u00d1OLA DE Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the 334 population aged 65 or over Mar\u00eda Pilar Arrazola Mart\u00ednez, Jos\u00e9 Mar\u00eda Eiros Bouza, Pere Plans Rubi\u00f3, Joan Puig-Barber\u00e0, Jes\u00fas Ruiz Arag\u00f3n, \u00c1lvaro Torres Lana Infection control in long term care institutions for the elderly: 346 A reflection document on the situation in Spain Emilio Bouza, Jos\u00e9 Augusto Garc\u00eda Navarro, Sergio Alonso, Juan Carlos Duran Alonso, Carina Escobar, Benito J. Fontecha G\u00f3mez , Mar\u00eda Isabel Galv\u00e1 Borr\u00e1s, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Francisco Javier G\u00f3mez Pav\u00f3n, Diego Gracia, Jos\u00e9 Guti\u00e9rrez Rodr\u00edguez, Martha Kestler, Fernando Mart\u00ednez Cuervo, Francisco Javier Mart\u00edn S\u00e1nchez, Carlos Melero, Rosario Men\u00e9ndez Villanueva, Patricia Mu\u00f1oz, Esteban Palomo, Juan Manuel P\u00e9rez-Castej\u00f3n Garrote, Jos\u00e9 Antonio Serra Rexach, Sebasti\u00e1n Jos\u00e9 Santaeugenia, Francisco Jos\u00e9 Tarazona Santabalbina, Mar\u00eda Teresa Vid\u00e1n Astiz Reduction Candel, Miguel Salavert, David Lorite Mingot, Marta Manzano Crespo, Paula P\u00e9rez Portero, Rafael Cuervo Pinto Influence of epidemiological and clinical factors in the reactogenicity to 392 Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study) Carlos Risco-Risco, Diego Mart\u00ednez-Urbistondo, Rafael Su\u00e1rez del Villar, Luis Ayerbe Garc\u00eda- Monz\u00f3n, Alberto P\u00e9rez-Rubio, Jos\u00e9 Barber\u00e1n-L\u00f3pez, David Andaluz-Ojeda, Paula Villares Fern\u00e1ndez Management of COVID-19 pandemic in hospital at home in two regional 400 Spanish hospitals. what it meant, who we cared for, who died and how assistance has evolved over time David S\u00e1nchez Fabra, Tina Herrero Jord\u00e1n, Alicia Alda Lozano, Victoria Duro Su\u00e1rez, Nuria Saura Blasco, Isabel Torres Ability of qSOFA1-lactate 30-day in the Emergency Department Agust\u00edn Juli\u00e1n-Jim\u00e9nez, Rafael Rubio-D\u00edaz, Juan Gonz\u00e1lez del Castillo, Eric Jorge Garc\u00eda- Lamberechts, Itziar Huarte Sanz, Carmen Navarro Bustos, Francisco Javier Candel, Pedro \u00c1ngel de Santos, Ra\u00fal Alonso Avil\u00e9s en nombre del grupo INFURG-SEMES High macrolides and fluoroquinolones resistance rate in 416 Mycoplasma genitalium in southern Tenerife Cristian Mateo Le\u00f3n, Diego Garc\u00eda Mart\u00ednez de Artola, Berta Pino-CalmReview OriginalsVolume 36 DE Pulmonary nocardiosis after covid-19 infection: case report and literature review 421 Jos\u00e9 Ortiz, Francisco Jover, Victoria Ortiz de la Tabla, Elisabet Bell\u00e9s Bell\u00e9s, Iv\u00e1n Prats S\u00e1nchez, Eric L\u00f3pez Gonz\u00e1lez, Jes\u00fas Aramburu Arnuelos, Albert Bernet S\u00e1nchez, Merc\u00e8 Garc\u00eda Gonz\u00e1lez Concordance between GeneXpert and Life Real Detection Kit in the diagnosis of 427 acute respiratory infections Celia Garc\u00eda-Rivera, Isabel Escribano, Esperanza Merino, Juan Carlos Rodriguez Kikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human papillomavirus I\u00f1igo Perez Abraguin, Laura Redondo Farias, Mar\u00eda Jos\u00e9 Lopez de Goikoetxea Use of ceftaroline in complex central nervous system infections 434 Alicia Alonso \u00c1lvarez, Efr\u00e9n S\u00e1nchez Vidal, Luc\u00eda Ramos Merino, Dolores Sousa Regueiro, Joaqu\u00edn Serrano Areba, Enrique M\u00edguez Rey, Pedro Llinares Celia Roig Mart\u00ed, Julia Bodega Azuara, Mayte Gil Candel, Vicent Esteve L\u00f3pez, Ra\u00fal Ferrando cases of Prevotella oris causing serious pleuropulmonary 439 Domingo Paz Roche Matheus, Gotzon Iglesias Hidalgo, Est\u00edbaliz Ugalde Z\u00e1rraga, Miren Josebe Unzaga Bara\u00f1ano, Jos\u00e9 Luis D\u00edaz de Tuesta del Arco Alternative viral diagnosis in suspected monkeypox 442 Jordi Reina, Elisa Gonz\u00e1lez de HerreroVolume 36 Number 4 August 2023 Letters to the editorISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Rev 2023;36(4): 334-345334Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over ABSTRACT Most of the complications and deaths related to seasonal flu 65 years) with comorbid - ities, and the influenza vaccine is the most effective way to prevent them. Immunization is amplitude of the response in elderly people, have been used in clinical practice since 1997 in their trivalent formulation and, since 2020, in their tetravalent formulation. Data from various studies show that these vaccines are not only safe for all age groups, with a reactogenicity profile similar to that of the con - ventional vaccine, but also that they are especially the immune titers after vaccination and sig to and to be effective as the high-dose vaccine in the population aged 65 or over. In this review, the scientific evidence on the efficacy and effectiveness of the MF59-adjuvanted vaccine in real clinical practice in people 65 years of age is analyzed through a narrative and descrip - tive review of the literature with data from clinical trials, - La gripe estacional es una infecci\u00f3n v\u00edrica aguda que al - gunos a\u00f1os puede alcanzar incidencias del 5-10% [1]. El riesgo de complicaciones, hospitalizaciones y fallecimientos por gri -Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad 1Hospital Universitario 12 de Octubre, Madrid, Espa\u00f1a 2Hospital Universitario R\u00edo Hortega, Facultad de Medicina, Valladolid, Espa\u00f1a 3Agencia de Salud P\u00fablica de Catalu\u00f1a, Espa\u00f1a 4\u00c1rea de Investigaci\u00f3n en Vacunas (AIV). Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunidad Valenciana (FISABIO), Valencia, Espa\u00f1a 5Hospital de la L\u00ednea de la Concepci\u00f3n, C\u00e1diz, Espa\u00f1a 6Direcci\u00f3n General de Salud P\u00fablica. Servicio Canario de la Salud, Santa Cruz de Tenerife, Espa\u00f1a 7Medicina Preventiva y Salud P\u00fablica. Universidad La Laguna, Santa Cruz de Tenerife, Espa\u00f1aMar\u00eda Pilar Arrazola Mart\u00ednez1 Jos\u00e9 Mar\u00eda April 2023 RESUMEN La mayor\u00eda de las complicaciones y fallecimientos rela - cionados con la gripe estacional ocurren en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s y con enfermedades de base, y la vacuna frente a la gripe es la forma m\u00e1s efectiva de prevenirlas. La inmu - nizaci\u00f3n es menos eficaz en los adultos mayores debido a la inmunosenescencia. Las vacunas adyuvadas con MF59, dise\u00f1a - das para mejorar la magnitud, persistencia y amplitud de la respuesta inmunitaria en personas de 65 a\u00f1os o m\u00e1s, se vie - nen utilizando en la pr\u00e1ctica cl\u00ednica desde 1997 en su formu - laci\u00f3n trivalente y, desde 2020, en formulaci\u00f3n tetravalente. Los datos de diversos estudios muestran que estas vacunas son seguras para todos los grupos de edad, con un perfil de reacto - genicidad similar al de la vacuna convencional, y que resultan especialmente efectivas para potenciar la respuesta inmunita - ria en la poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, al aumentar los t\u00edtulos de anticuerpos tras la vacunaci\u00f3n y reducir significativamente el riesgo de ingreso hospitalario. Las vacunas adyuvadas han demostrado otorgar protecci\u00f3n cruzada frente a cepas hete - r\u00f3logas y ser igual de efectivas que la vacuna de alta dosis en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s. En esta revisi\u00f3n se analiza la evi - dencia cient\u00edfica sobre la eficacia y la efectividad de la vacuna adyuvada con MF59 en la pr\u00e1ctica cl\u00ednica real en personas 65 a\u00f1os mediante una revisi\u00f3n narrativa y descriptiva de los datos publicados en ensayos cl\u00ednicos, estudios observacionales y revi - siones sistem\u00e1ticas o metaan\u00e1lisis. Palabras clave: adyuvada; MF59 Correspondencia: Dra. Mar\u00eda Pilar Arrazola Mart\u00ednez Servicio de Medicina Preventiva. Hospital Universitario 12 de Octubre Av. de C\u00f3rdoba, s/n, 28041 Madrid, Espa\u00f1a E-mail: mpilararrazola@gmail.comEficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345335El objetivo de este trabajo es analizar la evidencia cien - t\u00edfica sobre la eficacia y la efectividad de la vacuna adyuva - da con MF59 en la pr\u00e1ctica cl\u00ednica real en poblaci\u00f3n 65 a\u00f1os mediante una revisi\u00f3n narrativa [14] de los datos publicados procedentes de ensayos cl\u00ednicos, estudios observacionales y re - visiones sistem\u00e1ticas o metaan\u00e1lisis. METODOLOG\u00cdA Para elaborar este art\u00edculo, se realiz\u00f3 una b\u00fasqueda bi - bliogr\u00e1fica no sistem\u00e1tica en septiembre de 2022 en las bases de datos electr\u00f3nicas Medline (PubMed) y Embase empleando los siguientes descriptores: vacuna adyuvada, gripe, vacuna antigripal, MF59 y estudios publicados desde enero de 2014 hasta septiembre de 2022 que incluyeran a poblaci\u00f3n de 65 a\u00f1os o m\u00e1s. Tras revisar el contenido de las publicaciones, se seleccionaron aquellas que, a criterio de los autores, fueron m\u00e1s relevantes por presentar datos sobre la vacuna adyuvada con MF59 en la pr\u00e1ctica cl\u00ednica real en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s. Se revisaron un total de 19 estudios, incluyendo ensayos cl\u00ednicos, estudios observacionales y revisiones sistem\u00e1ticas/me - taan\u00e1lisis (Tabla 1). EFICACIA, INMUNOGENICIDAD Y SEGURIDAD DE LAS VACUNAS ANTIGRIPALES ADYUVADAS Ensayos cl\u00ednicos. A continuaci\u00f3n, resumimos los princi - pales resultados de eficacia, inmunogenicidad y seguridad de las vacunas adyuvadas frente la gripe en adultos 65 a\u00f1os procedentes de 5 ensayos cl\u00ednicos de fase 3 [15-19] (Tabla 2). En el ensayo cl\u00ednico con asignaci\u00f3n aleatoria (ECA) llevado a cabo por Frey et al. [15] (2014) se evaluaron en la tempo - rada de gripe 2010-2011 la inmunogenicidad, la seguridad y la eficacia de la vacuna trivalente adyuvada con MF59 (aTIV) en comparaci\u00f3n con la vacuna trivalente sin adyuvar (TIV) en sujetos con o sin comorbilidad. La eficacia, la reactogenicidad y los eventos adversos (EA) graves se evaluaron hasta el d\u00eda 366 tras administrar la vacuna. La vacuna aTIV indujo respuestas significativamente m\u00e1s elevadas de anticuerpos (por inhibici\u00f3n de la aglutinaci\u00f3n) (p<0,001) que las obtenidas por la vacuna pe es mayor en personas de 65 o m\u00e1s a\u00f1os, ni\u00f1os menores de 5 a\u00f1os, mujeres embarazadas y pacientes con comorbilidades [1]. Las epidemias de gripe anuales causan 290.000- 650.000 muertes en el mundo y 3-5 millones de casos de enfermedad grave [1]. La infecci\u00f3n por gripe duplica la mortalidad en los pacientes coinfectados por el virus SARS-CoV-2 [2]. En los pa\u00edses industrializados, la mayor\u00eda de las muertes relacionadas con la gripe ocurren en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s [1]. Se ha descrito una mortalidad de alrededor del 12% en mayores hospitalizados por gripe [3,4]. Adem\u00e1s, la gripe dis - minuye de forma notable la calidad de vida relacionada con la salud (CVRS), con una p\u00e9rdida de autonom\u00eda que puede provo - car gran discapacidad en hasta un 14,6% de las personas de 65 a\u00f1os o m\u00e1s [3]. La vacuna frente a la gripe es la forma m\u00e1s efectiva de prevenir la gripe y sus complicaciones [1]. Sin embargo, la in - munizaci\u00f3n es menos eficaz en las personas de 65 o m\u00e1s a\u00f1os debido a la inmunosenescencia [3-5]. Esto hace que los mayo - res muestren una respuesta menos intensa y efectiva a la va - cuna en comparaci\u00f3n con la poblaci\u00f3n adulta m\u00e1s joven [6,7]. Con objeto de mejorar la respuesta a la vacuna antigripal en los mayores se han propuesto diversas estrategias, tales como el uso de adyuvantes (por su efecto inmunoestimulador), v\u00edas de administraci\u00f3n alternativas, o vacunas atenuadas en lugar de inactivadas [8]. Las vacunas adyuvadas con MF59, dise\u00f1adas para mejorar la magnitud, persistencia y amplitud de la respuesta inmuni - taria en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, se vienen utilizando en la pr\u00e1ctica cl\u00ednica desde 1997 en su formulaci\u00f3n trivalente y, desde 2020, tambi\u00e9n en formulaci\u00f3n tetravalente [9-11]. Nue - ve estudios de evidencia con datos de pr\u00e1ctica cl\u00ednica ( real- world evidence ) publicados en 2020-2021, que analizaron va - rias temporadas consecutivas de gripe e incluyeron 53 millones de participantes, han demostrado que la vacuna con MF59 es m\u00e1s efectiva que las vacunas convencionales e igual de efecti - va que la de alta dosis en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s [12,13]. Esto complementa la evidencia de 12 estudios de efectividad, identificados en una reciente revisi\u00f3n, que compararon la va - cuna con MF59 frente a las vacunas convencionales no adyu - vadas y que incluyeron 14 millones de participantes [12,13]. Tipo de estudio N\u00famero de estudios incluidos N\u00famero de estudios con aTIV N\u00famero de estudios con aQIV* Ensayos cl\u00ednicos [15-19] 5 3 2 Estudios observacionales [20-31] 12 12 - Revisiones sistem\u00e1ticas/metaan\u00e1lisis [13,33,34] 3 3 -Tabla 1 N\u00famero de estudios incluidos en la revisi\u00f3n en funci\u00f3n del dise\u00f1o aQIV: vacuna antigripal tetravalente adyuvada y de dosis est\u00e1ndar; antigripal trivalente adyuvada y de dosis est\u00e1ndar *Debido a la comercializaci\u00f3n en 2020 de la primera vacuna aQIV, todav\u00eda no se dispone de datos en vida real para esta, por lo que la mayor\u00eda de datos de efectividad de las vacunas adyuvadas proceden de estudios realizados con la vacuna aTIV. Sin embargo, debido a la formulaci\u00f3n, composici\u00f3n en parte coincidente y proceso de fabricaci\u00f3n similar entre ambos tipos de vacuna, la evidencia de la efectividad de la vacuna aTIV resulta tambi\u00e9n pertinente para la vacuna aQIV.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345336Autor (a\u00f1o) [referencia]Dise\u00f1o n Temporada de gripe Resultados principales Frey (2014) [15] Fase 3, prospectivo, aleatorizado, controlado con placebo y enmascarado para el observadoraTIV: 3.541 TIV: 3.5412010-11 -aTIV: respuestas significativamente m\u00e1s elevadas vs. TIV frente a todas las cepas hom\u00f3logas y heter\u00f3logas, incluso en caso de comorbilidad -No se estableci\u00f3 la superioridad seg\u00fan los criterios predefinidos -Aunque la reactividad fue mayor en el grupo de aTIV, las reacciones fueron leves/moderadas y transitorias Essink (2020) [16] Fase 3, multic\u00e9ntrico, aleatorizado, doble enmascaramiento, de paralelos y controladoaQIV: 889 aTIV-1: 445 aTIV-2: 4442017-18 -aQIV: respuesta similar a aTIV frente a cepas de gripe hom\u00f3logas -El beneficio inmunol\u00f3gico de aQIV tambi\u00e9n se demostr\u00f3 en los subgrupos de 65-74, 75-84 y 85 a\u00f1os y en aquellos sujetos con alto riesgo de comorbilidad -aQIV y aTIV fueron inmunog\u00e9nicas 19,8% frente cepas y 49,9% frente a compatibles antig\u00e9nicamente -No se cumpli\u00f3 el criterio preespecificado para mostrar la eficacia de aQIV -85% de los aislamientos caracterizados no coincidieron con la cepa vacunal -aQIV: mayor protecci\u00f3n contra la gripe cl\u00ednicamente relevante durante las temporadas dominadas por el subtipo A(H3N2), antig\u00e9nicamente divergentes -Eficacia mayor en los casos asociados a fiebre m\u00e1s alta (enfermedad cl\u00ednicamente m\u00e1s significativa) -EA local m\u00e1s com\u00fan: dolor en el sitio de inyecci\u00f3n (16,3% aQIV y 11,2 % comparador) Cowling (2020) [17] Fase 3, aleatorizado, controlado, de HD-TIV: 200 2002017-18 -aTIV: mejor respuesta humoral y celular vs. QIV, especialmente para las cepas de tipo A -Efectos para las cepas de tipo B menos claros: elevados para la cepa B/ linaje-Victoria, especialmente con QIV -EA leves y transitorios -Algunas reacciones locales agudas fueron m\u00e1s frecuentes con aTIV o con HD-TIV vs. QIV -A medio plazo, menos EA como hinchaz\u00f3n, dolor o sensibilidad con aTIV vs. de vida de aTIV vs. HD-TIV -La proporci\u00f3n de pacientes que notificaron dolor moderado o intenso en el lugar de inyecci\u00f3n que limitara o impidiera la actividad con aTIV no fue inferior vs. HD-TIV (3,2% vs. 5,8 %; 2,7 -Cambios en las puntuaciones de CVRS: no fueron cl\u00ednicamente significativos y no difirieron entre los grupos -Los resultados de seguridad indican que ambas vacunas pueden usarse en campa\u00f1as de vacunaci\u00f3n preventivas en adultos mayoresTabla 2 Ensayos cl\u00ednicos aleatorizados con la vacuna antigripal adyuvada en adultos de 65 a\u00f1os o m\u00e1s aQIV: vacuna antigripal tetravalente adyuvada y de dosis est\u00e1ndar, aTIV: vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar, EA: efecto adverso, HD-QIV: vacuna antigripal tetravalente de alta dosis, HD-TIV: vacuna antigripal trivalente de alta dosis, sin adyuvar y de est\u00e1ndar.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345337Estudio (a\u00f1o) [referencia]Dise\u00f1o n Temporada de gripe Resultados principales Izurieta (2019) [21] Retrospectivo de cohortes que compara 5 vacunas>13x1062017-18 -Comparaci\u00f3n en EE.UU. de 5 vacunas (QIVc, QIVe, TIV, aTIV y HD-TIV) en la prevenci\u00f3n de hospitalizaciones -Eficacia de QIVc: 10-11% mayor que QIVe en evitar hospitalizaciones, visitas hospitalarias y consultas -Mayor EVr en reducci\u00f3n de visitas hospitalarias y n\u00famero de hospitalizaciones relacionadas con la gripe con QIVc y HD-TIV Izurieta (2020) [20] Retrospectivo de cohortes que compara 6 vacunas>12,7x1062018-19 -Comparaci\u00f3n en EE.UU. de 6 vacunas aTIV y HD-TIV) m\u00e1s efectivas que QIVe -Las vacunas QIV no mostraron diferencias significativas de eficacia entre las producidas en cultivo celular y las basadas en huevo -Las vacunas adyuvadas y la a HD-TIV a base de huevo fueron ligeramente m\u00e1s eficaces que las vacunas QIV basadas en huevo Izurieta (2021) [22] Retrospectivo de cohortes que compara 5 vacunas>12,7x1062019-20 en EE.UU. de 5 vacunas (HD-TIV, aTIV, QIVe, QIVc y QIVr) eficaces que QIVc -La vacuna recombinante fue moderadamente m\u00e1s eficaz que el resto, mientras que HD-TIV y aTIV fueron m\u00e1s efectivas que QIVe. Van -HD-TIV se asoci\u00f3 a menos visitas hospitalarias por causa ancianos del n\u00famero de hospitalizaciones (poblaci\u00f3n vacunada con aTIV vs. TIV) en EE.UU. -aTIV: m\u00e1s eficaz que TIV en prevenir hospitalizaciones por cualquier causa y por neumon\u00eda o gripe -Ambas mostraron una tasa de hospitalizaci\u00f3n respiratoria similar en una temporada de baja efectividad vacunal Pelton (2020) significativamente mayor en reducci\u00f3n de hospitalizaciones/ visitas a urgencias relacionadas con la gripe vs. QIV y TIV, y similar a HD- TIV -aTIV se asoci\u00f3 a una EVr significativamente mayor que TIV en evitar hospitalizaciones/visitas a urgencias por causa respiratoria Pelton vs. HD-TIV en la prevenci\u00f3n de hospitalizaciones y visitas a urgencias relacionadas con la gripe -Hospitalizaciones/visitas a urgencias relacionadas con la gripe similares entre ambas vacunas -aTIV: ligeramente m\u00e1s efectiva para prevenir las consultas relacionadas con la gripe y cualquier evento cardiorrespiratorio vs. HD-TIV Levin vs. HD-TIV en prevenci\u00f3n de hospitalizaciones y visitas a urgencias por eventos cardiorrespiratorios relacionados con la gripe -aTIV: eficacia similar a HD-TIV en la prevenci\u00f3n de hospitalizaciones/ visitas a urgencias relacionadas con la gripe, hospitalizaciones totales y hospitalizaciones/visitas a urgencias por causa cardiorrespiratoria relacionadas con la gripeTabla 3 Estudios observacionales con la vacuna antigripal adyuvada en adultos 65 a\u00f1osEficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345338vocaba una respuesta inmunitaria no inferior en comparaci\u00f3n con aTIV-1 y aTIV-2; as\u00ed como examinar la superioridad de aQIV frente a la cepa B, adem\u00e1s de analizar la reactogenicidad y se - guridad. Los t\u00edtulos de anticuerpos se determinaron antes de la vacunaci\u00f3n y a los 21 d\u00edas de la misma para cepas hom\u00f3logas. La vacuna aQIV cumpli\u00f3 con los criterios de no inferioridad frente a aTIV en cuanto a diferencia en la media geom\u00e9trica de los t\u00edtulos de anticuerpos (MGT) y tasa de seroconversi\u00f3n. Tambi\u00e9n cumpli\u00f3 con los criterios de superioridad para la cepa B. Todas las vacunas fueron inmunog\u00e9nicas y bien toleradas. En el ECA de Cowling et al. [17] (2020), adultos de 65- 82 a\u00f1os fueron asignados a recibir una vacuna tetravalente de dosis est\u00e1ndar (QIV), una vacuna aTIV, una vacuna trivalente TIV frente a todas las cepas hom\u00f3logas y heter\u00f3logas del virus de la gripe, incluso en sujetos con mayor riesgo de complica - ciones por presentar comorbilidad, aunque no se estableci\u00f3 la superioridad seg\u00fan los criterios predefinidos. Respecto la segu - ridad, la reactogenicidad fue mayor en el grupo de aTIV; pero las reacciones fueron leves o moderadas y de corta duraci\u00f3n. Essink et al. [16] (2020) realizaron un ECA con doble en - mascaramiento y multic\u00e9ntrico en el que los pacientes fueron asignados 2:1:1 a recibir una vacuna tetravalente adyuvada con MF59 (aQIV), una vacuna aTIV-1, correspondiente a la va - cuna autorizada para el hemisferio norte en la temporada de gripe 2017-2018, u otra vacuna aTIV-2 con la cepa B alternati - va. El estudio tuvo por objetivos evaluar si la vacuna aQIV pro -Estudio (a\u00f1o) [referencia]Dise\u00f1o n Temporada de gripe Resultados en cuanto a prevenci\u00f3n de eventos y complicaciones relacionadas con la gripe en EE.UU. -aTIV: mayor reducci\u00f3n de eventos m\u00e9dicos relacionados con la gripe vs. QIV y HD-TIV para ambas temporadas -En poblaci\u00f3n anciana de alto riesgo con comorbilidades de base, EVr de aTIV superior a QIV y similar a HD-TIV Boikos (2021) [29] Retrospectivo en cuanto a evitar consultas relacionadas con la gripe en EE.UU. -En comparaci\u00f3n con QIV, la efectividad de aTIV fue un 7,1% (IC 95%: 3,3- 10,8) y un 20,4% (16,2-24,4) mayor para prevenir consultas relacionadas con la gripe en las temporadas 2017-2018 y 2018-2019, respectivamente -Eficacia similar a HD-TIV en ambas en cuanto a prevenci\u00f3n de eventos y complicaciones relacionadas con la gripe en EE.UU. -aTIV: mejor EVr frente eventos hospitalarios y ambulatorios vs. QIV y HD- TIV -Resultados consistentes en todos los subgrupos de edad y en ambas temporadas Lapi (2022) [31] Retrospectivo de casos y controles anidadosaTIV: 5.610 TIV/QIV: 41.5942002-03 a 2018-19 (18 temporadas) -Eficacia relativa de aTIV frente a TIV/QIV en la reducci\u00f3n de hospitalizaciones por cualquier causa -En comparaci\u00f3n con la TIV/QIV, aTIV se asoci\u00f3 con una reducci\u00f3n del 12% de las probabilidades de hospitalizaci\u00f3n por cualquier causa -Los resultados para la temporada 2018-19 son consistentes para la vacuna aTIV pero no para la aQIV. aQIV: vacuna antigripal vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar, c: tecnolog\u00eda celular, e: basada en huevo, CVRS: calidad de vida relacionada con la salud, EVr: efectividad vacunal relativa, HD-TIV: vacuna antigripal trivalente de n: muestral, QIV: va - cuna antigripal tetravalente sin adyuvar y de dosis est\u00e1ndar, QIVr: vacuna de hemaglutinina recombinante, TIV: vacuna antigripal trivalente sin adyuvar y de est\u00e1ndar.Tabla 3 Estudios observacionales con la vacuna antigripal adyuvada en adultos 65 a\u00f1os (cont.)Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345339de alta dosis (HD-TIV) o una vacuna tetravalente de hemaglu - tinina recombinante (QIVr) autorizadas para la temporada de gripe 2017-2018. Se analizaron los sueros de 200 receptores de cada vacuna, antes y 30 d\u00edas despu\u00e9s de la vacunaci\u00f3n, para detectar anticuerpos frente a las cepas vacunales producidas en huevo (mediante inhibici\u00f3n de la aglutinaci\u00f3n, HAI) y frente al virus A/Hong Kong/4801/2014(H3N2) de cultivo celular (me - diante microneutralizaci\u00f3n, MN). Se evaluaron las respuestas de linfocitos T CD4+ y CD8+ espec\u00edficos de gripe en 20 par - ticipantes por grupo. Los aumentos medios ( mean fold rises , MFR) en los t\u00edtulos de para A(H1N1)pdm09 y A(H3N2), y de MN para A(H3N2) fueron significativamente superiores con las vacunas mejoradas frente a las de dosis est\u00e1ndar (p<0,05). De igual modo, en los receptores de la vacuna QIVr el t\u00edtulo frente a A(H3N2) fue 2,57 veces mayor que con la vacuna de dosis est\u00e1ndar; la magnitud de esta diferencia fue significati - vamente mayor que las diferencias de 1,43 y 1,33 observadas en los receptores de vacuna de alta dosis y vacuna adyuvada con MF59, en comparaci\u00f3n con los que recibieron una vacuna de dosis est\u00e1ndar. Los autores concluyeron que los sujetos que recibieron vacunas mejoradas (aTIV, HD-TIV o QIVr) mostraron una mejor respuesta inmunitaria (humoral y celular) respecto a los que recibieron la de dosis est\u00e1ndar. El ECA de Beran et al. [18] (2021), con doble enmascara - miento, fue realizado en 12 pa\u00edses en las temporadas 2016- 17 en el hemisferio norte, y en la 2017 en el hemisferio sur. Los participantes, estratificados en funci\u00f3n de la edad (65-74 y 75 a\u00f1os) y del riesgo de complicaciones de la gripe, se asig - naron al azar 1:1 a recibir aQIV o una vacuna no antigripal. Se trata del \u00fanico ensayo cl\u00ednico con resultados de casos de gripe confirmados por laboratorio. El resultado principal seg\u00fan pro - tocolo fue la eficacia absoluta de la vacuna en prevenir casos de gripe, confirmada por RT-PCR, frente a cualquier cepa de gripe en pacientes con s\u00edntomas de gripe y fiebre 37,2\u00baC. Se registraron un 3,6% de casos de gripe confirmados en el grupo de aQIV y un 4,5% en el comparador, la mayor\u00eda causados por el subtipo A(H3N2). Un 85% de los aislamientos caracterizados no coincidieron con la cepa vacunal. Aun as\u00ed, la vacuna aQIV mostr\u00f3 una eficacia seg\u00fan protocolo del 19,8% (IC 95% -5,3 a 38,9) frente a todas las cepas y del 49,9% (-24,0 a 79,8) fren - te a cepas compatibles antig\u00e9nicamente. Cabe destacar que la eficacia frente a casos de gripe con pruebas de laboratorio positivas en sujetos con fiebre 38,0\u00baC fue del 51,1% (28,2 a 66,7). La reacci\u00f3n m\u00e1s com\u00fan a la vacuna adyuvada fue el do - lor en el sitio de inyecci\u00f3n. La eficacia de la vacuna adyuvada fue mayor en los casos de fiebre m\u00e1s alta, que corresponden a enfermedad m\u00e1s relevante. Por \u00faltimo, en el ECA con enmascaramiento simple de Schmader et al. [19] (2021) se compararon la seguridad, la reactogenicidad y las variaciones en la CVRS tras la vacuna - ci\u00f3n con aTIV frente a HD-TIV en las temporadas 2017-2018 y 2018-2019. La proporci\u00f3n de pacientes que notificaron dolor moderado o intenso en el lugar de inyecci\u00f3n con aTIV fue simi - lar respecto a HD-TIV (3,2% frente al 5,8%; diferencia -2,7%; IC 95%: -5,8 - 0,4%). No se observaron EA de inter\u00e9s cl\u00ednico. Ning\u00fan participante precis\u00f3 atenci\u00f3n m\u00e9dica por una reacci\u00f3n a la vacuna y no se asoci\u00f3 ning\u00fan EA grave a la vacunaci\u00f3n. Los cambios en las puntuaciones de CVRS no fueron cl\u00ednica - mente significativos y no difirieron entre los grupos de edad con ambas vacunas. Estudios observacionales. Resumimos seguidamente la evidencia de 12 estudios observacionales [20-31] sobre la efectividad de la vacuna antigripal adyuvada en la pr\u00e1ctica cl\u00ed - nica (Tabla 3). Izurieta et al. llevaron a cabo 3 grandes estudios indepen - dientes, de cohortes y retrospectivos, en pacientes 65 a\u00f1os de la base de datos Medicare en EE.UU. [20-22]. En el primero de ellos [21], realizado en la temporada 2017-18 en m\u00e1s de 13 millones de sujetos que recibieron distintas vacunas frente a la gripe (QIVe basada en huevo, QIVc en cultivo celular; HD- TIV en huevo, aTIV o TIV), la efectividad vacunal relativa (EVr) de las vacunas de cultivo celular en relaci\u00f3n con la QIVe fue del 10% (IC 95%: 7-13%). La vacuna aTIV demostr\u00f3 ser lige - ramente m\u00e1s efectiva que las vacunas TIV (EVr IC 95%: 1,4-6,3%; p 0,05) basadas en huevo sin adyuvar en la prevenci\u00f3n de hospitali - zaciones relacionadas con la gripe, pero fue menos efectiva que la vacuna QIVc (EVr 7,5%; IC 95%: 5,3%; IC 3,3-7,3%; p 0,05). El segundo es - tudio [20], realizado en la temporada 2018-19, investig\u00f3 en 12 millones de personas la EVr en la prevenci\u00f3n de consultas hos - pitalarias asociadas a la gripe. La efectividad fue algo superior para la vacuna basada en huevo adyuvada (EVr 7,7%; IC 95%: 3,9-11,4%; p 0,05) alta dosis (EVr 4,9%; 1,7- 8,1%; p0,05) respecto a la QIV. En el tercero de estos estudios [22], en la temporada 2019-20, se estim\u00f3 la EVr de las vacunas HD-TIV, aTIV, QIVe, QIVc y la vacuna tetravalente recombinante (QIVr) en 12,7 millones de sujetos. Se observ\u00f3 una superioridad significativa en la EVr la vacuna QIVe en la prevenci\u00f3n de visitas hospitalarias, mientras que QI - Vc no fue significativamente m\u00e1s efectiva que QIVe (EVr 2,8%: -2,8-8,2%). En la temporada 2019-20 la circulaci\u00f3n del virus de la gripe A(H3N2) fue escasa, por lo que los resultados deben interpretarse teniendo en cuenta esta circunstancia. Un estudio de cohortes retrospectivo, llevado a cabo por Van Aalst et al. [23] (2020) en las temporadas de gripe 2016- 2017 y 2017-2018, compar\u00f3 la efectividad vacunal en casi 2 millones de personas 65 a\u00f1os que recibieron la vacuna HD- TIV frente a la aTIV. La EVr agrupada para ambas temporadas de HD-TIV frente a aTIV, en cuanto a hospitalizaciones rela - cionadas con problemas respiratorios, fue del 12% (IC 95%: 3,3-20%); 13% (-6,4-32%) para la temporada 2016-2017 y 12% (2,1-21%) para la 2017-2018. En un estudio observacional, McConeghy et al. [24] (2021) asignaron al azar 823 residencias de ancianos de estancia pro - longada para que ofrecieran a sus residentes (n=50.012) aTIV o TIV en la temporada 2016-2017. Se evalu\u00f3 la efectividad de aTIV frente a TIV en evitar hospitalizaciones. Las tasas de hospitalizaci\u00f3n por neumon\u00eda o gripe y por cualquier causa fueron menores con aTIV que con TIV (HR ajustado 0,80 [IC Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345340cionadas con la gripe en ambas temporadas 95%: 3,3-10,8%] y un 20,4% [IC 95%: 16,2-24,4%]). la primera temporada, la efectividad de aTIV fue estad\u00edsticamente supe - rior en los pacientes con diabetes; en la segunda, tambi\u00e9n fue significativamente superior en los pacientes con enfermedad pulmonar obstructiva cr\u00f3nica (EPOC), asma, infarto de miocar - dio, enfermedad cerebrovascular, enfermedad renal y c\u00e1ncer. Se observ\u00f3 una efectividad similar de aTIV respecto HD-TIV en ambas temporadas de gripe. En 2022, Imran et al. [30] estudiaron de forma retrospec - tiva la efectividad de aTIV, QIV y HD-TIV (temporada 2019- 2020) en 3.553.040 sujetos 65 a\u00f1os. La EVr total de aTIV fue del 27,5% (IC 95%: a del 13,9% (IC 95%: 10,7-17,0%) frente a HD-TIV. La efectividad de la vacu - na aTIV fue superior tanto en pacientes hospitalizados como ambulatorios. Los valores de EVr para pacientes hospitalizados (ingresos con cualquier diagn\u00f3stico) y consultas relacionadas con la gripe en pacientes ambulatorios fueron significativos en la comparaci\u00f3n entre aTIV y QIV. La EVr de aTIV frente a HD-TIV en pacientes hospitalizados no fue estad\u00edsticamente significativa cuando la gripe fue el diagn\u00f3stico principal de in - greso, aunque s\u00ed lo fue cuando la gripe se notific\u00f3 en cualquier posici\u00f3n de los diagn\u00f3sticos asociados al ingreso. Los hallazgos se mantuvieron en los subgrupos de edad (65-74; 75-84 y 85 a\u00f1os). La vacuna aTIV se asoci\u00f3 significativamente a menos consultas relacionadas con la gripe que las otras dos vacunas. En el estudio recientemente publicado de Lapi et al. [31] (2022) se ha analizado la EVr de las vacunas aTIV frente a las no adyuvadas (TIV y QIV) en la prevenci\u00f3n de hospitalizaciones por cualquier causa en 18 temporadas de gripe en atenci\u00f3n primaria. Este estudio realiz\u00f3 un an\u00e1lisis de casos y controles anidados empleando la base de datos Health Search e inclu - y\u00f3 una cohorte de 58.252 pacientes vacunados con aTIV, TIV o QIV. Durante las 18 temporadas de gripe estudiadas, se iden - tificaron 2.504 casos de hospitalizaci\u00f3n por cualquier causa y la vacuna aTIV se asoci\u00f3 a una reducci\u00f3n relativa en la proba - bilidad de ingreso por cualquier causa [12% (OR 0,88; IC 95%: 0,80-0,97; p<0,05)] en comparaci\u00f3n con las vacunas no adyu - vadas. Revisiones sistem\u00e1ticas y metaan\u00e1lisis. Tres revisiones sistem\u00e1ticas/metaan\u00e1lisis [13,33,34] recientes han estudiado la efectividad de la vacuna adyuvada con MF59 en pacientes ma - yores en la pr\u00e1ctica cl\u00ednica real (Tabla 4). La primera de ellas fue publicada por Coleman et al. [33] en 2021 y su objetivo fue determinar la efectividad de la vacu - na aTIV/aQIV en personas 65 a\u00f1os, comparado con la ausen - cia de vacunaci\u00f3n o la vacunaci\u00f3n con vacunas est\u00e1ndar o de alta dosis basadas en huevo. Este metaan\u00e1lisis encontr\u00f3 que aTIV redujo el n\u00famero de consultas debido a gripe confirmada, con estimaciones agrupadas del 40,7% (IC 95%: 21,9-54,9) y del 58,5% (IC 95%: 40,7-70,9) para visitas ambulatorias no ur - gentes y para pacientes hospitalizados. La estimaci\u00f3n agrupa - da de EVr fue del 51,3% (39,1-61,1; I 2=0%; p=0,42) en cuanto a hospitalizaciones relacionadas con gripe o neumon\u00eda. Las es - timaciones agrupadas de la EVr de aTIV en evitar consultas re -95%: 0,66-0,98; p=0,03] y 0,94 [0,89-0,99; p=0,02]). La tasa de hospitalizaci\u00f3n por cualquier causa respiratoria fue similar en ambos grupos de vacunados, en una temporada donde la efectividad vacunal se consider\u00f3 baja [32]. Durante la temporada 2017-2018, Pelton et al. [25] (2020) evaluaron la efectividad de la vacuna aTIV respecto a otras vacunas antigripales (HD-TIV, QIV, TIV) en prevenir eventos cardiorrespiratorios relacionados con la gripe en m\u00e1s de 1,82 millones de personas. La vacuna aTIV fue m\u00e1s efectiva en re - ducir las consultas relacionadas con la gripe y otras hospitali - zaciones/visitas a urgencias por causa respiratoria en compa - raci\u00f3n con el resto de vacunas. En cuanto a hospitalizaciones/ visitas a urgencias relacionadas con la gripe, aTIV mostr\u00f3 una EVr significativamente mayor que a HD-TIV. Tambi\u00e9n se asoci\u00f3 con una EVr significati - vamente mayor que TIV en cuanto a hospitalizaciones/visitas a urgencias por causa respiratoria (aTIV vs. [4,6-9,7%]). Se demostr\u00f3 un beneficio significativo de aTIV en los eventos relacionados con la gripe o respiratorios en comparaci\u00f3n con el resto de vacunas. En la temporada 2018- 2019, este mismo autor public\u00f3 (2021) la efectividad vacunal de aTIV en comparaci\u00f3n con las mismas vacunas en prevenir eventos cardiorrespiratorios y relacionados con la gripe [26]. En este caso, la vacuna aTIV fue m\u00e1s efectiva en reducir las consultas relacionadas con gripe que la HD-TIV (6,6%; IC 95%: 95%: -3,7-7,3%) en prevenir hospitalizaciones/visitas a urgencias relacionadas con la gripe, pero m\u00e1s efectiva en re - ducir las hospitalizaciones/visitas a urgencias por enfermedad cardiorrespiratoria (EVr 2,6%; IC 95%: 1,9-3,2%; p<0,0001). Otro estudio retrospectivo, llevado a cabo por Levin et al. [27], compar\u00f3 la efectividad vacunal de aTIV con la de HD-TIV en la prevenci\u00f3n de hospitalizaciones/visitas a urgencias rela - cionadas con la gripe y enfermedades cardiorrespiratorias. La EVr de aTIV fue similar a la de HD-TIV en evitar hospitaliza - ciones/visitas a urgencias relacionadas con la gripe (3,1%; IC 95%: -2,8-8,6%), hospitalizaciones totales (-0,7%; IC 95%: -1,6-0,3%) y cualquier a urgencias enfermedad cardiorrespiratoria (0,9%; IC 95%: 0,01-1,7%). Boikos publicaron en 2021 dos estudios retrospec - tivos correspondientes a las temporadas 2017-2018 y 2018- 2019 [28,29]. En el primero de ellos [28] se compar\u00f3, en m\u00e1s de 10 millones de estadounidenses 65 a\u00f1os, la efectividad de aTIV, QIV y HD-TIV en t\u00e9rminos de prevenci\u00f3n de consultas re - lacionadas con la gripe. En 2017-2018, la EVr de aTIV frente a QIV fue de (IC 2018-2019, de (IC de a HD-TIV (IC 95%: 3,1-10,6%). El segundo [29], realizado en las mismas temporadas, compar\u00f3 la efectividad de aTIV, QIV y HD-TIV en evitar consultas relacionadas con la gripe en m\u00e1s de 3,8 millones de pacientes con al menos una comorbilidad. Respecto a QIV, aTIV fue m\u00e1s efectiva en evitar consultas rela -Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345341Autor (a\u00f1o) [referencia]Dise\u00f1o N\u00ba estudios Temporada de Metaan\u00e1lisis: 162006-07 a 2019-20 -Estudios no intervencionistas publicados en revistas revisadas por pares y literatura gris desde 1997 hasta el 15 de julio de 2020, incluidos ensayos aleatorizados por grupos -Conforme a los est\u00e1ndares metodol\u00f3gicos Cochrane y las gu\u00edas PRISMA-P -Dos revisores extrajeron los datos de forma independiente -El riesgo de sesgo se evalu\u00f3 mediante ROBINS-I -aTIV: EV absoluta significativa y mejor EVr vs. TIV y QIV -aTIV: EVr similar a la vacuna de alta dosis en poblaci\u00f3n 65 a\u00f1os G\u00e4rtner (2022) [13] Revisi\u00f3n sistem\u00e1tica 11 an\u00e1lisis de 9 estudios 2006-07 a 2008-09 2011-12 a 2019-20 -Ensayo s controlados aleatorizados, estudios observacionales y revisiones sistem\u00e1ticas publicados entre el 7 de febrero de 2020 y el 6 de septiembre de 2021 -Los estudios se evaluaron con la herramienta Cochrane de riesgo de sesgo, ROBINS-I o AMSTAR 2 -9 de l os 11 an\u00e1lisis: aTIV significativamente m\u00e1s eficaz vs. TIV y QIV en reducir los eventos cl\u00ednicos relacionados con la gripe y los brotes de gripe -7 de los 11 an\u00e1lisis: aTIV eficacia similar a HD-TIV en reducir los eventos m\u00e9dicos relacionados con la gripe, la duraci\u00f3n de la estancia hospitalaria y las hospitalizaciones/ visitas a urgencias -3 de los 11 an\u00e1lisis: aTIV m\u00e1s eficaz que HD-TIV en reducir las consultas relacionadas con la gripe -La vacuna adyuvada y la de alta dosis son alternativas eficaces para los programas de vacunaci\u00f3n en adultos mayores y son preferibles a las vacunas convencionales de dosis est\u00e1ndar Domnich (2022) [34]Revisi\u00f3n sistem\u00e1tica 52 estimaciones de la EVr de 10 art\u00edculos2016-17 a 2019-20 -Ensayos controla dos aleatorizados y estudios observacionales publicados hasta el 08 de abril de 2022 -Conforme a los est\u00e1ndares metodol\u00f3gicos de las gu\u00edas PRISMA -Dos revisores extrajeron los datos de forma independiente -El riesgo de sesgo se evalu\u00f3 mediante ROBINS-I -La herramie nta GRACE (good research for comparative effectiveness) se aplic\u00f3 a los estudios que cuantificaban de aTIV/aQIV frente HD-TIV/HD-QIV -Las vacunas antigripales adyuvadas y de alta dosis est\u00e1n actualmente aprobadas para los adultos mayores -Las pruebas comparativas disponibles se limitan a estudios observacionales con datos del mundo real -Los resultados sobre la eficacia relativa de las dos vacunas contra la gripe son inconsistentes -Los estudios patrocinados por la industria tienden a informar de resultados m\u00e1s favorables -Los datos actualmente disponibles no apoyan ninguna preferencia de una vacuna sobre otraTabla 4 Revisiones sistem\u00e1ticas y metaan\u00e1lisis de evidencia en vida real con la vacuna antigripal adyuvada en adultos 60 a\u00f1os aTIV: vacuna antigripal de vacunal relativa, HD-TIV: vacuna - sis, TIV: vacuna antigripal trivalente sin adyuvar y de dosis est\u00e1ndar. Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345342lacionadas con la gripe fueron del 13,9 % (4,2-23,5; I 2=95,9%; p<0,01) comparada con TIV, del 13,7% (3,1-24,2; 2=98,8%; a QIV, (-2,9-8,5; I 2=94.5%; p<0,01) comparada con HD-TIV. Se concluy\u00f3 que aTIV mostr\u00f3 una EV absoluta significativa, una mejor EVr en comparaci\u00f3n con la vacuna TIV/QIV de dosis est\u00e1ndar, y una EVr similar a HD-TIV en poblaci\u00f3n 65 a\u00f1os. La segunda revisi\u00f3n sistem\u00e1tica, publicada por G\u00e4rtner et al. [13] en 2022, compar\u00f3 la eficacia y la efectividad de las va - cunas aTIV/aQIV frente a las de dosis est\u00e1ndar (TIV/QIV) y de alta dosis (HD-TIV/QIV) en personas de 65 a\u00f1os o m\u00e1s, para complementar la revisi\u00f3n sistem\u00e1tica de 2020 de las vacunas antigripales mejoradas llevada a cabo por el Centro Europeo para la Prevenci\u00f3n y el Control de Enfermedades (ECDC) [12]. Se identificaron 11 an\u00e1lisis de 9 estudios que inclu\u00edan 53 mi - llones de participantes. En 9 de los 11 an\u00e1lisis la vacuna aTIV fue significativamente m\u00e1s efectiva que TIV y QIV en resultados relacionados con la gripe por entorno cl\u00ednico y presuntos bro - tes de gripe [EVr de aTIV entre el 7,5% (IC 95%: 4,2-10,6%) y a 95%: el 36,3% (IC 95%: 31,0-41,2) frente a QIV]. Siete an\u00e1lisis encontraron una efectividad similar de aTIV frente a HD-TIV en reducir el n\u00fame - ro de consultas relacionadas con la gripe, el tiempo de estancia hospitalaria y las hospitalizaciones/visitas a urgencias. Y en dos an\u00e1lisis aTIV fue significativamente m\u00e1s eficaz que HD-TIV en reducir las consultas relacionadas con la gripe [EVr del 6,6% (IC 95%:2,7-10,3% y del 16,6% (IC 95%: 10,8-22,0), respectiva - mente]. En general no se encontraron diferencias significativas entre ambas vacunas para las variables analizadas. El riesgo de sesgo de los estudios identificados fue de moderado a alto. La tercera y \u00faltima revisi\u00f3n sistem\u00e1tica, publicada por Domnich et al. [34] en 2022, compar\u00f3 la eficacia y la efecti - vidad de la vacuna adyuvada (aTIV/aQIV) frente a la de alta dosis (HD-TIV/HD-QIV). Durante la b\u00fasqueda se identificaron 10 estudios que cumpl\u00edan los criterios de inclusi\u00f3n, todos ellos observacionales, con un dise\u00f1o de cohorte retrospectivo y elevado tama\u00f1o muestral. Todos fueron realizados en EE.UU. entre las temporadas de gripe 2016-2017 y 2019-2020. No se encontraron estudios que incluyeran aQIV ni HD-QIV [34]. Aunque la mayor\u00eda de las estimaciones de EVr agrupada fueron cercanas a la nulidad, algunos estudios mostraron una efec - tividad ligeramente superior para una vacuna u otra. En con - creto, de las 52 estimaciones de la EVr de aTIV frente a HD-TIV o viceversa en poblaci\u00f3n 65 a\u00f1os, la mayor\u00eda (31/52; 59,6%) no fueron significativas. Entre las estimaciones significativas, 13 (25,0%) favorec\u00edan a la vacuna aTIV, mientras que las 8 res - tantes (15,4%) eran favorables a HD-TIV. El an\u00e1lisis conjunto mostr\u00f3 que la vacuna aTIV fue superior a la HD-TIV (p < 0,05) frente a: todas las consultas m\u00e9dicas relacionadas con la gri - pe (hospitalizaciones, visitas a urgencias y consultas externas) (9,7%; IC 95%: 5,0-14,2; I 2=75,6%); consultas hospitalarias (tanto hospitalizaciones como visitas a urgencias) por neumo - n\u00eda (2,2%; IC 2=45,2%). Por el contrario, aTIV fue menos efectiva (p < 0,05) que HD-TIV frente a las hospitalizaciones por causa respiratoria (-13,9%; IC 95%: -25,4-3,4; I 2 = 0%) y las consultas hospitalarias (tanto estancias como visitas a ur - gencias) por eventos coronarios (-1,2%; IC 95%: -2,2 - -0,2; I 2 = 0%). No hubo diferencias significativas para otros par\u00e1me - tros. Las estimaciones de EVr se limitaron a criterios de valora - ci\u00f3n cl\u00ednicos no confirmados por laboratorio (consultas m\u00e9di - cas, hospitalizaciones, etc.) y el riesgo de sesgo de los estudios fue moderado. DISCUSI\u00d3N Esta revisi\u00f3n de la evidencia sobre la eficacia, efectividad y seguridad de la vacuna antigripal adyuvada con MF59 en po - blaci\u00f3n de 65 a\u00f1os o m\u00e1s comprende diversos ensayos cl\u00ednicos, estudios observacionales y revisiones sistem\u00e1ticas realizados en distintas temporadas de gripe. Los resultados demuestran que las vacunas adyuvadas generan mayores t\u00edtulos de anti - cuerpos y respuestas m\u00e1s sostenidas en el tiempo en compara - ci\u00f3n con las vacunas no adyuvadas de dosis est\u00e1ndar. El uso de grandes bases de datos del mundo real que in - tegran diferentes fuentes de informaci\u00f3n (incluidos datos pro - cedentes de hospitales y farmacias) [26,28] permite evaluar la efectividad de las vacunas y complementar los resultados obtenidos a trav\u00e9s de ECA. Entre los trabajos revisados se in - cluyen estudios basados en varias fuentes de datos que explo - ran m\u00faltiples criterios de valoraci\u00f3n y que permiten ampliar el espectro de casos relacionados con la gripe, abarcando desde casos m\u00e1s graves (pacientes hospitalizados) hasta los menos graves (pacientes ambulatorios o sin hospitalizaci\u00f3n). En este sentido, los trabajos de Pelton et al. (2021) e Imran et al. (2022) indican que la vacuna aTIV parece ser m\u00e1s efectiva en el en - torno ambulatorio al reducir las consultas relacionadas con la gripe en comparaci\u00f3n con otras vacunas [26,30]. Cabe destacar los estudios de gran tama\u00f1o muestral rea - lizados en pacientes procedentes de bases de datos como Me - dicare [20-22]. Las fuentes empleadas permitieron analizar re - sultados relevantes como las hospitalizaciones en los cuidados de rutina en un contexto real, dif\u00edciles de obtener en cualquier ECA. Estos estudios concluyeron que las vacunas HD-TIV y aTIV fueron m\u00e1s efectivas que la QIVe, y apoyan que la cantidad de ant\u00edgeno y el uso de adyuvantes pueden contribuir a incre - mentar la efectividad vacunal. Dado que el efecto de la gripe se extiende m\u00e1s all\u00e1 de la enfermedad respiratoria, es importante comparar la efectivi - dad de las vacunas en cuanto a otros resultados cl\u00ednicos re - levantes, como los eventos cardiovasculares [23,26,27,29]. El estudio de Pelton et al. [26] que evalu\u00f3 varios aspectos rela - cionados con la enfermedad cardiorrespiratoria, demostr\u00f3 que la vacuna aTIV fue similar a la HD-TIV en prevenir hospitaliza - ciones/visitas a urgencias relacionadas con la gripe, pero m\u00e1s efectiva en reducir las hospitalizaciones/visitas a urgencias por enfermedad cardiorrespiratoria. Sin embargo, en el estudio de Van Aalst et al. [23], los datos agrupados para ambas tempo - radas de gripe muestran que la vacuna HD-TIV se asoci\u00f3 a me -Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345343nos visitas hospitalarias por causa respiratoria que aTIV, lo cual refleja que no existe consistencia entre los distintos estudios revisados. De igual modo, dado que el riesgo de morbilidad y morta - lidad por gripe aumenta con la edad entre los adultos mayores [35,36], es importante evaluar la efectividad de las vacunas en este grupo poblacional. Los estudios analizados en esta revi - si\u00f3n demuestran que las vacunas antigripales adyuvadas pre - sentan resultados favorables en la poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, generando una respuesta inmunitaria m\u00e1s robusta y sostenida en el tiempo [17,18] que se traduce en una reducci\u00f3n de las hospitalizaciones y las visitas/consultas a urgencias [25-27]. Esta ventaja se mantiene en los distintos grupos poblacionales (65-74 a\u00f1os; 75-84 a\u00f1os y 85 a\u00f1os) [30], un aspecto cr\u00edtico dada la creciente fragilidad de los pacientes con la edad. Por otro lado, con relaci\u00f3n a las variantes v\u00edricas, varios de los estudios revisados demuestran que la vacuna antigripal ad - yuvada es m\u00e1s eficaz frente al subtipo A(H3N2) [17,18], cl\u00edni - camente importante en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, e induce una mejor protecci\u00f3n cruzada que las vacunas no adyuvadas, especialmente la formulaci\u00f3n aQIV, ya que incluye una cepa B adicional (B/linaje Yamagata o Victoria). En el ECA de Essink et al. [16] la vacuna aQIV adyuvada con MF59 cumpli\u00f3 con los criterios de superioridad para la cepa B frente a una vacuna aTIV-1 y otra aTIV-2 con una cepa B alternativa. Las vacunas tetravalentes, que incluyen las cepas A y B recomendadas por las autoridades sanitarias, tienen el potencial de ofrecer una protecci\u00f3n m\u00e1s amplia que las trivalentes. Adem\u00e1s, esta revisi\u00f3n muestra que, en temporadas con deriva antig\u00e9nica, la vacuna adyuvada mejora los resultados de inmunogenicidad en comparaci\u00f3n con otras vacunas est\u00e1ndar. El estudio de Beran et al. [18] avala el beneficio de las vacunas antigripales adyuvadas en temporadas con una discrepancia sustancial entre las cepas circulantes y vacunales. Levin et al. destacaron que la EVr fue similar entre aTIV y HD-TIV pese a que hubo poca o ninguna circulaci\u00f3n significativa de A(H3N2) durante la temporada de 2019-2020, variante que a menudo contribuye de manera importante a las hospitalizaciones y la mortalidad relacionadas con la gripe en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad [27]. En los 2 estudios de Boikos [28,29], la deriva antig\u00e9nica de A(H3N2) fue mayor en la temporada 2018-2019 que en la 2017-2018, lo cual otorg\u00f3 un mayor beneficio a la vacuna aTIV. Desde el punto de vista de la seguridad, los resultados del estudio de Schmader et al. [19] respaldan el uso de cualquiera de las vacunas aTIV o HD-TIV para prevenir la gripe en adultos mayores. Este estudio fue el primero en determinar los efectos de la vacunaci\u00f3n antigripal en la calidad de vida de los pacien - tes, sin diferencias significativas entre ambas. Se confirm\u00f3 la seguridad de la vacuna adyuvada, tal y como ya demostraron Pellegrini et al. en 2009 con datos procedentes de 64 ensayos cl\u00ednicos [37]. En t\u00e9rminos econ\u00f3micos, el uso de la vacuna adyuvada se considera una intervenci\u00f3n coste-efectiva [38]. Tal y como se estima en el estudio de Fochesato et al. (2022) [38] el coste incremental por a\u00f1o de vida ajustado por calidad que aporta la vacuna aQIV frente a la est\u00e1ndar es de 2.240 euros desde la perspectiva del pagador, considerando una EVr del 34,6%. El uso de vacunas adyuvadas puede suponer un ahorro para el Sistema de Nacional de Salud espa\u00f1ol, tal y como revelan de los datos de coste-efectividad disponibles [27,38-40]. El ahorro en costes sanitarios directos con la vacuna adyuvada trivalente se ha estimado en 63,6 millones de euros en comparaci\u00f3n con la HD-TIV, debido especialmente a la diferencia de precio entre ambas vacunas [38]. Por otro lado, utilizar la vacuna adyuvada en toda la poblaci\u00f3n 65 a\u00f1os podr\u00eda suponer un ahorro de hasta 82 millones de euros respecto la vacuna no adyuvada [39]. La protecci\u00f3n conferida por la vacuna antigripal es fun - damental en t\u00e9rminos econ\u00f3micos si se tiene en cuenta que el coste de una epidemia de gripe puede alcanzar los 56,7 millo - nes de euros por mill\u00f3n de habitantes en los pa\u00edses industria - lizados [41]. Finalmente, es preciso mencionar que, entre los estudios analizados, aportan m\u00e1s valor aquellos realizados en varias temporadas de gripe, pues sus resultados son m\u00e1s f\u00e1cilmen - te extrapolables a nuevas temporadas, as\u00ed como aquellos en los que se ha realizado el diagn\u00f3stico virol\u00f3gico de gripe. La utilizaci\u00f3n de definiciones de gripe ligeramente distintas en los distintos trabajos y la ausencia de esta confirmaci\u00f3n diag - n\u00f3stica de laboratorio en algunos de ellos puede limitar la comparaci\u00f3n de los datos [29-31]. Hay muchas variables cu - ya definici\u00f3n ha cambiado a lo largo del tiempo, por lo que las revisiones e investigaciones deben actualizarse de forma constante. A ello es preciso a\u00f1adir otros factores ligados a la susceptibilidad de las distintas cohortes, los cambios en las va - cunas y la deriva antig\u00e9nica de los virus. CONCLUSIONES Los resultados de ensayos cl\u00ednicos aleatorizados realiza - dos con vacunas antigripales adyuvadas con MF59 en diver - sas temporadas de gripe demuestran que \u00e9stas generan una respuesta inmunitaria con mayores t\u00edtulos de anticuerpos y respuestas m\u00e1s sostenidas en el tiempo respecto a vacunas no adyuvadas. Tambi\u00e9n presenta mejores resultados frente al sub - tipo A(H3N2) e induce una mejor protecci\u00f3n cruzada que las vacunas sin adyuvante. Los datos post-comercializaci\u00f3n reafirman que las vacu - nas adyuvadas y las de alta carga presentan una efectividad similar en cuanto a hospitalizaciones relacionadas con gripe y en pacientes de alto riesgo. Adem\u00e1s, demuestran que la vacuna antigripal adyuvada es m\u00e1s inmunog\u00e9nica que otras vacunas de dosis est\u00e1ndar en temporadas con deriva antig\u00e9nica, y que presentan un buen perfil de seguridad. Con la evidencia revisada, puede concluirse que las va - cunas adyuvadas son alternativas efectivas y seguras para ser incluidas en los programas de vacunaci\u00f3n en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad, y que son preferibles a las vacunas con - vencionales de dosis est\u00e1ndar como estrategia de prevenci\u00f3n frente a la gripe.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-345344AGRADECIMIENTOS A Adelphi Targis S.L. por el apoyo de medical writing . FINANCIACI\u00d3N Seqirus Spain, S.L. ha promovido el desarrollo de este tra - bajo financiando los servicios de medical writing . Los autores han desarrollado y consensuado el contenido con independen - cia de la fuente de financiaci\u00f3n. CONFLICTOS DE INTERESES Los autores declaran que han recibido honorarios por la participaci\u00f3n en grupos asesores que valoraron la informaci\u00f3n aportada en este manuscrito, y se valor\u00f3 la oportunidad de una revisi\u00f3n narrativa de la evidencia disponible. Los autores declaran que no han recibido honorarios adicionales derivados de su participaci\u00f3n en la elaboraci\u00f3n, escritura, revisi\u00f3n o valo - raci\u00f3n cr\u00edtica del manuscrito. BIBLIOGRAF\u00cdA 1. Organizaci\u00f3n Mundial de la Salud (OMS). OMS, 2018 [citado 16 di - ciembre 2022]. Disponible en: https://www.who.int/es/news-room/ death more than doubled in people who also had flu, English data show. BMJ. 2020;370:m3720. doi:10.1136/bmj.m3720. 3. McElhaney JE, Kuchel GA, Zhou X, Swain SL, Haynes L. T-cell immu - nity to influenza in older adults: A - D. Vaccination in the elderly: The challenge Immunol. 2018;40:83-94. 5. Assir N, Govind S, Aspinall R. Effec - tiveness of influenza vaccine in aging and older adults: Compre 2012;7:55-64. Lev\u00eaque A, Moren A, Sulli - van SG. F. Inactivated Giudice G. The history of MF59 \u00ae adjuvant: A phoenix arose from the ashes. Expert Rev Vaccines. 2013;12:13-30. doi:10.1586/erv.12.140. 10. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Centro de Informaci\u00f3n de Medicamentos. Ficha t\u00e9cnica Chiromas. [citado 16 diciembre 2022]. Disponible en: https://cima.aemps.es/cima/do - chtml/ft/63566/FT_63566.html. 11. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Centro de Informaci\u00f3n de Medicamentos. Ficha t\u00e9cnica Fluad Tetra [citado 16 diciembre 2022]. Disponible en: https://cima.aemps.es/cima/do - 16 diciembre 2022. 12. European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and en - hanced seasonal influenza vaccines for the prevention of labora - tory-confirmed influenza in individuals aged 18 years and over, 2020 16 et al. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review recently published literature real-world data. Vaccine doi:10.1016/j.vaccine.2022.04.019. G, knowledge: literature reviews. Inform Ma - nag. U, Narasi - et al. of the safety and immunogenicity of an MF59 \u00ae-adjuvanted with a non-adjuvanted doi:10.1016/j. vaccine.2014.07.013. 16. Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus al. Comparative immunogenicity of several enhanced influenza vaccine options for Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, et al. Prevention of influenza during mismatched seasons in W, Auerbach H, ter EB, et al. Safety, Reactogenicity, and Health-Related of 2021;4:e2031266. doi:10.1001/jamanetworko - pen.2020.31266 .Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al. Rev Esp Quimioter 2023;36(4): 334-34534520. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Rela - tive Effectiveness of Influenza Vaccines Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines J Dis. 2019;220:1255-64. doi:10.1093/infdis/jiy716. 22. Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, et al. Com - parative effectiveness of influenza vaccines among U.S. Gravenstein S, Mor V, Mahmud SM, Wilschut J, Post - ma M, et al. Comparative effectiveness of high dose versus adju Davidson HE, Canaday DH, Han L, Saade E, Mor V, et al. Cluster-randomized Trial of Adjuvanted Versus Nonadju - vanted Trivalent Influenza Clin. Infect Dis. 2021;73:e4237-43. doi:10.1093/cid/ciaa1233. 25. Pelton SI, Divino V, Shah D, Mould-Quevedo J, Dekoven M, Kris - hnarajah G, et al. Evaluating the relative vaccine effectiveness of trivalent influenza Shah D, Mould-Quevedo J, DeKo - ven A 2021;39:2396-407. doi:10.1016/j.vacci Shah Dekoven M, Mould-Quevedo J, Pelton SI, et al. Comparing the clinical and outcomes associa - trivalent influenza among adults aged 65 O'brien J, Sylvester GC, JA. Re - Trivalent Medical 65 GC, of the adjuvanted influenza vaccine in doi:10.3390/vaccines9080862. 30. Imran M, Puig-Barbera J, Ortiz JR, Fischer L, O'Brien D, Bonafede M, et al. Relative Effectiveness of A, Marconi C. Adjuvanted ver - sus 362. 32. Blanton. Season and of in - vaccine years of age or older, a syste review Int J Infect Dis. 2022;122:855-63. doi:10.1016/J.IJID.2022.07.048. 35. Mart\u00ednez A, Soldevila N, Romero-Tamarit A, Torner N, Godoy P, Rius C, et al. Risk factors associated with severe outcomes in adult hospitalized P\u00e9rez-Rubio in Clinical Cioppa G. MF59- adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis a safety database. Vaccine 2009;27:6959-65. doi:10.1016/j.vaccine.2009.08.101. 38. Fochesato A, Sottile S, Pugliese A, M\u00e1rquez-Pel\u00e1ez S, Toro-Diaz H, Gani R, et al. An Economic Evaluation of the Adjuvanted Quadri - valent Influenza Vaccine Compared with Standard-Dose Quadri Bouza JM. Impacto econ\u00f3mico y sanitario de la utilizaci\u00f3n de vacuna antigripal adyuvada con MF59 en pobla - ci\u00f3n mayor de 65 a\u00f1os en Espa\u00f1a. Rev Esp Quimioter. 2018;31:43- 52. PMID: 29355006. 40. Ruiz-Arag\u00f3n Vaccines (Ba sel) 2022;10:1-12. doi:10.3390/vaccines10020176. 41. Commission of the European Communities. proposal for a cou - ncil recommendation on \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Rev of to parties, with the frequent predisposing easily transmissible. This leads to ask what can be done to prevent infection in this environment and more specifically what is the state of the art of the matter in a Western European nation such as ours. The Board of Trus - tees of the Health Sciences Foundation has asked itself a series of questions on the subject compliance the the best indicators of the processes and therefore, the need to promote in Spain a document of recommendations to avoid infections in this pop -Infection control in long term care institutions for the elderly: A reflection document on the situation in Spain 1Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Departamento de Medicina, Universidad Complutense de Madrid (UCM), Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, y CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid. 2Director General del Consorci de Salut i Social de Catalunya. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda 3Adjunto al director de LA RAZ\u00d3N y director del suplemento A TU SALUD 4Hospital San Juan Grande. Jerez 5POP (Plataforma de organizaciones de pacientes) 6Consorci Sanitari Integral. Consorci de Salut i Social de Catalunya. 7Residencia de Personas Mayores Heli\u00f3polis. Junta de Andaluc\u00eda. Sevilla. 8Secci\u00f3n de Epidemiolog\u00eda y Prevenci\u00f3n. Consejer\u00eda de Sanidad de Canarias. Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda (AEV). 9Servicio de Geriatr\u00eda. Hospital Central de la Cruz Roja \"San Jos\u00e9 y Santa Adela\". Universidad \"Alfonso X el Sabio\". Madrid 10Fundaci\u00f3n de Ciencias de la Salud 11\u00c1rea de Gesti\u00f3n Cl\u00ednica de Geriatr\u00eda. Hospital Monte Naranco, Oviedo. Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA). Grupo de Trabajo Infecciones y Vacunas de la Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. 12Servicio de Microbiolog\u00eda Cl\u00ednica y E. Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid. 13Centro Polivalente de recursos para personas mayores El Cristo. Adscrito al Organismo Aut\u00f3nomo ERA (Establecimientos Residenciales para Ancianos del Principado de Asturias). Sociedad Espa\u00f1ola de Enfermer\u00eda Geri\u00e1trica y Gerontol\u00f3gica. 14Hospital Cl\u00ednico San Carlos. Grupo de investigaci\u00f3n de urgencias y emergencias del IDiscc. Facultad de Medicina de la Universidad Complutense de Madrid. 15Consultor Senior Instituto de Investigaci\u00f3n. Hospital de la Princesa, Madrid. 16Servicio de Neumolog\u00eda. Hospital Universitario La Fe, Valencia 17Departamento de Medicina, Universidad Complutense de Madrid (UCM), Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, y CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid. 18Fundaci\u00f3n de Ciencias de la Salud. Madrid. 19Direcci\u00f3n Asistencial, Badalona Serveis Assistencials. 20Servicio de Geriatr\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Profesor Titular de Medicina. Facultad de Medicina. Universidad Complutense CIBER de Fragilidad y Envejecimiento Saludable (CIBER-FES). Instituto de Salud Carlos III. Madrid 21Programa de Atenci\u00f3n Integrada Social y Sanitaria de Catalu\u00f1a. Departament de Salut. Generalitat de Catalunya. 22Servicio de Geriatr\u00eda. Hospital Universitario de La Ribera. Alcira, Val\u00e9ncia. CIBER de Fragilidad y Envejecimiento Saludable (CIBER-FES). Instituto de Salud Carlos III Madrid 23Servicio de Geriatr\u00eda, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Madrid. Jefe de Secci\u00f3n de Geriatr\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Profesor Asociado. Departamento de Medicina, Universidad Complutense. CIBER de Fragilidad y Envejecimiento Saludable (CIBER-FES). Instituto de Salud Carlos III. Madrid.Emilio Bouza1* Jos\u00e9 Augusto Garc\u00eda Navarro2* Sergio Alonso3 Juan Carlos Duran Alonso4 Carina Escobar5 Benito J. Fontecha G\u00f3mez 6 Mar\u00eda Isabel Galv\u00e1 Borr\u00e1s7 Am\u00f3s Jos\u00e9 Garc\u00eda Rojas8 Francisco Javier G\u00f3mez Pav\u00f3n 9 Diego Gracia 10 Jos\u00e9 Guti\u00e9rrez Rodr\u00edguez 11 Martha Kestler12 Fernando Mart\u00ednez Cuervo13 Francisco Javier Mart\u00edn S\u00e1nchez14 Carlos Melero15 Rosario Men\u00e9ndez Villanueva16 Patricia Mu\u00f1oz17 Esteban Palomo18 Juan Manuel P\u00e9rez-Castej\u00f3n Garrote19 Jos\u00e9 Antonio Serra Rexach20 Sebasti\u00e1n Jos\u00e9 Santaeugenia21 Francisco Jos\u00e9 Tarazona Santabalbina22 Mar\u00eda increasing percentage of the elderly live during the last years of their lives in nursing homes. Although these institutions are intended to mimic life at home as much as possible, they have characteristics that make them quite similar to a \"nosocomiun\", i.e. an establishment for the treat - Correspondence: Emilio Bouza MD, PhD. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n. C/ Dr. care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379347nursing homes are also a nosocomium, i.e. a place where the sick are cared for and treated and where the transmission of pathogenic microorganisms is possible and frequent. We know a prevention measures in other nosocomial facilities, as Long-Term Care Facilities (LTCF). The aim of this work has been to try to compile the availa - ble information on infection control and prevention in LTCF in a Western European country such as Spain, trying to explore what room there is for improvement. For this reason, the Board of Trustees of the Health Sciences Foundation formulated a series of questions on the existing regulations for the prevention of infection in LTCF in our country, on their degree of compliance and on the exist - ing indicators used to this process. The questions were distributed among a multidisciplinary group of experts in this field from very different points of view, including the vision of patients' associations, the media, people speaker and the conclusions were then discussed by the whole group to reach a summary of the situation accepted by all. What follows are the questions and answers that were asked. All authors have read and re-examined the complete text and gave their approval to it. IS THERE A REGIONAL OR NATIONAL PROGRAM IN SPAIN ON INFECTION PREVENTION IN LONG- TERM CARE FACILITIES (LTCF)? There is no common regional or national program on the prevention of nosocomial infection in of morbidity and mortality in the elderly, both in hospital care and in pri - mary care consultations and, of course, in nursing homes. In LTCF there is a high of infection and colonization by multi-resistant microorganisms rate of patient transfers to referral hospitals and that there are very few diagnostic resources in nursing homes, making the management of nosocomial a is respiratory, followed by urinary tract, skin and soft tissue, gastrointestinal tract and ocular. Outbreaks can also occur relatively (ESBL). In order to of nosocomial infection whose morbidity and mortality need not be highlight - ed. To this end, a multidisciplinary group of experts in different aspects of this problem has been convened and asked the pro - posed questions. The questions were discussed by the group as a whole and led to a series of conclusions agreed upon by the participants. and soft tissue infection, pneumonia. Control de la infecci\u00f3n en residencias de ancianos: Documento de reflexi\u00f3n sobre la situaci\u00f3n en Espa\u00f1a RESUMEN Un porcentaje progresivamente creciente de las personas mayores viven durante los \u00faltimos a\u00f1os de su vida en residen - cias de ancianos. Dichas instituciones, aunque pretenden re - medar lo m\u00e1s posible la vida en el hogar, tienen caracter\u00edsticas que las hace bastante parecidas a un nosocomio, es decir a un establecimiento destinado al tratamiento de enfermos. La pro - pia convivencia entre los ancianos, el hecho de compartir cui - dadores y la exposici\u00f3n muy importante a terceras personas, junto con las frecuentes enfermedades predisponentes a la in - fecci\u00f3n de esta poblaci\u00f3n, hacen que la infecci\u00f3n sea frecuente entre los residentes y que adem\u00e1s sea f\u00e1cilmente transmisible. Esto nos lleva a preguntarnos qu\u00e9 puede hacerse para prevenir la infecci\u00f3n en este medio y m\u00e1s concretamente cu\u00e1l es el es - tado del arte de la cuesti\u00f3n en una naci\u00f3n de Europa Occiden - tal como la nuestra. El patronato de la Fundaci\u00f3n de Ciencias de la Salud se ha formulado una serie de preguntas sobre el tema de la prevenci\u00f3n de la infecci\u00f3n en las Residencias de Mayores, la estructura de la misma, la legislaci\u00f3n vigente, el cumplimiento de las medidas indicadas, los indicadores de los procesos y por ende, la necesidad de fomentar en Espa\u00f1a un documento de recomendaciones para evitar infecciones en esta poblaci\u00f3n cuya morbilidad y mortalidad no necesitan ser resaltadas. Para ello, se ha convocado a un grupo multidisci - plinar de expertos en distintos aspectos de este problema a los que se les han formulado las preguntas propuestas. Las pre - guntas han sido discutidas por el grupo en su conjunto y han conducido a una serie de conclusiones consensuadas entre los participantes. Pasamos, a continuaci\u00f3n a relatar los resultados de la reuni\u00f3n. Palabras clave: Infecciones en el anciano, prevenci\u00f3n de la infecci\u00f3n, infec - ci\u00f3n nosocomial, infecci\u00f3n urinaria, infecci\u00f3n respiratoria, infecci\u00f3n de piel y partes blandas, neumon\u00eda INTRODUCTION Nursing homes logically try to reproduce living conditions for their inhabitants as close as possible to those at home. However, they are still places where people with frequent and important underlying conditions close proximity other and share caregivers in a common habitat. In this sense, Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379348the acquisition and transmission of infections in residents and staff. Indirectly, some of the legislation inforce in Spain that is to protect hazards in be applied, although this is not specifically the focus of our discussion. Regarding biosafety, the Biosafety Law (Law 15/1994 of June 3, BOE, 1994) must be applied, which incorporates the Community Directives (EEC, 90/219 of April 23, 1990) into the Spanish legal system. This law was developed in a Royal Decree (RD 664/1997, May 12, 1997, BOE, 1997), on the workers against risks related to exposure to biological agents at work. The EU has advanced in this protection by including a directive on the / EC of the European Parliament and the Council of 18 September 2000). There is another legislative block that develops the reg - ulations on and September 15) Epidemiological Surveillance Catalonia criteria for the preven - tion and of this disease in Spain 352/2004, of July 27), which establishes control of legionellosis. Undoubtedly, all the legislative aspects on risk analysis and control of critical points in the food chain (ARCPC) included in different state for protection against infection in LTCF in is general legislation on aspects such as hygiene and measures against contami - nation in the food chain and specific legislation on pro - tection against issued by central govern - ment authorities. WHAT SHOULD BE THE BROAD OUTLINES PLAN FOR COMMUNICABLE INFECTIONS IN LTCF? Three major thematic areas can be distinguished in this potential plan. 1.- General prevention measures aimed at reducing the generic risk of infections related to care or the environment where there should be sections such as infections the elderly, for which reason it would be necessary to clearly define the di - agnostic standards for infection in this setting. Although there have been attempts to introduce standardized criteria for de - fining infection in these centers, they have not been validated in our country and not universally used [2]. the monitoring and control of nosocomial infection [3], at this level of care there are no quality data that would allow immediate living in LTCF. This population is very vulnerable and is affected by other risk factors such as immunosuppression associated with advanced age, comorbidity, the use of immunosuppressive treatments and other risk factors that are etc.). of professionals does not have the level achieved in our hospitals (there is a high number of geroculturists with basic training and a very small number of nurses and physicians), which makes it diffi - cult to establish measures to contain the risk of infection both in patients/residents and between them and the professionals working in the institutions [4]. An infection prevention plan in LTCF should be - ry in all these centers and be accompanied by an appropriate training program for the professionals working in them, the establishment of a registry of infections by MDR microorgan - isms, the collaboration of the microbiology services and the health authorities of the area, and effective communication between these resources and primary and hospital care. As an initial and minimum step, it would be necessary to develop a surveillance program, with special care in applying standard precautions, with special emphasis on hand also to measure infection It correct use of antibiotics in this population. Conclusion There are no common regional national nosocomi al infection prevention programs It is urgent to establish a prevention plan with min - imum requirements, at least, that includes training of professionals, an infection surveillance and registry sys - tem, collaboration with reference hospital services and an adequate antibiotic use policy. IN THE ABSENCE OF A SPECIFIC REGULATION, WHAT DOES THE LAW IN SPAIN REQUIRE? It has already been mentioned that there is that on term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Esp Quimioter need for microbiological studies and anti - biotic treatment in some 11. Monitor antimicrobial consumption. 12. Continuing education. Conclusion There is a need for a general plan with guidelines for the prevention and management of infections in LTCF with at least three major sections: general prevention measures, protocols and C. IT OR CONTROL? We believe so. To ensure compliance with any protocol or procedure in a nursing home, it is essential that it is led by a professional, who has the support and recognition of the center's management, and who is a reference point for the care team for the transmission of information to the rest of the professionals of both the center itself and the Public Health Service [15]. The presence of a physician in charge of each is not mandatory in different Spanish autonomous communities [16], But in order to be accredited, there must be nursing staff. Therefore, the responsible person could be, if there is one, the physician of the residence, or one of the nurses of the center. The person assigned to be responsible for the care team of the LTCF must have sufficient knowledge and experience in the control and management of infectious diseases (clinical man - ifestations, mechanisms of He/she will be the one who must transmit all the information to the rest of the professionals - Proper handling of personal protective equipment - Safe handling of waste and sharps - Cleaning system, storage and transport of bed linen and user's linen - in residential centers. context of institutionalized elderly people, it is necessary to adequately train professionals in the detection and appropriate management of the most prevalent infections in this type patients. Thus, Immunization professionals (flu, pneumococcus, hepatitis B, SARS-CoV-2, ...). - Prevention and management of urinary tract - idential centers. - Prevention and management colonization the institutional - ized elderly in order to protect residents and reduce the threat of antibiotic resistance is a global priority. The Centers for Dis - ease Control (CDC) and others recommends that all nursing homes in nursing homes may be unnecessary inappropri are some Spain outside around the Geriatrics Service of Granollers proposes 12 interventions and measures to improve the optimization treatment this population [14]: Avoid prescribing without a face-to-face medical as - sessment. This is related to an increase in the use of broader spectrum antimicrobials. 2. Reconsider the treatment of respiratory infections control long term care institutions for elderly: A reflection document on the situation in SpainE. Bouza, referring to environmental conditions that A.- Material requirements - The Centers must be located in healthy and integrated areas or close to urban centers. - Residential area units will not be admitted in basements or crawl spaces. The areas must be sufficiently ventilated and illuminated, preferably with natural light. - They shall have drinking water, with adequate pressure, from the public water supply. If it comes from water catchment or capacity, they shall have a reserve tank with capacity for at least one day. - Hot water in sanitary appliances and kitchen with a that high - er than 20\u00baC. - Evacuation of water to the municipal sewage system or to a sewage treatment plant. In any case, it is forbidden to pour into cesspools. - Bedrooms: Usable area of 5.50 square meters per person in the case of disabled persons and 7.50 square meters per per - son in the case of wheelchair users. - The maximum capacity per bedroom will be six people. The bedrooms must have natural light and ventilation. - Toilets: When they are collective, they will be differenti - ated by sex. The minimum endowment will be a toilet, a sink, a shower and a bidet for every six people or fraction exceeding two people. - Living quarters: With a minimum area of 1.80 m2, per resident, (depending on the recording) with a minimum of 12 square meters. - The resulting surface may be subdivided into smaller ones and, in any case, when it is larger than 60 m2, it must be separated to allow for different environments: play area, read - ing area, TV, etc. - The living rooms must be exterior. - Dining room: It shall have a surface area of at least 1 m2 per person, with a minimum of 10 m2. B.- shall that all users receive, by their own means or those of others, the necessary medical attention. - There shall be a and to provide the corresponding services. The full-time staff/user ratio for valid users; and 0.35 for assisted users. - Every user will have, in his or her bedroom, a suitable lockable closet with shelves and hangers; a bed equipped with of the institution, as well as to the residents and their fami - lies, ensuring that all the necessary measures for the preven - tion of infections are carried out. On the other hand, he/she will inform the Public Health System of relevant events and also the Primary Care physician responsible for the care of the residence, as well as the Hospital Geriatric Specialized Services [17-19]. Their work is essential for the early detection of any case of transmissible infectious disease, as has been demonstrated in the COVID-19 pandemic, as well as for the rapid implemen - tation of the contingency and isolation plan to prevent trans - mission to the rest of the residents. Social and sanitary coordination is essential for the cor - rect functioning of all these protocols, and should be promot - ed by the competent political authority, with very favorable experiences in different Communities during the present pan - demic [20-23]. The SARS-COV-2 pandemic has highlighted the need figure of a Coordinator or person in charge in the resi - dences for the prevention and control of the infection, being required by International Institutions (WHO) the State and different Autonomous Communities [18,20,21,24,25]. Previously, there were numerous mi during the care of colonized/infected residents in residential centers of the Junta de Andaluc\u00eda. As well as with antibiotic optimization programs to should be used to pre - vent new outbreaks of this or any other infectious disease transmitted compliance homes, a person responsible for it should be appointed within the LTCF healthcare team. This person will have the support of the institution's management and will be the center's point of reference, in charge of transmitting all the guidelines to the rest of the col - leagues and to the residents and family members, as well as acting as a contact person with those responsible for health care in the Public Health Service. It must be a phy - sician, if there is one, or a nurse. emphasize that the LTCF are con - ceived as homes, not as health centers. In the specific case of the Community of Madrid, there is an order [29], which develops Decree 91/1990, of October 26, - thorization Regime for Services and Centers for Social Ac - tion and Social Services, which contains the criteria to be met by the centers. The following paragraphs extract those Infection control care for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379351Conclusion There is a specific regulation of the Consejer\u00eda de In - tegraci\u00f3n Social of the Community of Madrid that con - tains the environmental criteria to be met by the centers. In relation to the minimum conditions, the regulation is very clear about the location the LTCF and the material and functional requirements, although it seems too toler - ant in some other aspects. WHAT ARE THE ESSENTIAL DATA IN ASSESSING THE RISK OF INFECTION OF A PERSON LIVING IN A LTCF? It is a requirement to have an individual file for each user, which includes a complete assessment history, treatments, so - cial and medical reports. At the time of admission to a nursing home, the resident arrives with an Individual Care Plan pre - pared by the Dependency Service, drawn up by whomever the regional regulations establish. These are usually social work - ers or multidisciplinary teams. In other countries (Germany) it is drawn up by the healthcare field. The user provides all the medical information available to him/her. In the comprehensive geriatric assessment (CGA), for which different scales can be used, least the following as - should - Personal preferences and advance directives - Quality of life - Physical status: basic and instrumental activities of daily living, gait and balance, frailty - Mental - Complete and up-to-date pharmacological treatment - Risk of falls and pressure ulcers - Pain On the specific point of the subject that concerns us, which is the assessment of the risk of infection on admission, we have not found standard recommendations, but we believe it is necessary to have at least the following data in the pa - tient's specific the corresponding clothing; a bedside table; a light point with a lamp or wall lamp at the head of the bed; a power outlet; a mat. - Each room will have shutters, blinds or curtains that can block the passage of outside light. - Varied menus and dishes will be provided according to the needs of the users. The menus will be previously supervised by a and caloric intake. In addition to the regular menu, other dietary menus will be prepared for those users who require them. Meals and cooked dishes, either with its own service or with an arranged service, will arrive at the appropriate temperature to their re - cipients. Likewise, there must be a cold chain to preserve and store food. - Daily personal hygiene must be guaranteed for users who cannot look and as often as circum - stances require. - change of linen and underwear of the users shall be done whenever necessary, and in any case daily. Other gar - ments shall be changed as often as necessary. - The change of bed linen shall be made whenever required by circumstances, and in any case weekly, as well as each time there is a new admission. periodicity be required Special attention shall be paid to the maintenance, up - keep and repair, if necessary, of furniture, installations and premises, in order to prevent deterioration, as well as to all machines, boilers, installations or instruments which, if they involve a risk, shall be handled exclusively installers. - Center, in addition to complying with the general legislation in force on hygiene and health, must guarantee, in a special way: The general and permanent cleaning of the building and its dependencies, especially those of more intense use, as well as its disinfection. The annual disinsectisation and rat extermination, or as many times as circumstances require. The establishment of specific rules or guidelines for in crockery and cutlery after use, as well as other instruments in common use. In centers with a capacity of more than 50 users, there should be a suitable space for the temporary storage of waste in closed buckets. This law is clear on the basic environmental requirements residences for the elderly, although the \"tolerance with \"dormitories for up to 6 people, toilets for 6 people or very low staffing ratios\" is surprising.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp diphtheria and virus. Likewise, health - care and direct care personnel in the centers should be vaccinated, at least, against influenza and SARS-CoV-2. WHAT MEASURES HAVE BEEN SHOWN TO BE EFFECTIVE IN URINARY TRACT INFECTION IN ELDERLY? Urinary the of healthcare-associated infections. On the oth - er hand, the presence of asymptomatic bacteriuria in institu - tionalized patients is high, with figures of 25-50% in women and 15-40% in men [4]. This bacteriuria is benign, and several studies have the of bac - teriuria, whether or not accompanied by pyuria, is of no benefit and may even be harmful [60]. Therefore, screening and treat - ever, frequent di agnosis of UTI the presence of dysuria or fever, chills or confusion present with altered mental status, falls, lack of appetite or more awkward mobility and have a positive urine culture are diagnosed with UTI, leading to overdiagnosis and inappropriate use of antibiotics, which is very common in these centers [62]. In recent years, many initiatives have been developed to improve the management of this problem and to optimize the use of antibiotics UTIs patients), in which symptoms associated with the genitourinary system were observed, was safe and was associated with a clear reduction in antibiotic use [63]. Despite this, the application of these criteria in patients with advanced dementia remains a matter of debate and over - use of antibiotics is especially prevalent in this subgroup of patients. A descriptive study in patients with advanced demen - tia living in nursing homes showed that only 19% of probable UTIs treated antibiotics met these criteria antibiotics, this treatment was not associat - ed with any improvement in survival. The specific measures that have been In addition to the Comprehensive Geriatric Assess - (CGA), an assessment of the risk infection should be carried out on admission to nursing homes, the specif - ic items of which are far from being agreed upon and far from constituting a standard. In our opinion, they should include, at or not of latent tubercu - losis and the colonization status against such as MRSA. WHAT VACCINES SHOULD BE OFFERED IN A NURSING In the elderly, vaccination takes on greater immune people living in LTCF for the elderly, where the presence tional dependence cognitive impairment puts them at greater risk of falling ill and, if they do fall ill, more clinical complications and a higher risk of death [47]. of Gerontology depending on personal and pertussis and Varicella-Zoster virus infection may also be indicated. Regarding the influenza vaccine, for this type of population and with the aim of increasing its effec - tiveness, it is achieve a minimum annual vaccination cov - erage against the influenza virus of over 75%, both in institu - tionalized persons and in the health and direct care personnel of the centers [49-55]. It should be noted of elderly persons against SARS-CoV-2 (COVID-19) is indicated from the be - ginning of the year 2021. A considerable number of vaccines against SARS-CoV-2 are under study and research. In our country, institutionalized elderly people have been vaccinated in the vaccination strategy against COV - ID-19 of the Ministry of Health, depending on the results of future clinical trials, the data registered in the Drug Pharma - covigilance System and the distribution and availability of vaccine doses, the most appropriate vaccines for each health condition, age group, risk factors and place of residence can be selected from among the different types of vaccines.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379353number of beds in the residence, but not the lower occupancy rate, and 3) the public ownership of the residence, 4) the lower number of beds in the residence, but not the lower occupancy rate, and 5) the lower number of beds in residence [10,73]. These observed MDR infections. Conclusion effective measures Programs to optimize the use of antibiotics, the - cording of infections, the incorporation accessible protocols and the involvement of the medi - cal director of the residency are key to its success. WHAT MEASURES TO REDUCE RESPIRATORY INFECTION HAVE BEEN SHOWN TO BE EFFECTIVE IN LTCF? Respiratory infections are a very frequent cause mortality diagnostic tech nologies Measures the elderly must into account intrinsic and ex - trinsic risk factors for infection. In relation to the environment, the effective measures are included in the World Health Organization (WHO) document, which brings together the guidelines and recommendations to be followed, in to incorporating immunization for healthcare personnel [88,89]. There are recommen - dations for the maintenance of ambient air quality in these institutions and programs for the control of legionellosis [90]. There nursing homes is not ed by legislation and is rarely opinion, its implementation variable and subject to improvement. Many programs and interventions have been put in place to decrease the rate of urinary tract infection in residential fa - cilities ranging from staff anti demonstrated education strategies, local guidelines and periodic review and feedback on antibiotic use [66,67]. In the case of urinary tract infection, these programs have been shown to involved leadership, pharmacy knowledge, education, action, collection and periodic report - ing of infection data. In a baseline analysis, prior to the implementation of this standard in the residencies, it was shown that the most fre - quent existing measures were: the existence of written guide - lines on antibiotic use and the registry of antibiotics used. The more specific and time-consuming the existence of approval mech - anisms control of were used less frequently and improved when the figure of the trained pre - ventivist was in place [70]. The lack of nursing knowledge of antibiotic policies was a major obstacle to their implementa - tion. The involvement in the programs of the medical director of the LTCF, the nursing director and the specific preventivist is key to their implementation, for several reasons, including the high mobility of health personnel in these centers [72]. In a survey conducted in different US facilities infec - tion prevention and control programs in residences and the changes between 2014 and 2018 the existence of use of collectors, of ul - tions. The policies that were associated with the greatest in - crease in these preventive measures were: 1) the existence through scientific societies, 2) the lower Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379354HOW IS AND SOFT TISSUE INFECTION RESIDENTS? Skin acquired - tial facilities are common, with an estimated prevalence of 5% [108], the third most frequent cause of infection after urinary and respiratory infections in this group of patients. Overall, 10% of the elderly who take antibiotics in nursing homes do so because of a skin or soft tissue infection [109] which are of di - verse etiology bacterial, fungal and, occasional - ly, present a The most frequent point of entry for skin and soft tissue infections are solutions of continuity due to small wounds, trauma surgical wounds [111]. Finally, health care centers and nursing homes have a high prevalence of skin and soft tis - sue infections and colonization by MDRs, among which MRSA stands out, with a carrier rate in health care centers and nurs - ing homes that ranges between 8% and 25% [112]. For all these reasons, the prevention and control of SSTIs is an important However, literature is scarce in well-conducted clinical trials that evaluate the efficacy of the different methods for their prevention and the recommen - dations are generally based on experiences obtained groups skin ing, taking special care of the skin folds (submammary and inguinal), which should be dried of cotton garments is useful. The main problem of the skin of the elderly is skin dryness or xerosis, which affects 80 percent of people over 75 years of age, and which is combated with an adequate intake of liquids and the application of moisturizing creams all over the body surface on a daily There is data been done mainly in younger groups such as the military [117,118] and there is no evidence of its efficacy in institution - alized elderly populations. There is also no evidence of nasal decolonization to prevent MRSA infections in nursing It is advisable to evaluate carrier status upon admission to the institution, before outbreak situations, and in patients who return or go to hospitals or change insti - tutions. Therefore, it is not necessary to screen for nasal carriers of S. aureus in general, unless there is a history of having been plan has been proposed to assess air quality nursing periodically. This proactive approach can pave the way for the establishment of mandatory standards for in - door air quality in nursing homes that will promote the health, well-being and quality of life of LTCF residents and reduce medical costs [91]. As regards the control of legionellosis in residences for the elderly, there is no uniform legislation in the different countries and, when it exists, it is frequently not complied with. We therefore believe that this regulation and the - sponding periodic environmental control would be advisable [92]. In the individual aspects, there is no doubt that the im - plementation of vaccination programs for both residents and caregivers is an essential factor for the reduction and control of respiratory infection influenza viruses and SARS-COV-2 [30,33,49,55,93-96]. There are also prospects for the use of vaccine against RSV in the elderly population [97]. Antivirals are not recommended as chemoprophylaxis, ex cept as part of interventions to control institutional outbreaks of influenza [98-101]. Its efficacy, for the most widely used (Oseltamivir), than hospital admissions for any cause. Observational studies find the use of Oseltamivir and mortality reduction [103] but no rand - omized trial has demonstrated this. All have been conducted in healthy individuals where the mortality rate due to influenza is very low. The efficacy of pneumococcal vaccination is of PCV7, PCV10 and PCV13 in individuals over 65 years of [104,105]. PPV23 data in adults. not associated with a substantial reduction in all-cause mortality, possibly be - cause of heterogeneity or lack of power of the studies. In the CAPiTA trial (Community-Acquired Pneumonia Im - munization Trial in compared in im - munocompetent adults over 65 years of age versus placebo in a randomized, double-blind trial involving 84,496 adults aged 65 years or older. The protective efficacy of this vaccine for different points was estimated between 45% and 75.0%. Conclusion There are nursing by (Influ however, legislation and its imple - mentation are necessary.Infection control long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379355As we have mentioned, some of the most frequent viral infections are preventable by vaccination, so it is convenient to have a record of whether the elderly person has been vac - cinated, the date of vaccination, whether when the patient is admitted to the nursing home, I be - lieve it is convenient to know his serology status against the human immunodeficiency virus (HIV), and against hepatitis A, B and C viruses. We believe that it should also be recorded when the patient was vaccinated against hepatitis A and B and make sure that he has received the previous year's influ - enza vaccine [124], COVID-19 and, as soon as it is available in our environment, the Varicella Zoster Virus (VZV) vaccine for adults. In addition to the above, and whenever possible, the per - centage of workers, residents, and visiting family members who have received the influenza vaccine should be recorded each year. A recent study (SHELTER study) conducted in 57 nursing homes in 7 European countries has shown that both correct vaccination against pneumococcus re - duce mortality residents, regardless of - ities and cognitive status [124-126]. This evi - dence, together the reduction in makes it an quality objective. On the other hand, it is clear that the degree of influen - za vaccination among nursing home employees, which ranged 15-97% study, is clearly considered a quality criterion, since non-compliance with this obligation puts residents at unacceptable risk of suffering serious con [127]. also a sick person. It is also advisable to record the number visits to the that the elderly workers have improve the safety of interns of These proposals and staff, as well as of infection by these viruses and admissions they required, should be available.colonized or infected in close contact with a colonized/infect - ed case or if the resident has a history of having recently been in other centers with an endemic an elderly by MRSA should be a reason for exclusion for admission and participation in a health care center. colonized infected MDR mi - croorganisms should, possible, be placed in a single room, not isolated and following universal measures. If this is not possible, they should share a room with another person with the same problem. If this is also not possible, they can share a room with another person who does not have wounds, catheters, drains or They should never share room with an immunosuppressed user. In case of ulcers or colonized skin wounds, these must be well treated and cov - ered with a dry dressing before sharing activities in common rooms of the residence. There should be no restrictions on visitors, since in general, they have a low risk of acquiring an infection due to the protection of their saprophytic flora and can establish contact, but with the appropriate hygienic measures (hand washing, use of gloves if necessary). Nor are worker controls necessary, except in the case of outbreaks if it is suspected that they may be the epi - demiological cause. Conclusion Skin and soft tissue infections (SSTI) are in the elderly population Their reduction re - quires measures and of - such as skin lacerations or uncontrolled blood glucose. There is no evidence of the need for routine screen - ing for S. aureus carrier status, nor of the efficacy of systematic nasal decontamination or intermittent use of chlorhexidine showers. in a 31.6% of the elderly with patients studied). number of patients in a nursing home who get the flu and the number of residents and workers who are vaccinat - ed are, in our opinion, clear indicators of the quality of care provided to the elderly in this respect [123]. These would be the most important indicators, in our opinion. But, if possible, some more could be included, as we will see below.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-3793562.- The rapid classification of residents, based on their COVID history and diagnostic tests, allows these institutions to create separate areas and circuits for \"positive\" persons who have overcome the disease or have evidence of disease activity [134]. 3.- Adequate allocation of staff, particularly - cination, allowed, in these separate units, to assign to a par - ticular caregiver staff, those unvaccinated and who had not passed the disease. Prior to vaccination, in non-COVID patient areas, it was appropriate to place passed the be an effective for the of a full 14 days after diagnosis of COVID-19 although it is possible that shorter times may be equally kept in mind that prolonged isolation predisposes residents to greater physical and mental deconditioning. 6.- Actions on personnel It is very important to work with caregivers in nursing homes, given that during the COVID pandemic stress consistent procedures handling different situations. The recommendations of the Japanese Geriatric Society are interesting in this regard [139]. Conclusion The parameters that can best indicate the situation of COVID-19 and its prevention in nursing homes are, in WHAT ARE THE PARAMETERS ON SARS-COV-2 INFECTION STATUS THAT SHOULD BE AVAILABLE IN HOMES? is not the purpose of this discussion to insist on the ter - rible impact that COVID has had on the elderly population and particularly among those living in nursing homes but to estab - lish what should be the program of action for nursing home authorities to prevent diseases such as COVID-19 and its easy transmission among residents. The challenges that the COVID-19 pandemic has posed to LTCF have been analyzed Giri et al [131] a of publications on the subject. They retrieved 348 articles, of which 76 were included in the thematic review. Eight articles referred to (e.g., availability of personal protective equip - ment, health and social care policies in place). The papers also ex - in nursing renovation, and modification of nursing home facilities for COVID-19 control of future public health emergencies. [132]. Among the measures that deserve special mention are: 1.- The massive use of diagnostic tests that has made it possible to identify a high proportion of asymptomatic or ol - igosymptomatic and isolation Indicators elderly to the nursing home Serology against A, B and C, VZV, SARS-CoV-2 Previous year's vaccination status each patient VZV vaccine registry Annually throughout the residence Influenza cases in the LTCF Cases of RSV in the residence Cases of Zoster in the residence Visits to the emergency department for upper respiratory tract infections Percentage of staff, interns and visiting received flu vaccine Percentage of term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379357to have an advance directives document to know the patient's desire to escalate treatment, referral to hospital, intubation or others. These data should be recorded in the clinical history to be taken account in decision management of pneumonia. Among the infection management and evolution indica - tors, three related to antibiotic treatment and oxygen therapy stand out. In relation to the evolution of the respiratory infec - tion, a universal indicator in the management of pneumonia is the use of antibiotics in the first 8 hours after the diagnosis of pneumonia. This is based when are started in the first 8 hours from diagnosis. For this reason, in the various SEPAR regulations [142] in a consensus elderly [143] is a universal and indi among those nursing homes. Simultaneously, the measurement of O2 saturation to de - termine the need for oxygen therapy and its subsequent pre - scription and delivery is included as an indicator of quality of care. If it is indicated and not prescribed, the reason for this should be indicated in the clinical history, since it may be due to the patient's decision. The third indicator for assessing the evolution is the need for transfer to hospital due to worsening and the need for therapeutic escalation, expressed as a percentage of the total infections. There are some programs developed specifically in nursing homes in the USA that as an indicator the reduction of hospitalization of patients to enhance treatment in the nursing home. This program called INTERACT (Intervention to reduce acute care transfer) has also been analyzed to determine its safety, given that it could cause complications or have adverse this on patients [144]. The last indicator of evolution and management is the change from intravenous to oral medication when clinical stabil - ity occurs, as long as there is capacity for oral intake. Clinical sta - bility is possibly the best indicator of good therapeutic response our opinion, the following: 1.- Evolution of the percentages of residents and staff vaccinated against COVID-19. 2.- Number of new cases detected each month in both and staff those occurring in vaccinated and and outbreaks of infection. 4.- Last date of revision and update of protocols for prevention and management of COVID-19. IN NURSING HOMES, WHAT ARE THE BEST INDICATORS OF THE EVOLUTION OF BACTERIAL RESPIRATORY INFECTION? Since viral infection and its indicators have already been discussed in other sections, we will focus on pneumonia as a quality parameter to be monitored in nursing homes. In (CAP), which expression, quality of care indicators identify and measure care that is associated either with a better prognosis of the process or with a better use of treatments. Most indica - tors have been described in hospitalized patients and in pop nursing for of Vulnerable Elders) expert group, pneumonia is one of the target processes for defining indicators and im - plementing quality of care [140,141]. In these indicators, they exclude group of patients with advanced cognitive impair - ment or with The indicators selected in pneumonia and/or influenza by this group are in total. the elderly [105], There are few that the impact qual - ity indicators on pneumonia care in nursing homes. In people with advanced dementia, mortality is very high despite the use of antibiotics, and even if life is prolonged, it may be only in days, lengthening the dying process. As a starting requirement, in nursing homes, it is essential Management Indicators pneumonia process in nursing homes for the elderlyInfection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. seniors frequently [150, of publications on outbreaks of enteric infections in nurs - ing homes, the publications of 75 outbreaks are used for a me - ta-analysis. Sixty-nine percent of the outbreaks were associated with viral agents and 31% with bacterial agents. Transmission was mainly foodborne (52%) for those of bacterial origin and person-to-person (71%) for viral outbreaks. Norovirus infection was associated with 58% of hospitalizations but with the highest mortality, however, were enteric infections caused by control measures for these outbreaks are mainly general and food hygiene measures but none of the 75 published outbreak reports in proton pump inhibitors [152-154]. The elderly are a recognized risk group for CDI and outbreaks of CDI in institutions for the elderly are fol - low-up of gastrointestinal tract (GTI) in this popula are the following: 1.- Incidence density of diarrhea in the institution (sum of patient days with diarrhea versus total daily stays). 2.- Evolution the number outbreaks of - tion episodes of C. difficile infection. 4.- Days of treatment with oral antibiotics and fluoro - quinolones per 1,000 stays in the institution. Conclusion Gastrointestinal infections can cause outbreaks in nurs - ing homes. We believe that it is necessary to have specific protocols for their prevention and management. The most elementary indicators of these processes seem to us to FIGURES? Urinary Tract Infection (UTI) accounts for 49% of all in -and good evolution. Therefore, in daily practice, among other things [142]. In the published guidelines on CAP, it is contemplated that if the patient has a temperature less than or equal to 37.2\u00baC in the last 48-72 hours and does not have more than one instability criterion, the antibi - otic regimen can be terminated. In general, in the use of antibi - otics, more days than of such as CDI and others. components hospitalized for It should be elderly with multiple pathologies, stability can be delayed until day 5-7 without this meaning that there is a poor evolution. In fact, a publication on people living in nursing homes shows that up to 57% achieve clinical stability within 5 days to consider each baseline, the cut-off point baseline saturation and not necessarily to normal saturation. In the same way, the level of consciousness must be assessed with reference to the previous to terms hospitalization or mortality stand out. Conclusion Nursing homes should have figures on the evolution of the incidence density of pneumonia in the population they serve. proportion cases with treatment within 8 hours of diag - nosis, the time to clinical stabilization, the duration of antimicrobial treatment and the time to switch to oral treatment should also be > level care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp - ganisms. SHOULD THERE BE REGISTRY TO TRACK PRESSURE ULCERS? In a recent systematic review that included 17 valid stud - ies, the frequency of pressure ulcers is estimated very varia - bly in different nations. Prevalence rates ranged from 3.4 to 32.4% although the in different countries are not explained by methodological differences and data from many developed nations are missing [172]. In a study of more than 700 nursing homes in Japan, the prevalence of pressure ulcers was and the monthly inci - dence was 1.9% [173] and in the United States in a sample of 2,936,146 residents in LTCF had stage 2, 3 or 4 pressure ulcers in 8.4% and deep tissue infections in 1.7% [174]. We are therefore talking admission, quantification and classification of pressure ulcers, a management manual with periodic re - views [176]. It is necessary to have the so-called \"minimum - ta set\" (MDS) to account for the such Ulcer Scale or RESVECH 2.0 [177-182] For all these reasons, we believe that the set of parame - ters aimed at monitoring the problem of pressure ulcers as a predisposing element to skin and soft tissue infection should include the evaluation of the risk both on admission and periodically, of and their categorization, and the verification of the periodic review of a document for their prevention and management. In addition, episodes of skin and soft tissue infections mentioned homes include the classification of residents according to the risk of pressure ulcers, the evolution of the preva - lence of pressure ulcers and their classification by sever - ity. It is also necessary to record the number of episodes of skin and soft tissue infections over time and evidence of the periodic review of written protocols for prevention and treatment of pressure ulcers.fections in nursing homes and its incidence is estimated to be around 1 episode per 1000 stays in studies in Austria [163] and Germany [164]. must in women [60,108]. Urinary catheter-associated UTI is a common cause of sepsis, admission and antimi - crobial - teriuria is 100% and the incidence of symptomatic UTI is es - timated at 3-7 episodes per 1,000 catheterization days [166, 168]. Symptomatic UTI, defined as the presence of fever not attributable to another cause, has been estimated at 6 to 11 episodes per 1,000 catheterization days in institutionalized el - derly people [169]. In this regard, it is important to define urinary tract infection as the growth in culture of 103 CFU/mL of uropathogenic bac - teria in the presence of symptoms or signs consistent with urinary tract infection with no syndrome. trolled studies measuring the efficacy to bladder catheterization. when soon as possible. Intermittent catheterization may reduce the risk of bacteriuria, and is associated with a lower risk of complications and bacteremia [108]. For the control of UTI in of increase incidence or an infectious outbreak. The indices we suggest to monitor this process in nursing homes could be the following: 1.- Proportion procedures. 1000 Proportion of episodes of UTI caused by MDR. Conclusion: homes should be tracked by indices such Infection control long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379360Conclusion We recommend the recording caused by multidrug-resistant microorganisms (MDR) and not the systematic search for colonization by these microorganisms, which should only be carried out as part of actions derived from specific problems. This recommendation is due to that the evidence is currently insufficient to provide recommendations patients colonized with MDR. SHOULD THERE BE A USE OF ANTIMICROBIAL AGENTS IN NURSING HOMES? Improving the use of any healthcare set - ting (human and veterinary) is a national priority, and this ap - plies to all settings, residential and sometimes inappropri - ate and, as a pharmaceutical group, they are the most pre - scribed in a residential facility. The facilities have a policy on anti - biotic use (PROA program), for which the CDC has developed a program focused on 7 key elements [196]: - Commitment of the center to carry out antibiotic policy program. - Responsible for specific training. Antibiotic Periodic reports of results to prescribers and nurses. - Training program. The approach to the use of ATB in institutionalized set - tings is not an exclusively local problem; it must be understood in territorial terms. The exchange of patients and, therefore, of the microbiota means that the resistance maps of the centers must be drawn up according to the resistance profiles a specific territory. For infection control in residential centers, there are series of safe practices that should be \"mandatory\", such as the use of gloves, hand hygiene (with its 5 moments) and the occlusion of wounds or ulcers. In addition to these practices, there are measures control and prevent the spread of MDRs use system ATB prescribing and administration BY problem of growing impor - tance that is no longer limited to al. recently [188] showing the prevalence of colonization by different MDRs is highly variable from one continent to another. O'Fallon et al. conducted a study with active search for MDRs in nursing home residents and found that 22.8%, environmental sam - cultured immunodeficiencies, mobility and transfers between residence lead to an increased of healthcare-associated infections and, carrier status [164,188,190]. A very important and modifiable risk factor is the high use of antimicrobials during the year in the institution. In addition to the morbidity-mortality aspects, a European study has recently that pa - with MDR infection estimated at an average of 12,682 euros per case (ranging from 2,449 to 153,263 euros per episode). In this study, the mean duration per case of MDR infection in nursing homes was 163.3 days [191]. In general, the literature estimates that the success of decolo - nization measures in nursing homes is very low [192]. The reasons given are, on the one hand, poor health conditions of elderly resi - dents combined with poor compliance and, on the other hand, lack of hygienic knowledge of nursing staff. In 2019, the able to find a firm recommendation on the pa that should be systematically obtained to correctly moni this problem, nor on the impact that obtaining them has on its control. Therefore, our current recommendation does not require a systematic search for MDR colonization in institutions for the care of the elderly. However, we believe it is advisable to record infections caused by MDR microorganisms and latter case it is not genuinely an MDR.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. \"telecounselor\" to be very necessary, who should be a professional with ex - tensive training in geriatrics and infectious diseases, reporting to the territorial Health Services, who can act by stimulating and advising on valuable practices, lead - ing-implementing PROA policies in his her area of reference. Given the great variability among of pos - sible outbreaks of infections and the training programs for professionals. IS FEVER A GOOD MARKER OF INFECTION IN THE ELDERLY, AND ARE DAYS WITH FEVER PER YEAR A PARAMETER TO BE MEASURED? Fever, whether present or absent, is not a good marker of infection in the elderly if it is not accompanied by other values. Up to 30% of older adults with active bacterial or viral infec - tions do not have fever [198,199]. Likewise, the presence of fever is not an exclusive marker of infection, as elevated after excessive sun expo - sure, as in the case of heat stroke [198,199]. Given the unspecificity of fever as a symptom caused by multiple conditions, fever days per year is not a useful param - eter in relation to the presence of infections [200]. On the oth - er hand, the number of proven annual infections is important (those for which there is microbiological evidence as well as clinical compatibility). In this case, in is possible to implement a non-pharmacological prophylaxis or, in case of of the previous one, also pharmacological prophylaxis. Conclusion Fever not a good marker of infection in the older adult as it is neither sufficiently sensitive nor sufficiently specific for the systematic recording or analysis pre - profiles. But more important than having or not hav - ing such a registry is the development of a global program on infection control in the centers. This program, if coordinated on a territorial basis, is much better, since the resistance pro - files are linked to a territory and to the reference hospitals of the Health Area. In the implementation of these programs, it can be use - ful to take as a reference the recommendations of the 7 key points elaborated by the CDC (Centers of Disease Control) for later the question of whether there should be a registry on the use of ATB in nursing homes, the answer is yes, but especially within the framework of a global program on the rational use of antibiotics and coordinated with the poli - cies and resistance maps of the territory. Conclusion The consumption of antimicrobials in a nursing home a quality indicator. The denominator to be used can be the 1,000 days of stay and the numerator can be given in total Defined Daily Doses and of the large groups of antibiotics. IS THERE A NEED FOR A \"TELE-ADVISOR\" WITH EXPERTISE IN INFECTION CONTROL IN THE LTCF? WHAT HIS/HER JOB BE? we residential centers from a territorial perspective, which, in our country, is articulated around the territorial PROA programs. This \"tele - counselor\" should play a key role in leading and validating the treatment and infection control programs in the residential centers in his or her area of reference. His task would be to serve as a link between the residen - tial centers and the reference hospital of the territory, to elab - orate and validate the resistance maps of frequent in most infections (mainly and cutaneous). - Protocolization of the prescription. Analysis of action plans. - Control of the resistance profile of the center and prepa - ration of the resistance map of the Health Area. - PROA. - Validate and collaborate in the training program of the professionals of each center. - Monitor number of UTIs and most common - Monitor bronchoaspirations. Establish treatment protocols. care for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp of infection in various the need for maintenance of antimicrobial therapy. WHO SHOULD SIT AT A CONSENSUS TABLE TO ELABORATE A PROGRAM SUCH AS THE ONE WE ARE DISCUSSING? Infection prevention and control should be seen as a effort in which everyone, representatives of institutions and organizations, the scientific and medical community, residen - tial centers and their direct and personnel, as well as the patient himself, should take part. The public administration is key not only in its regulatory role and as guarantor of the protection and safety of citizens and, in particular, of the most vulnerable groups, but also in the monitoring of regulatory compliance. Its role in the dis - semination of guidelines, health recommendations and rigor - ous information focused on prevention and action in the event of infection is also relevant. On the other hand, the role is fundamental. and physiotherapists performing of the patient's condition and the special care that person In and workers are knowledgeable about the patient's situation, the person's environment in routine ger - iatric care and in any type of health or residential center. The management of the centers should be represented to ensure that safety and protection protocols are applied by all staff, both direct and indirect care (kitchen staff, cleaning, main - tenance, etc.). In this sense, it is necessary that information is disseminated to all levels of the organization and that all personnel working in the facilities, as well as other personnel who may have access to the center, are aware of and apply measures to guarantee the protection of the resident and the rest of the personnel. Likewise, it is necessary to provide these personnel necessary resources for of co-responsibility of the patient and his/her environment in this area is essential. It is necessary to know the doubts and barriers they face in order to work on a pre - ventive program that really meets their needs and is effective. It is essential to very useful in in - creasing compliance with rates [201,202]. A checklist is a tool assist in the work; it generally con - sists of a list of tasks that when performed are verified with a check following positive indicators: it improves quality standards and the use good practices, allows critical information to be condensed, helps errors of omission It has it is time-con to avoid compromising work performance. The order of workflow and routine established in resident care. For its implementation, it is necessary to carry out a series of programs in the organi - zational culture of the institution: an educational and train - ing plan for users of the checklist, support for be person or persons responsible for the infection plan of the residential center [203]. The \"check list\" can be focused on individual patients but it can also be done periodically with the resources of the whole institution. The one dedicated to assessing the situation of in hand - vice closest to the patient's bed. [114,204,205]. The presence of endovascular lines and the question of the need to maintain them. The presence of bladder catheters or other urinary drain - age devices and the question of the need to maintain them. The existence of tachypnea or of skin and soft tissue infections. Administration of antimicrobials within the last 24 h. Recent the patient's alertness or carry it out facilitates their incorpo - tasks facilities, we recommend that a daily check of some items be performed on each hygiene, the existence and need for maintenance of invasive pro - cedures such as IV or urinary catheters, and the presence Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter taken made public. infections in these centers should also be the are mostly privately managed 0.7% an of 2.5% of GDP in the EU-8), any infection control program should be ac - companied by the corresponding economic report to prevent centers from to implement it adequately for economic reasons. In addition to the health authorities in the establishment of plans and their monitoring and follow-up, the involvement of hospital reference services and pharmacy services is very important for the control of an adequate use of antibiotics in this population. It is also necessary to be very strict in monitoring schedule in leaving its services. Patient organizations should be informed of the estab - lishment and monitoring of the control plan, of the incidents in its development, of the existence of nosocomial infection outbreaks and of the measures adopted during visits to these centers to minimize the design of the plan should be technical. Conclusion The initiative for the establishment of nosocomial in - fection control plans in nursing homes is a responsibility of the health authorities. The results of the control pa - rameters should be in the public domain. WHAT CAN BE APPLIED FROM ALL THIS TO THE ELDERLY LIVING AT HOME? The prevention of infection in the elderly living in their own homes, although not primarily the subject that concerns us, is also an aspect of the utmost interest. It has many points in common with what has been discussed for nursing homes, but also differential aspects. In addition, the place of residence of the elderly is variable and there are often changes of resi - dence from their own home to long-stay residences and vice versa. In view of the need to decide how to apply these meas - ures in older adults living in the community, we will refer to those pertinent to the prevention of infection and the reduc - tion of the risk of communicable diseases. These measures must be coordinated from the Primary Care setting and are an inseparable part of the connected fabric of our health system. Aspects such as the vaccination program and schedule for the do not merit emphasis in and readers are referred to respiratory infection, followed by urinary tract infection tissue in -their relatives and caregivers the preventive measures and, al - so, the corrective measures in the event of infection, in order to encourage the greatest sense, patients' associations become a valuable ally, acting as a chan - nel to get the information to these groups and also to convey the needs to public decision-makers involved. Finally, the media become an important source of - formation and play an educational role that cannot be over - looked. The media to shape opinion and raises awareness, as a preliminary step to a change in behavior fo - cused, in this case, on the protection of the individual. We would like to end with a reflection on the commit - ment of society in general to our elderly and also to their fam - ilies and caregivers, both formal and informal. We are experi - encing an aging population that is leading to significant in morbidity of elderly people with health conditions that require support. For this support to be effec - tive, to meet existing needs and to protect the individual, it is necessary for all the agents involved to work in and leadership. Conclusion for of associations and representatives of the administration and the media. WHO IS RESPONSIBLE in - fection control programs in nursing homes lies with the health authorities. It is the health authorities who should establish what type of registers should be up, clearly indicating their content (variables to be collected), the source of the data, the perio - dicity, the subsequent analysis and the reports to issued. It should also be established who and for establishing infection control programs in these centers. The scientific content of the program should always be established in collaboration with the country's scientific - reference ensure that the latest available all times. Patients and citizens should be informed of the record of infection in these centers, as well as the programs put in place to control it. The reporting of nosocomial infection outbreaks Infection control elderly: A reflection document on the situation in SpainE. Bouza, the monthly mor - tality rate fluctuated around 3% in men and 2% in women. Overall mortality was 34% at one year. The most represented by this work, pneumonia appears as the cause of 4% of deaths, sepsis with 3.2% and a miscella - neous of infections with In Spain, according to \"Envejecimiento en (Ageing network) report, the mortality rate due to infections in the total population over 65 years of age is about 80 /100,000 inhabitants and year and is one of the few that did not vary between 2006 and 2017 [215]. In a study carried out in public nursing homes in Madrid in 2013, and published as a doctoral thesis, all the deaths of pa - tients living in LTCF were studied, which numbered 713 out of a total of 5,956 places, representing 12%. The average length of stay of the deceased was 37 months. A total of 57.7% died in the nursing home and 42.2% in the hospital at a mean age of 88.9 years. The principal cause of death was not collected in 51% of cases and was due to pneumonia and other infectious processes in 8% of cases, followed heart failure, one year after admis - sion to a nursing home does not include among elderly dying in a direct consequence of infection is poorly known since the few studies available have been done on the basis of death certificates. The data obtained allow us to estimate that infection is a direct cause of death in at least 8 to 12% of the elderly. Pneumonia and sepsis of urinary ori - gin are the leading causes. ARE THERE DATA ON THE IMPACT OF IMPLEMENTING A PROGRAM SUCH AS THE ONE WE DISCUSS ON THE QUALITY OF LIFE AND SURVIVAL OF THE ELDERLY? In the literature it is tract infections [218,219], hand hygiene [220] travenous fluids and antimicrobial agents [221]. There is not as much evidence on the effectiveness of global programs such as those discussed in this paper, let alone their impact on quality of life and survival [222]. A systematic interventions impact changes in practices did always lead to better prognosis for residents [223]. The authors rec -fection, and in its fundamental aspects the prevention of in - fections of these organs follows the same principles as in the case of patients living in nursing homes [206,207]. A particular aspect of infection prevention in the elderly living at the possible acquisition of infections from younger members of the Another aspect is programs im - prove the use of antimicrobials (PROA programs) that exist at the community level in Primary Care in some areas, led by Family Physicians [11,28,208-212]. There is evidence that the inappropriate use of antibiotics has direct consequences on It therefore a system that elim - inates all barriers between the patient's home and the health system and leads to the use of new technologies to promote multidirectional communication for the benefit of all types of patients who at some point in their evolution or permanently will remain in the community. Conclusion Infection the elderly, the acquisition of infection from younger people in the family environment and finally PROA programs for the rationalization of the use of antibiotics at home. DO WE KNOW WHAT PROPORTION OF ELDERLY PEOPLE DIE IN NURSING HOMES AS A RESULT OF INFECTION? It is difficult to know the causes of death of patients liv - ing in nursing homes, because there is no reliable registry of them. This is a problem that exists in different countries and is described in the literature, so the data are not accurate most of the time. In the cases in which the cause of death has been evaluated, it is generally taken from death certificates, with the limitations that this implies [213]. The main study on this subject, carried out years ago in the USA, evaluated the cause of death in people over 60 years of age who lived in nursing homes and during a 15-year fol - During this period, 75% died, 2,372 of the 3,164 peo - ple included in the study, with a mean age of 81+/-8 years. The main cause of death was cardiovascular in 63% of cases, followed by infections in 21%, most of them (15% of the to - tal) sepsis of urinary origin, 65 admitted to Infection control term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379365HOW SHOULD THIS INFORMATION BE DISPLAYED AND USED THE DAILY LIFE OF A NURSING HOME? The aspects that we consider key to the knowledge of this information in the residence are: 1. The existence of an education program on infections and on the measures that work, which is periodically given to all the technical staff, geroculturists, responsible for nursing home care. 2. The involvement of the medical and care managers in the nursing home (medical director, nursing director...) in facili - tating in information, al - gorithms useful in decision making (e.g., in case of suspect - ed urinary tract infection, or in case of fever without clear focus, or in case of a COVID +.....). 4. The existence of a registry on infections and antibiotic use in each residence, monitored sectorially like the one we are discussing. 5. The inclusion of all these data among the important data to be evaluated in the quality control of the residences: a) preventive register treated in the nursing home and referred to the hospital, c) record of vaccinations d) existence of a consultant e) contingency plans for epidemics such as COVID. 6. Preparation of an annual report on infection in residences by Public Health / General Directorate of Social and Health Centers. Conclusion Information on health authorities who will anonymously distribute them widely, not only to professionals but also to family members. SHOULD THE HEALTH AUTHORITY REQUIRE A SET OF DATA LIKE THE ONES WE ARE TALKING ABOUT INTO A CENTRAL DATABASE FOR PROFESSIONAL AND PUBLIC KNOWLEDGE? Management to prevent healthcare-associated infections is a typical example of the use of one of the general principles of quality with reference and identify problems relating very initiatives (improving frequently encountered challenges (frequent staff turnover, work over - load, attitudes, lack of resources, etc.). Some of the elements that should be included are re - cultures, hand hygiene, isolation precautions, programs for residents and staff, and a good antimicrobial use control program [201]. The results of a program aimed at nursing surface clean - ing and hand hygiene have been published. It included online training, recording of surface cleaning, monitoring of hand hygiene survey of a non-significant reduction in to - tal infections (19.9%) were number of antimicrobial treatments, nor in tainly deserves great attention. A study in 184 American homes with 1,626 participants showed perform hand hygiene [130]. An - other study showed that the training and qualifications of the nosocomial infection manager in each residence was related to indicators of good antimicrobial was not inclusion in national surveillance systems, at least in the United States, did not occur until there was a financial incen - tive to report CDI episodes. The residences that signed up first were those that had accredited is clear interventions most ef - fective in improving the quality of life and survival of pa - tients in aspects training both workers and residents. It is recommended that nursing homes adhere to official con - trol and audit programs.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379366Conclusion Recording and reporting infections to a central data - base is an effective measure to increase knowledge, de - velop prevention health care and im - services provided. The data collected should be publicly available so that their analysis can benefit the center itself, but also other residential centers by promoting best care practic - es. The participation of a nursing home in an infection registry system and the quality of the data provided, as well as the impact of the prevention measures carried out, should be considered as care indicators in the evalu - ation of a nursing home. IS THE PRESS AWARE OF THIS ISSUE AND WHAT ROLE SHOULD IT PLAY? It is difficult to say whether journalists working in the me - dia are sufficiently aware of the situation in nursing homes and the control of infections that can occur in them. In our opin - ion, the answer is no, and there are several reasons for this. The first, and fundamental, is the lack of specialization prevailing in the written press, radios, televisions and web pages. The pre - vious economic and financial crisis had its consequent impact on the media. The former newsrooms, divided into areas with specialists in different subjects (economics, politics, events, religion, environment, education, health, etc.) were adapting to an environment marked by lower sales of copies and/or a drop in advertising revenues. This led to staff reductions and the emergence of the figure of the generalist journalist, a pro - fessional who knows everything, but, in reality, hardly knows anything. Thus, it is not uncommon that journalists who used to report on religion or science have had to start reporting in recent years on television, culture, entertainment, or politi - cal parties, to cite just a few examples. The result has been a worsening of the quality of reporting that has become more acute over time. Not only are the news stories on a variety of subjects worse, but also less information of their own is being produced, which pushes all the media to deal with the same subjects, reducing the information spectrum. The second rea - son for the media's neglect of information on nursing homes is purely journalistic. Information on senior centers competes for space in the society and local sections with others on reli - gion, education, environment, health, science and, sometimes, even events. We know from experience that it is very difficult to get a space with these competitors when, on top of that, it has been reduced as a consequence of the economic crisis. If there are ten news items on different topics and there are only three pages to publish them, information on residences has all the chances of being left out. And a third factor is the intrinsic nature of the information on this type of care for the elderly. What is newsworthy in the information on LTCF? There is usually little and, moreover, it is a field in which the principle of \"good news is not news\" applies: in the end, only negative units. This comparison should stimulate a careful analysis of the process of care and options for improvement [228]. In order to achieve good infection control care [229]. The implementation of a registration system and the re - porting of infections to a central database is a measure that has proven to be effective in increasing knowledge of infec - tions and establishing health policies for the control and pre - scription of antibiotics [230]. Experience in nursing homes is limited, even at the international level. Since 2012 the enrollment of residences for infection re - porting to the National Health Safety Network (NHSN) in the United States has been a national priority since the Centers for Disease Control and Prevention (CDC) put the spotlight on LTCF [231]. The assessment made by the nursing homes that have registered in the NHSN is quality of care in the centers. Other advantages that the recording and reporting of in - fections can provide are to reinforce detection of infection rate of a nursing home or nursing homes in a care area with triggering factors, to facilitate the tracking of and to promote patient safety [232]. In the United States, it was found that the benefits were perceived in centers that participated that participated on a basis. The main reason for not wanting to participate was the workload involved or the absence of a professional to take responsibility for this task [233]. Therefore, the answer to the question posed is affirmative. From our point of view, reporting makes one respon - sible for However, order for the implemen - tation to be successful, an adequate knowledge of the most prevalent infections in homes must be obtained be carry training programs for center profes - sionals and provide them with double support, to clarify doubts, consolidate learning and hospital setting there is more tradition and knowl - edge of the importance of submitting information with a \"feed-back\". It is very important for motivation that the res - idencies obtain information from the data they provide to the registry system, which should be accompanied by an analysis of the data collected and a proposal for intervention [234]. The a positive control care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): places, but the average figure is BC. The second, the so-called industrial revolution, began in England in the mid-19th century, but did not become glob - al until well into the 20th century. Between these two dates, the human species remained in a type of society that is often referred to as \"agricultural culture\". The basic occupation was the cultivation of the land, a task assigned to men. These were the so-called \"productive\" activities. The other major sector was that of \"reproductive\" activities, reserved for women, who were responsible, among other things, for raising children and caring for the elderly. This was carried out in dwellings that today are called \"patriarchal\" (think of the Catalan farmhous - es, the Galician pazos or the Castilian manor houses), in which three or even four generations coexisted, and in which there was a permanent system of care for children, the elderly and the sick. The elder, on the other hand, was the most revered member of the community, if only because he was the ori - gin, not only biologically but also economically, of the whole group. This is what sociologists usually call the \"patriarchal fam - ily\". In it there were several very significant facts. One, that there were always elders in it. Another, that they were respect - ed and revered for their own condition. And a final one, that they all considered it natural that they should be cared for in their own home. To throw them out or send them elsewhere would have been considered socially and morally execrable. Things began to change with the industrial revolution. In - dustrial warehouses appeared in the suburbs of the cities, if only because cheap labor was plentiful there. The large patri - archal dwellings gave way to apartments or city apartments, in which only one generation, or at most two, can live. This is the so-called \"nuclear family\". Since both members of the family need to work, caring for children, the elderly and the certainly not chronic ones. In such cases, the support of other institutions is necessary. In the case of illnesses, these are hospitals, which are now taking on a new role, taking on a special role. And in the case of the elderly, the solution has been found in the establishment of an extensive network of assisted living facilities. The very organization of life in modern society has made them indispensable. The old man usually looks at these institutions with a sidelong glance and with caution. He is well aware that in the traditional society, the one in which he was born, the old people's home was judged as morally and humanly negative. The old man had dedicated his life to his family, and it seemed logical that the family should not abandon him when he was no longer useful. In fact, the impossibility of caring for the el - derly in the family has generated an enormous guilt many of doing so in the of nuclear families. It is clear that families cannot be blamed. But the problem does not end there. We have organized modern society around the basic principle of the economy, efficiency. This became the news ends up being published or disseminated. Positive news has no place. The outbreak of the pandemic in March 2020 brought in - formation about nursing homes and the elderly out of ostra - cism and suddenly became front page news, especially during the first wave. In our opinion, the information disseminated about what happened in them was biased by political confron - tation and conditioned by the above, producing a of \"perfect storm\". The image that was finally transmitted to the public by the media was that the facilities were a perfect breeding ground for the spread of the virus, governed by satrap and exploitative businessmen, and left to their own devices by the health authorities. This image does not coincide with reality despite the avalanche of deaths al - legedly due to Covid-19 that occurred inside them, especial - ly during the first wave of the pandemic. The residences have been in the news again since the third wave, coinciding with the vaccination process against the SARS-CoV-2 virus that has been carried in them since December 27th. The authorities judiciously decided to start inoculating the doses in this group because it is the one with the highest case fatality rate. Spe - cifically, from June 22 to the present day, 22% of those over 90 years of age who were infected have died from Covid, a percentage which stands at 14.2% among those aged 80 to 89 years and 5.3% among those aged 70 to 79 years, according to data compiled by the Carlos III Health Institute and the Na - tional Epidemiological Surveillance Network. Conclusion The mass media has little and deficient information on the problems of infection transmission in nursing homes and on the possibilities of reducing these risks. The reasons for this are to be found in the decrease of specialized health sections in many media since more than a decade ago. WHAT ETHICAL ISSUES ARE RAISED BY THE TOPICS AND POSITIONS THAT HAVE BEEN DISCUSSED THROUGHOUT THIS MEETING? Our era is peculiar for several reasons. One of them is that people's average life expectancy has more than doubled compared to earlier times, such as the beginning of the 20th century. This phenomenon has been accompanied by others no less significant: the secondary and tertiary sectors of the economy have come to occupy most of the population, so that as the countryside was depopulated, urban concentrations became megacities. Another phenomenon of no lesser impor - tance has been the access of women to productive work. All this has created a new situation, unprecedented in the annals of human history, which no one could have foreseen and for which no one was prepared. Let us briefly recall the previous situation, which, maintained several millennia, at least from the Neolithic revolutions until the arrival of the industrial revolution. The first took place at different dates in Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, al. and therefore much more subtle and difficult to control. In the age of efficiency, the el - derly are seen as a hindrance, a burden or a burden. This leads, also unconsciously, to their discrimination. To the point that one does not know what to call an elderly person, because the terms all end up having term for old either iuvenis or These are terms that in classical Latin were applied only to living beings, and especially to people. For things other terms were used, vetus and novus. A book is new or old, etc. guiding category of human activity from the 18th century on - wards, when, with Adam Smith and his disciples, economics became a scientific discipline. And this is the criterion that governs industrial work, which revolutionized human life from that same century onwards. In industrial society, in contrast to agricultural society, the culture of efficiency dominates. Thus, inefficient people become part of the debit side, not the credit side, together with the sick, the lazy, the thugs, etc. The old, by definition, is inefficient. In modern culture, this has a very negative social and even moral connotation. It is Country Date Approach to linked to COVID-19Number of deaths in care homes linked to COVID-19Number of care home resident deaths as % of all COVID-19 deathsNumber of deaths in care homes as % of all COVID-19 deaths Australia 22/01/2021 C 909 685 75% Austria 24/01/2021 C 1,837 719 39% Finland 22/01/2021 C 644 France 20/01/2021 C + C 169 32 0 19% 0% Hungary 27/08/2020 C 612 142 23% Ireland 13/12/2020 P 2,110 1,084 51% Israel 12,774 6,529 51% New Zealand 12/01/2021 C + P 25 16 64% Norway 20/01/2021 C C 3,371 1,875 56% South Korea 07/09/2020 C 336 27 0 8% 0% Spain 22/01/2021 C + P 66,557 15/01/2021 C 88,674 29,381 21,615 33% 24% Wales (UK) 15/01/2021 C + P 5,884 1,470 1,267 25% 22% N. Ireland (UK) 15/01/2021 C + P 2,124 862 642 41% 30% Scotland (UK) 17/01/2021 C + P 7,448 3,266 2,867 44% 38% United As above C P 104,130 34,979 26,391 34% 4 term care for elderly: A reflection document on the situation in SpainE. Bouza, al. Rev Esp Quimioter 2023;36(4): 26,299 (10.56% of for nursing homes). excess was concentrated 2020-January 2021 excess mortality was similar regardless of the place provision, except in October 2020 and from February 2021 where there was lower excess mortal - ity in people with residential care than in home support\" [235]. (The total number of deaths due to COVID-19 includes only those confirmed, so the figures may be lower than the real ones, particularly in the first part of the pandemic). A certain percentage of deaths in nursing homes, not easy to quantify, is due to the biological condition of the a - sponse. But another percentage, not negligible, has to do with the lack of specialized care, sometimes with overcrowding and, finally, with the fact that in certain places they have been dis - criminated against, denying them transfer to health centers. In the case of Spain, this has even been stated in guidelines issued by some autonomous is discrimination, which ends up being mistreatment, and which is sometimes overt, but other times it is subtle and, on certain occasions, is even unknown even to the people who practice it. Hence the need to educate the popula - tion in general, and particularly those who are directly involved in nursing home care. TRANSPARENCY DISCLOSURE For transparency purposes, please note that GSK has con - tributed to the funding of with those of GSK. GSK always recommends the use of its products in accordance with the data sheet approved by the health authorities. REFERENCES 1. Department of Health and Health Protection Agency UK. Prevention and control of infection in care homes - an resource. 2013. Available at: https://assetspublishingservicegovuk/govern - ment/uploads/system/uploads/attachment_data/file/214930/Care- Home-Resource-Summary-Feb14-2013pdf . 2. Department of Health and Human resources, Agency for Helthcare Research and Quality. A Unit Guide To E. [Nosocomial infections in long- term health care facilities]. 2014;32(3):191-8. DOI: 4. al. Infections in long-term care populations in Well, in the modern world, unlike what happened in all pre - vious centuries, the old man will be called \"old\" (derived from vetus), so that \"senecto\" (derived be relegated to the category of cultism. And since old is a clearly deroga - tory term when applied to human beings, others have been sought to replace it. One is \"elder\", which comes directly from the French, and the other from the Latin antiquus. Despite ap - pearances, it also a term to things, not people. So what to call them? From this point on, the proliferation of euphemistic terms began. There has etc. Basically, we do not know what to call them properly, be - cause the terms, although at first they may seem correct, soon take on a negative meaning, which brings the specter of discrimination. It is a problem to properly discrimination the elderly. In English, term \"ageism\" has taken hold and was soon imported into our language as \"ageism\". Some, more purist, proposed as an alternative \"eta\u00edsmo\" or \"eda\u00edsmo\". The Fund\u00e9u of the Real Academia Espa\u00f1ola says that the correct term is \"edadismo\", which, however, has not yet been incorporated into the official dictionary. From all that has been said so far, it would seem natural that the mistreatment of the elderly would take place in fam - ily homes, given their precarious conditions. But the Covid-19 pandemic has shown that discrimination so subtle and that it also affects those institutionalized in assist - ed living facilities, and that those who are trained to care for and assist this type of person are not exempt from it. In this regard, the data that have just become known are very reveal - ing. Of every 100 institutionalized in nursing homes, 17 have died during the pandemic in the Community of Madrid, 14 in those of Castilla la Mancha and 11 in those of Castilla-Le\u00f3n and Extremadura. The number of deaths in homes for the el - derly is close to 30,000, according to provisional data from the Ministries of Social Rights, Health and Science and Innovation. According to IMSERSO data, during the first wave it is possible to \"estimate as plausible a range between 47% and 50% of deaths in residences with respect to the total number of deaths due to COVID-19 disease in the first wave. If this estimate is valid, and according to some preliminary interna - studies, Spanish would of of centers with re - spect the total number of COVID-19 deaths in intermediate parameters for the first wave, similar to those of the United Kingdom (45%), France (46%), Sweden (46%), Scotland (47%) or Northern Ireland (49%); and above Denmark (35%), Austria (36%), Israel (39%) or Germany (39%) [18] (Table 4). The total number of deaths in nursing homes has not yet been calculated, but according to IMSERSO data, as of May 31, 2021, \"there is a very high impact on excess mortality in people with care in nursing homes, with an excess of deaths Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379370Mayores. DGdP. Normativa sobre Centros Residenciales de Perso - nas Mayores. Consejer\u00eda de Igualdad y Bienestar Social. Junta de Andaluc\u00eda. Disponible en: https://wwwjuntadeandaluciaes/export/ drupaljda/Normativa_centros_mayorespdf . 2007:1- 78. 17. Organizaci\u00f3n Mundial de la Salud. Prevenci\u00f3n y control de infec - ciones en los centros de atenci\u00f3n de larga estancia en el contexto de la COVID-19. 2020:6. 18. Ministerio de derechos sociales y agenda 2030. Secretar\u00eda de Es - tado. Informe del grupo de trabajo de Covid en Residencias. Min - isterio de Derechos Sociales y Agenda 2030. Available at: https:// wwwmscbsgobes/ssi/imserso/docs/GTCOVID_19_RESIDENCIASpdf . 2020:115. 19. Ministerio de Sanidad Consumo y Bienestar Social. Gu\u00eda de pre - venci\u00f3n y control frente al COVID-19 en residencias de mayores y otros centros de servicios sociales de car\u00e1cter residencial. 2020. 20. Junta de Andalucia. Consejer\u00eda de Salud y Familia. Estrategia de actuaci\u00f3n en residencias de mayores y centros sociosanitarios de la consejer\u00eda de salud y familias Plan de actuaci\u00f3n en Residencias, Consejer\u00eda de Salud Junta de Andaluc\u00eda Available at: https://ww - wjuntadeandaluciaes/export/drupaljda/SyF-DocumentoPlanActua - cionResidenciaspdf . 2020:34. 21. SERGAS. Medidas de prevenci\u00f3n y control de riesgo de diseminaci\u00f3n del covid-19 y otras enfermedades infecciosas de transmisi\u00f3n por contacto (incluido gotas) en las residencias de ancianos. Availa - ble at https://coronavirussergasgal/Contidos/Documents/263/ IRR_060420_Residencias_Control_infecci%c3%b3npdf . 2020:9. 22. M\u00e9dicos sin Fronteras. Plan de contingencia para residencias. Or - ganizaci\u00f3n de servicios y estructuras.5. 23. Gobierno de Arag\u00f3n, Departamento de Sanidad y Departamento de Ciudadan\u00eda y Derechos Sociales. Gu\u00eda para la elaboraci\u00f3n del plan de contingencia destinado a centros de servicios sociales de naturaleza residencial para la atenci\u00f3n de personas mayores y personas con discapacidad. 2020. Available at: https://www. aragon.es/documents/20127/2523242/Guia+de+Plan+de+con - tingencia+residencias+240720-.pdf/c3a443b7-b0c6-07e1-ad78- c9819119405d?t=1596625169 24. World Health Organization. Prevenci\u00f3n y control de infec - ciones en los centros de atenci\u00f3n de larga estancia en el con - texto de la COVID-19 . Available at http://appswhoint/iris/bit - stream/10665/112656/1/9 7892 41507134_engpdf. 2020. 25. Ministerio de Sanidad. Documento t\u00e9cnico Recomendaciones a Residencias de Mayores y Centros Sociosanitarios para el Covid-19. Ministerio de Sanidad. 2020:9. Available at: https://www.sanidad. gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/doc - umentos/Centros_sociosanitarios.pdf 26. Men\u00e9ndez R. La Geriatr\u00eda de Enlace con residencias en la \u00e9poca de la Covid-19. Un nuevo modelo de coordinaci\u00f3n que ha llega - do para quedarse. Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. 2021;56:157-65. DOI: https://doi.org/10.1016/j.regg.2021.01.002 27. Organizaci\u00f3n M\u00e9dica Colegial. Covid-19 y las residencias y cen - tros sociosanitarios. Organizaci\u00f3n M\u00e9dica Colegial.17. Available at: https://www.cgcom.es/covid-19/informacion-y-documentacion/ comision-asesorathe DOI: 10.1111/jgs.12153 5. Chami K, Wazi\u00e8res Lejeune B, Carrat F, Piette F, et al. Guidelines for infection control in nursing homes: a Delphi Journal infection. 2011;79(1):75-89. DOI: 10.1016/j.jhin.2011.04.014 6. Tinelli M, Tiseo G, Falcone Prevention of the spread of E, of tions in Home Residents: DOI: 10.1016/j.jam - da.2021.06.031 11. Serrano M, Barcenilla F, E, Pujol M, Gudiol F. Prevalence of healthcare-associated infections in long-term care facilities Buttazzi R, Jans B, Moro ML, et al. Antimicrobial use in European long-term care facilities: results from the third point prevalence survey of healthcare-associat - ed infections and in Long-Term Care Facilities: A Call to Action. Journal of the American Medical Directors Association. 2016;17(2):183.e1- 16. DOI: 10.1016/j.jamda.2015.11.013 14. Hospital Geaneral de Granollers. Doce intervenciones PROA en Cen - tros Sociosanitarios. . Available home leaders' and experiences of resources, staff - ing and competence levels and the relation to hospital readmis - sions - a case study. BMC health services research. 2018;18(1):955. DOI: 10.1186/s12913-018-3769-3 16. Junta de Andaluc\u00eda, Consejer\u00eda para la Igualdad y Bienestar Social, Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, al. Esp McGeer AJ. Prevention pneumonia in care facilities: Davidson HE, Canaday DH, Han L, Saade E, Mor V, et al. Cluster-randomized trial of adjuvanted vs. non-adjuvanted trivalent influenza vaccine in 823 U.S. nursing Clinical in - fectious diseases : an official Infectious Diseases Society of America. 2020. DOI: 10.1093/cid/ciaa1233 44. Ino H. Vaccine mandate in long-term Geron Tirado-Balaguer M, Gil-Fortu\u00f1o M, et al. Vitamin D status and la - tent tuberculosis infection: conversion in nursing homes, Spain. Int J Lung 2020;24(3):278-86. DOI: 10.5588/ijtld.19.0365 46. Khan A, Seminara Challenge in Older Nursing Home Residents: A Brief view. J Med Res. 2019;11(6):385-90. DOI: 10.14740/jocmr3763 47. Bouza E, Ancochea-Berm\u00fadez J, Campins M, Eir\u00f3s-Bouza JM, Far - gas J, Garc\u00eda Rojas A, et al. The situation of vaccines for the pre - vention of infections in adults: An opinion paper on in Spain. Rev Esp Quimioter. 2019;32(4):333-64. PMC: 6719651 48. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones de vacunaci\u00f3n para adultos y mayores 2019-2020. . Available at Morbidity COV - Nursing Homes and Long-Term Care Facilities in Vaccin 2021;17(3):673-80. DOI: 10.1080/21645515.2020.1788327 51. Kenny \u00c1, C, Byrne M. Barriers to seasonal in - fluenza uptake Boccalini et Utility of Healthcare System-Based Interventions in Im de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones para el manejo de la epidemia Covid en Residencias de Mayores. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. 2020:4. 29. Consejer\u00eda de Integraci\u00f3n Social de la Comunidad Aut\u00f3noma de Madrid. Orden 612/1990, de 6 de noviembre, por la que se desar - rolla el Decreto 91/1990, de 26 de octubre, relativo al R\u00e9gimen de Autorizaci\u00f3n de Servicios y Centros de Acci\u00f3n Social y Servicios Sociales. Available at http://wwwmadridorg/wleg_pub/secure/nor - mativas/contenidoNormativajsf ? 1990. 30. Spreckelsen O, Luque Ramos A, Freitag M, Hoffmann F. Influenza vaccination rates before and after admission to s40520-017-0825-5 Liu S, Champion JD. COVID outbreak after the 1st dose Weaver L, Rusyniak D, Blackburn J. Willing - ness of Long-Term Care Staff to Receive a COVID-19 Vaccine: A Single State Survey. Journal of the American Geriatrics Society. 2021;69(3):593-9. DOI: 10.1111/jgs.17022 33. Salmer\u00f3n R\u00edos S, Mas Romero M, Cort\u00e9s Zamora EB, Tabernero Sa - huquillo MT, Romero Rizos L, S\u00e1nchez-Jurado PM, et al. Immuno - genicity of the in frail or disabled nursing residents: COVID-A DOI: Kosami K, Sasaki K, Kimura Y, et al. Association between length of residence and prevalence of MRSA HJ, Blane B, Brennan G, Morris D, et al. Transmission of methicillin-resistant Staphylococcus aureus DM, Boehm S, Das S, Patel PA, O'Brien J, Hines C, et al. Impact of Detection, Education, Research and Decolonization methicillin-re colonization and transmission at 3 journal of infection control. 2014;42(1):60-2. DOI: 10.1016/j.ajic.2013.06.004Infection control in long term care institutions for elderly: A reflection document on the situation in SpainE. Esp Quimioter 2023;36(4): 2014;174(10):1660-7. 10.1001/jamainternmed.2014.3918 65. Dufour D, Mitchell SL. Survival After Suspected Urinary Tract Infection in Individuals with American Geriatrics Society. 2015;63(12):2472-7. DOI: 10.1111/jgs.13833 66. Monette C, Boivin JF, Sourial N, nursing home residents? long-term facility urinary tract infections in long-term Home Infection Prevention and Control Programs From 2014 to 2018. Journal of the American Medical Directors Associa - a Novel Method: Wisconsin, 20162019. Jour - nal of the American Medical Directors Association. 2020;21(1):29- 33. DOI: 10.1016/j.jamda.2019.09.003 75. Childs A, Joyce NR, McConeghy KW, van Aalst R, N, Pham B, Cormack GV, et al. Preventing the transmission of COVID-19 and 53. Tan HY, Lai E, Kunasekaran M, Chughtai AA, Trent M, Poulos et al. and of TI, Ogarek J, Gozalo P, Zhang T, Mor V, Davidson HE, et al. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season. Asso ciation. for workers who care for people aged 60 or older R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV- 19 and against SARS-CoV-2 care facilities 2021;2(5):100264. DOI: 10.1016/j.xcrm.2021.100264 58. Mor V, Gutman R, Yang X, White EM, McConeghy KW, Feifer RA, et al. Short-term impact the American Geriatrics 10.1111/jgs.17176 59. Matthews A, Hooton TM. Infectious Diseases Society of and asymptomatic bacteriuria 61. Loeb Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, et al. Development of minimum criteria for the initiation of anti - biotics in residents of long-term-care facilities: results of a con epidemiology. 2001;22(2):120-4. Juthani-Mehta Lohfeld McGeer A, Simor A, Stevenson K, et al. Effect of multifaceted JL, Habtemariam D, Kiely management in home residents with advanced dementia. JAMA internal med -Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-37937389. Dey P, Halder S, Collins Promoting care workers: a randomized controlled trial. Journal of public health medicine. 2001;23(4):346- 8. DOI: 10.1093/pubmed/23.4.346 90. Lynch RM, Goring R. Practical to Improve Air Flow in Long-Term Care Resident Rooms to Reduce COVID-19 Infec - tion Risk. Journal of the American Medical Directors 2020;21(7):893-4. DOI: 10.1016/j.jamda.2020.04.001 91. Reddy M, Heidarinejad M, B, Adequate in - door air quality in nursing homes: medical need. Sci Total Environ. 2021;765:144273. DOI: 10.1016/j.scitotenv.2020.144273 92. Barker KA, Whitney EA, Blake S, Berkelman RL. A Review of Guide - lines for the Primary Prevention of Legionellosis in Long-Term Care Facilities. Association. 2015;16(10):832-6. DOI: 10.1016/j.jamda.2015.05.015 93. Nisbet LC, Cobbledick AM, Smith TE, Bryant PA, Lawrence J. Op - portunistic influenza vaccination in the home: broadening access in isolated times. Arch Dis Child. 2020. 10.1136/archdis - child-2020-320273 94. Frentzel E, Jump RLP, Archbald-Pannone Nace DA, Schweon SJ, Gaur S, et al. Recommendations for Mandatory Influenza From 2020;21(1):25-8.e2. DOI: 10.1016/j.jamda.2019.11.008 95. Men\u00e9ndez Colino R, Merello de Miguel A, Argentina F, Barcons Marqu\u00e9s M, Chaparro Jim\u00e9nez B, L\u00f3pez Hern\u00e1ndez P, et al. [Evolu - tion of COVID-19 at nursing homes from the second wave to vac - cination. Description of a coordination program between Primary Care, Geriatrics and Public Health.]. Rev Esp Salud Publica. 2021;95. 96. McConaghy M, Sartaj M, Conway BR, Aldeyab MA. An assessment of the impact of the vaccination program on coronavirus disease 2019 (COVID-19) outbreaks in care homes in Northern of amanta - dine chemoprophylaxis on severity of outbreaks in JR, Gaglani M, Reis M, Zimmerman RK, et al. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and - ing care: a rapid DC, coronavirus dis - ease 2019 (COVID-19) outbreaks in long-term care homes: A proto - col for room moving cohorting. control and - ities and the Coronavirus Epidemic: Practical Guidelines for a Pop - ulation at Highest Risk. Journal of the American Medical Directors Association. 2020;21(5):569-71. DOI: 10.1016/j.jamda.2020.03.004 80. Bosco E, van Aalst R, McConeghy KW, Silva J, Moyo P, Eliot MN, et al. Estimated Cardiorespiratory to metapneumovirus a long-term Topinkova E, Richter T, Denkinger M, et al. Influenza and pneumococcal vaccination in older adults living in nursing home: a survival analysis on the shelter study. Eur J Public Health. 2017;27(6):1016-20. DOI: 10.1093/eurpub/ckx150 83. Black CL, Williams WW, Arbeloa I, Kordic N, Yang L, MaCurdy T, et Trends in Influenza and Pneumococcal Vaccination Among US Nursing Home Residents, 2006-2014. Journal can Medical Directors Association. 2017;18(8):735.e1-.e14. DOI: 10.1016/j.jamda.2017.05.002 84. Omura T, Matsuyama M, Nishioka S, Sagawa S, Seto M, Naoe M. As - sociation Between the Swallowing Reflex and the Incidence S, PP, Leoni E. Plan for the control of Legionel - la infections in long-term 10.1016/j.ijheh.2011.08.007 86. Machado M, Valerio M, \u00c1lvarez-Ur\u00eda A, Olmedo M, Veintimilla C, Padilla B, et al. Invasive pulmonary aspergillosis in DOI: 10.1111/myc.13213 87. Guinea J, Torres-Narbona M, Gij\u00f3n P, Mu\u00f1oz P, Pozo F, Pel\u00e1ez T, et al. Infectious Guidelines Review in Health Care. Geneva: Health Organization Copyright \u00a9 World Health Organization 2014.; 2014.Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379374Braekeveld P, Pathirannehelage S, McGov - ern A, Gatenby P, et al. Association between glycaemic control and common infections in people with Type 2 diabetes: a soft infections in rheumatoid patients hospital epidemiology. Ellis MW, Tribble DR, et al. Opportunities and Obstacles in the Prevention of Skin de Andaluc\u00eda. Secreatar\u00eda Genral de Salud P\u00fablica y Consu - mo. Direcci\u00f3n General de Salud P\u00fablica y Ordenaci\u00f3n Farmac\u00e9utica. Servicio de Vigilancia y Salud Laboral. Recomendaciones para la prevenci\u00f3n de la transmisi\u00f3n de microorganismos multirresistentes durante la atenci\u00f3n a residentes colonizados/infectados en centros residenciales. 2017:75. 120. Ye C, Zhu W, Yu J, Li Z, Fu Y, Lan Y, et al. Viral pathogens among elderly Kestler M, Mu\u00f1oz P, Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other CH, target conditions for of care improve - ment in vulnerable older adults. 10.1111/j.1532-5415.2000. Dolar V, Gucwa AL. A comparative analysis of vaccine ad - SB, Polivka-West 101. Havers FP, Campbell AP, Uyeki TM, Fry AM. Commentary: A His - torical Review of Centers for Disease Control and Prevention An tiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe The Journal J, Whitley RJ, S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis KA, Plevneshi A, A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza hos - America. 2007;45(12):1568-75. DOI: 10.1086/523584 104. Bouza E, Brenes FJ, D\u00edez Domingo J, Eiros Bouza JM, Gonz\u00e1lez J, Gracia D, et al. The situation of infection in the elderly in Spain: espanola de - : publicacion oficial de apia. DOI: for pneumococcal Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococ - cal pneumonia in adults. The New England journal 10.1056/NEJMoa1408544 Jump on Approach to Diagnosis and Management. of American I, Kanti V, et al. and factors 10.12968/jowc.2020.29.Sup7.S16 Abizanda Pea. Vacunaci\u00f3n y pol\u00edticas de prevenci\u00f3n y manjeo de infecciones en el medio residencial. Tratada de medicina geri\u00e1trica 2nd Edition. Fundamentos de la atenci\u00f3n sanitaria a los mayores. Elsevier Espa\u00f1a 2020:1019-27. 113. Maelegheer K, Dumitrescu I, Verpaelst N, Masson H, Broucke C, Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Rev Esp Quimioter 2023;36(4): 346-379375ukowicz M, et al. Mental Health Impact - ic on Long-Term Care Facility Personnel in of Directors 2020;21(11):1576-7. DOI: 10.1016/j.jamda.2020.09.020 139. Kuzuya Y, Katsuya T, Nishikawa M, Hirahara S, et Society statement \"recom - mendations for medical and long- term care during the D, Rubenstein L, Young R, Schnelle J, Roth C, et al. Quality indicators for the management of medical conditions in nursing home residents. Journal of the American Medical Di - rectors Association. 2005;6(3 Suppl):S36-48. DOI: 10.1016/j.jam - da.2005.03.022 Solomon D, Rubenstein L, Young R, Schnelle J, Roth C, et al. Quality indicators for the management of medical condi - tions in nursing home residents. Journal of the American Medi - cal Directors Association. 2004;5(5):297-309. DOI: 10.1097/01. Jam.0000136960.25327.61 142. Men\u00e9ndez R, Torres A, Aspa J, Capalastegui A, Prat C, Rodr\u00edguez de Castro F. Neumon\u00eda adquirida en la comunidad. Normativa de la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Ac - tualizaci\u00f3n Mart\u00edn-S\u00e1nchez FJ, Llinares R, Mujal A, Navas E, et al. Guidelines for the management of commu - nity-acquired pneumonia in the elderly patient. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2014;27(1):69-86. 144. Tappen RM, Newman D, Huckfeldt P, Yang Z, Engstrom G, Wolf DG, Medical Directors Association. 2018;19(10):907- 13.e1. DOI: 10.1016/j.jamda.2018.06.017 145. Durazzo M, Campion D, Fagoonee S, Pellicano R. Gastrointestinal tract disorders in the elderly. Minerva Med. 2017;108(6):575-91. DOI: 10.23736/s0026-4806.17.05417-9 146. DE, Yang Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Ad - vice From the American Gastroenterological Association. Gastroen - outbreak of acute gastroenteritis associated with group A Rotavirus outbreaks and their impact in elderly care facilities: a of the literature. Age and ageing. 2010;39(3):299-305. 10.1093/L, et al. Accuracy of in Unit - AM. Improving care for nursing home-acquired pneumonia in a man - aged care environment. The American journal of managed care. 2004;10(10):681-6. Daugherty JD, journals and medical 130. Trautner BW, Greene MT, Krein AJ, et Eur Geriatr Med. 2021:1-10. DOI: 10.1007/s41999-021-00531-2 132. Wang Z. Use the Environment to Prevent and Control COVID-19 in Senior-Living Facilities: An Analysis Rolland Y, Schols J, Cherubini A, Miot S, O'Neill D, et al. 2020 to Collison Walker Huisingh-Scheetz J, S, al. Three-Tiered COVID-19 Cohorting Strategy and Implications for Memory-Care. J. The impact of Cov - id-19-related distancing on the well-being of nursing home resi - dents and their family 10.1016/j.ijnsa.2021.100031 McGilton Gordon A, Chu CH, Z\u00fa\u00f1iga F, Sanchez MG, et al. Uncovering the Devaluation of Nursing Home Staff Dur - ing COVID-19: Are We Fuelling the Next Health Care Crisis? Journal of the American Medical Directors Association. 2020;21(7):962-5. DOI: 138. E, Mazurek J, Ci -Infection control long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. R, et al. Prospective Surveillance of Healthcare-Associated Infections in Residents in Four Long-Term An - surveillance for healthcare-associated infections in Ger - man nursing residents. The Journal of hospital infection. 2005;60(1):46-50. Jackson MM, Nicol - le Definitions of infection for surveillance in long-term care DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomat - ic Bacteriuria: 2019 Update by the Infectious Diseases of America. of America. 2019;68(10):1611-5. 10.1093/cid/ciz021 168. urinary infections reported National Healthcare Safety Network, January 2010 through July 2018. American journal of infection control. 2020;48(2):207- 11. DOI: 10.1016/j.ajic.2019.06.006 171. Hooton TM, Cardenas Geerlings SE, Rice JC, et treatment catheter-associated infection International Clinical America. 2010;50(5):625-63. 10.1086/650482 172. Anthony D, Alosoumi D, Safari R. Prevalence of pressure ulcers in long-term a L, Garvan C, Lyon D, Stechmiller J. Risk Factors for Pressure Ulcers Including Suspected Injury in - ing Home Facility Residents: Analysis of National Minimum Data Set 3.0. Adv Wound Care. Med 151. Greig JD, MB. DOI: 10.1017/s0950268808000757 152. Bermejo Boixareu C, [Updated review Barney GR, Nelson DL, Nicholas JA, Yang H, et al. Use Clostridioides Hospi American A, Novak M, Vladarova M, Wilcox M, et al. An Outbreak of Clostridium difficile Infections - ifloxacin-Resistant PCR Ribotype 176 Genotyped as PCR Ribotype M, L, Recurrence of Clostridioides difficile Infection Elderly from Western Medicina 2020;56(9). DOI: 10.3390/medicina56090439 157. Grace E, - Endres Dotson KM, Poblete McPherson J, Lancaster C, Bass\u00e8res E, et al. Environmental transmission of Clostridioides difficile ribo - type LC, M, et al. Transmission of Clostridium difficile 10.1017/ice.2018.106 160. Mallia G, Van Toen J, Rousseau J, Jacob L, Boerlin P, Greer A, et al. Examining the of Clostridium a healthcare facility in southern Ontario, Canada. The Journal - tion. 2018;99(4):461-8. DOI: 10.1016/j.jhin.2018.01.020 161. Guh AY, Mu Y, Baggs J, Winston LG, Bamberg W, Lyons C, et journal of infection control in long term care for elderly: A reflection document on the situation in SpainE. Bouza, al. Rev Esp Multidrug-resistant gram-negative bacteria at a multidrug-re - sistant bacteria in nursing homes in Germany: a Core of Antibiotic Stewardship in Nurs - ing Homes the Safety Network. Clinical an Grahn D, 1985;33(12):859-63. DOI: 10.1111/ 200. Outzen of gerontological nursing. 2009;35(5):17-23; 10.1097/01.Asw.0000481115.78879.63 for pressure ulcers in long-term care hospitals in the Re - public Care: Pressure Ulcers, Skin Tears, and Moisture-Associated Skin Damage Data Update. Adv Skin Wound Care. 2017;30(9):415-29. 10.1097/01.Asw.0000521920.60656.03 177. Bates-Jensen D, L, Jorge J, Al-Samarrai N, et al. The minimum data set pressure ulcer indicator: does it care ulcer Thomas DR, Rodeheaver GT, Bartolucci AA, Franz RA, Sussman C, Ferrell BA, et al. Pressure ulcer scale for healing: derivation and validation of the PUSH tool. The PUSH Task Force. Adv Wound Care. 1997;10(5):96-101. 181. Sussman C. Presenting a draft pressure ulcer scale to monitor heal - ing. Adv Wound Care. 1997;10(5):92. 182. Bates-Jensen BM. The Pressure Sore Status Tool a few thousand assessments later. aureus in nursing home residents in northern Ger many. The Journal of hospital infection. 2011;78(2):108-12. DOI: 10.1016/j.jhin.2011.02.011 184. Greenland K, Rijnders Haenen A, Spalburg E, van de Kassteele J, al. Low prevalence of methicillin-resistant Staph - ylococcus aureus in DOI: 10.1111/j.1532- 5415.2011.03325.x V, Kim D, Peterson E, Dunn J, Whealon M, al. Methicillin-resistant Staphylococcus aureus (MRSA) in 10 nursing homes Infection control and hospital epidemiology. 2011;32(1):91-3. DOI: 10.1086/657637 186. Rooney O'Leary MC, Loughrey McCalmont M, Smyth B, Donaghy P, et al. Nursing homes of extended-spec - trum 10.1093/jac/dkp220 187. Murphy CR, Quan V, Kim D, Peterson E, Whealon M, Tan G, et al. Nursing home characteristics methicillin-resistant ME, al. and Risk Infection control in long term care institutions for the elderly: A reflection document on the situation in SpainE. Bouza, et al. Esp Quimioter 2023;36(4): 346-379378envejecimiento.csic.es/estqadisticas/indicadores/residencias/indez.htlm 216. Campos-Dompedro JR, JM. RC. Mortalidad en centros residenciales para mayores dependientes: estudio de variables asociadas. . Tesis doctoral T38413 Disertaci\u00f3n 2016 Available at: Universidad com - plutense de Madrid Servicio de tesis doctorales y publicaciones acad\u00e9micas https://ucmonworldcatorg/ . 2016. 217. van Dijk PT, Mehr DR, Ooms Madsen R, American Geriatrics al. A Multifaceted Antimicrobial Stewardship Program for the Treatment of Uncomplicated Residents. 219. Mody J, Krein SL, McNamara SE, Trautner BW, et DOI: - 220. Chen YH, Wu YH, Chiang HT, et al. Imple mentation a quality improvement program to enhance hand hygiene in nursing homes in Taiwan. Journal of microbiol - ogy, immunology, and infection = Wei mian M, Gjelstad S, Lindb\u00e6k A structured training pro - gram for health workers in intravenous treatment with 222. Simmons S, Schnelle J, Slagle J, Sathe NA, Stevenson D, Goodenough B, YH, Etherton-Beer C, MacAndrew M, et al. A Systematic Review of Interventions to Change Staff Care Practices in Order to Improve Resident Out - comes - ing a of an Infection Control Program in Nursing Homes: Results of a Matched Cluster Randomized Trial. the American Medical Directors 2017;18(8):707-12. 10.1016/j.jamda.2017.03.003 225. Pol - icies: A National Study. Inquiry : a journal of medical organ - National Healthcare Safety 2016;32(3):585-607. PW, Bennett G, Bradley S, Drinka P, Lautenbach E, Marx J, et al. SHEA/APIC guideline: prevention control in the control Hales B, Terblanche M, Development of med - ical checklists for improved quality of patient care. International journal for quality in health care : journal of the International So - ciety for Quality in Health Care. 2008;20(1):22-30. DOI: 10.1093/ intqhc/mzm062 204. Fuentes. V ea. Recomendaciones para la Prevenci\u00f3n de la Trans - misi\u00f3n de Microorganismos Multirresistentes durante la Atenci\u00f3n a Residentes Colonizados/Infectados en Centros Residenciales. 2017:75. 205. World Health Organization. Hand hygiene in outpatient and home- based care and long-term care facilities: a guide to the application of the WHO multimodal hand hygiene improvement strategy and the \"My Five Moments For Hand Hygiene\" approach. 2012. 206. Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Infect. 1999;14(2):173-83. 207. Torres OH, Gil E, Comas MT, Saez ME, Clotet S, Ramirez HD, et al. [Impact of B, Bielicki JA. The potential negative impact of antibiotic pack on antibiotic steward - in 10.1016/j.medmal.2016.02.001 210. JS, al. JA, - ic 2020;7(7):ofaa244. 10.1093/ofid/ofaa244 212. nursing home during 15-year follow-up. of the American Medical Directors Association. 2000;1(3):95-6. 214. Braggion M, Pellizzari M, Basso C, Girardi P, Zabeo V, Lamattina MR, et al. Overall mortality and causes of death in newly admitted DOI: 10.1007/s40520-019-01441-x 215. Envejecimiento en Red - EnR. Un perfil de las personas mayores en Espa\u00f1a, 2019 Indicadores estad\u00edsticos b\u00e1sicos. 2019:38. Available at: Infection control in long term care elderly: A reflection document on the situation in SpainE. 2019;47(1):59-64. 10.1016/j.ajic.2018.06.018 voluntary accred - homes. Rehabilitation nursing : - for surveys of Dick Bell ND, Chastain AM, et al. Self-reported National Healthcare Safety Network knowledge and enrollment: A national survey of nursing homes. American journal of control. A, Dick AW, Bell JM, et al. The expansion of National Healthcare Safety Network - ment and Lessons 2019;47(6):615-22. DOI: 10.1016/j.ajic.2019.02.005 233. Mukamel home participation in quality reporting make C, Knapp M, McDaid D, et al. COVID-19: Implications for the Support of People with Social Care Needs in England. J 2023. by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Quimioterapia doi:10.37201/req/023.2023 Rev Esp Quimioter 2023;36(4): 380-391380Reducci\u00f3n del riesgo de progresi\u00f3n en receptores de trasplantes infectados por SARS- CoV-2 tratados con anticuerpos monoclonales. RESUMEN Los receptores de trasplantes de \u00f3rganos s\u00f3lidos (TOS) presentan un alto riesgo de infecci\u00f3n por el virus SARS-CoV-2 debido al tratamiento inmunosupresor y m\u00faltiples comorbili - dades. La COVID-19 puede ser potencialmente mortal en re - ceptores de TOS, con un aumento de la probabilidad de pro - gresi\u00f3n a enfermedad grave. Este trabajo presenta una revisi\u00f3n actualizada del impacto de la COVID-19 en receptores de TOS. En los receptores de TOS no vacunados, la COVID-19 se asocia con una alta tasa de mortalidad, hospitalizaci\u00f3n, ingreso en la UCI y deterioro del injerto o rechazo. En los pacientes vacuna - dos, incluso con pauta de vacunaci\u00f3n completa, se reduce el riesgo de mortalidad, pero el curso de la COVID-19 puede con - tinuar siendo grave en funci\u00f3n del tiempo desde el trasplante, el estado neto de inmunosupresi\u00f3n y haber sufrido rechazo o disfunci\u00f3n del injerto. Los receptores de TOS presentan una baja inmunogenicidad a las vacunas de ARNm y respuesta su - b\u00f3ptima. El tratamiento con anticuerpos monoclonales (AMC) en receptores de TOS no hospitalizados con alto riesgo de en - fermedad grave, se asocia con menores tasas de hospitaliza - ci\u00f3n, visitas a urgencias, ingreso en UCI, progresi\u00f3n a enferme - dad grave y muerte. Sin embargo, se requieren nuevas vacunas y opciones terap\u00e9uticas, teniendo en cuenta la tendencia del virus SARS-CoV-2 a adaptarse y a evadir tanto la inmunidad natural como la inducida por la vacuna. Palabras clave: trasplante de \u00f3rgano s\u00f3lido, COVID-19, SARS-CoV-2, inmunosu - presi\u00f3n, vacunas, anticuerpos monoclonales, sotrovimab.Reduction in the risk of progression of y Microbiolog\u00eda Cl\u00ednica, Coordinaci\u00f3n de Trasplantes, Banco de Tejidos, Hospital Cl\u00ednico San Carlos, Hospital Cl\u00ednico Universitario San Carlos, Madrid, Spain. 2Unidad de Enfermedades Infecciosas (\u00c1rea Cl\u00ednica M\u00e9dica). Grupo de Investigaci\u00f3n de Infecci\u00f3n Grave, Instituto de In - vestigaci\u00f3n Sanitaria (IIS) La Fe, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain. 3Medical Department, GSK, Madrid, Spain. Francisco Javier Candel1 Miguel Salavert2 David Lorite Mingot3 Marta Manzano Crespo3 Paula P\u00e9rez Portero3 Cuervo Pinto3Review Article history Received: March 2023; 23 March 2023 of solid organ (SOT) are at higher risk severe the need of hospitalization, admission to the intensive care unit (ICU) and mechanical ventilatory support. This article presents an updated review of different aspects related to the outcome of COVID-19 in SOT recipients. In unvaccinated SOT recipients, COVID-19 is associated with a high mortality rate, in-patient care and ICU admission, or disease. ed SOT recipients even after full vaccination, there is a reduc - tion of the risk of mortality, but the course of COVID-19 may continue to be severe, influenced by the time from transplant, net at with lower rates of hospitalization, emergency pro and death. However, and options are required, particularly in light of the tendency of the SARS-CoV-2 virus to adapt and evade both natural and Javier Candel. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Coordinaci\u00f3n de Trasplantes, Banco de Teji - dos, Hospital Cl\u00ednico San Carlos, Hospital Cl\u00ednico Universitario San Carlos, C/ Profesor Mart\u00edn Lagos s/n, E-28040 Madrid, Spain. E-mail: franciscojavier.candel@salud.madrid.orgReduction 380-391381(kidney, liver, and heart) being transplantation a safe practice, with a low risk of transmission, regardless of the presence of symptoms at the time of procurement [8]. From another perspective, transplant recipients may be at a higher risk of infection by SARS-CoV-2 due to the use of immunosuppression, underlying comorbidities, and frequent contact with the healthcare system. However, they are al - so more likely to be diagnosed early because of a more overt symptomatology than immunocompetent subjects or due to closer follow-up at the hospital or the transplant center. In Spain, in SOT (n = 665) and hematopoietic stem cell transplant (HSCT) (n = 113) COVID-19 2020, the incidence of COVID-19 was twofold the Spanish general population [9]. The mortality rate was 27%, with age > 60 years, lung transplantation, and hospital-acquired COVID-19 as risk factors for death. the pandemic, from 20-25% a result of increased and early of SARS-CoV-2 test - ing, adherence to non-pharmaceutical interventions (face cov - ering, hand hygiene, physical distancing) to control spread implications for [8]. Although the likely to move to in SOT recipients [11-13], there are still limited data on the risk of poor out - comes and progression of SARS-CoV-2 infection, response to SOT. Therefore, - evant studies addressing these aspects is here presented. The aim review is to provide clinicians involved in organ donation evidence for an optimal approach to the care of SOT patients in daily prac - tice, in particular in reference to how COVID-19 - den, and governments' responsibilities to ensure the health and safety of their communities. The coronavirus disease 2019 (COVID-19) had also had a major impact on solid organ transplantation (SOT), specially on the mortality of these pa - tients, since they are more likely to develop severe forms of the disease as compared to the general population. This may be because they are unable to mount a robust immunity against SARS-CoV-2. Although effective treatment options the ongoing pandemic tation activities. horts of consecutive kidney, liver, lung, and heart transplants from 16% reduction activity comparing rates in 2020 and 2019 [1]. An analysis of the impact of COVID-19 pandemic on the size of US transplant waiting lists candidate listings [2]. A review of data provided by the Network of Organ comparing of kidney transplant can who noted a decline in SOT in all organ types, with living donor programs generally suspended or cur [5-7], recent evidence has also shown that there is low risk for a transplant to get antibodies on the course of the disease. Reduction 1 prospective studies which had been pub - lished in 2020 that provided clinical outcomes of COVID-19 transplant recipients (n = 1485) vs. non-transplant controls. The overall quality of the evidence, according to Newcastle-Ot - tawa Scale (NOS) ranging from 7 to 9, was moderate. SOT re - cipients were predominantly male and more to present higher risk of intensive % SOT recipients with the general population by sex, and comorbidities, 0.046). review of cohort studies, case series, case-control studies, and case reports published in 2020, 164 publications were identified with 3,451 cases of SARS-CoV-2- infected SOT recipients, in In a study of the largest database on COVID-19 in the United States (National COVID Cohort Collaborative) [16] based on SOT patients who were tested COVID-19 between Janu - ary November SOT positive test for SARS-CoV-2. The outcome in the 90 days after COVID-19 positivity was ana - lyzed. The presence of COVID-19, compared to SOT patients without COVID-19 positivity, significantly increased or death of any cause) (OR 1.92), as well as the risk of graft (OR 2.35), and graft failure Compared with all other organ types, kidney transplant recipi - had the highest graft loss. is a life-threatening disease 1,046 patients March and May 2021 showed a mortal - ity rate of (HR 1.5, 95% CI 1.5-2.2, p = 0.023). In a review of eight studies published from January 2020 to January 2021, that evaluated COVID-19 infection in 494 liv -the overall management of SOT recipients and the use of mAbs as an available treatment to reduce the risk of progression of these patients (Figure 1). It should be even though focuses on antibodies, antivirals. METHODS A narrative review was carried out to cover all the points of interest to be reflected, being these both the risk of COV - ID-19 disease progression of SOT patients when infected by SARS-CoV-2 and the use of mAbs as early treatment to avoid COVID-19 progression. The information of interest was divided into four blocks, including: 1) outcomes in unvaccinated SOT recipients, 2) response - 3) outcomes in vaccinated SOT recipients, and effect of treatment with monoclonal antibodies on the course of COV - ID-19 in SOT recipients. The literature search was conducted in MEDLINE/PubMed database (mortal*[ - Title/Abstract])). Also, (vaccin*[Title/Abstract]) was added in the search of the second and third blocks, and ((monoclonal anti - body [Title/Abstract]) OR (mab [Title/Abstract]) OR (treatment [Title/Abstract])) in the search of the fourth block. The search period ranged from June 2021 to May 2022 and was limited to articles published in English. In September 2022, the fourth block search was actualized, extending the search date to that moment. Also, relevant publications that provide key information for the aim of this review, were also allowed to be included. Hematopoie obtained from all articles in - cluded in the present review. After excluding publications with the other formats, such as editorials, comments articles, and agreement of the selected The were IN SOT RECIPIENTS In this block, three studies, a systematic review and me - ta-analysis [14], a structured review [15], and a cohort were focused on the outcomes of in SOT, whereas another three calcineurin inconsistency with re - gards to the impact of time since transplantation on vaccine response. The seroconversion after second dose of COVID-19 mRNA vaccines evaluated in a - ences ( = 0.55) were observed subgroup analysis based on the type of transplantation (kidney vs. others [heart, lung, and liver]). A 80%) (18.2% to 62%) immunosuppres - the immune response. In lung) and 200 age- and sex-matched controls [23], in which anti-receptor-binding domain (RBD) immunoglobulin IgG was measured after two doses of BNT162b2 vaccine, humoral (36% SOT vs 97.5% controls. levels to months after the first vaccine dose were increasing age (risk ratio [RR] 1.23 per decade increase), being less than 1 year from transplantation (RR 1.55), lung (RR 1.63), and kidney (RR 1.70) as type of organ transplantation with liver reference, the use of 1.54) or corticosteroids (RR 1.45) as immunosuppressive therapy, de o cancer Other studies ney receiving the second dose of a mR - NA vaccine [24]. The seroconversion rate ranged between age, high-dose corticosteroids in the last 12 months, and maintenance im -er transplant recipients, 80% required hospital admission and 17% ICU care (of which 21% required mechanical ventilation) [18]. The overall mortality rate was 17%. review admitted to the ICU ( p < 0.0001) and up to 68% in those who required mechanical and 48%, respectively. There was a higher mortality risk associated with ARDS (OR 19.59), need of ICU care (OR 13.39), mechanical ventilation (OR 3.80), and age 60 years (OR 3.90). Take home message Unvaccinated SOT recipients with COVID-19 have a sig - nificant high risk of progression against SARS-CoV-2 to con - an important related to re - jection or other major adverse events. For this section of the review, selected reports two with studies in SOT recipients [30,31] were also included to give information about the effect of a third or fourth dose. A systematic review that assessed the immunogenicity of after complete or absence of neutralizing transplantation and [31]. In further study ana - lyzed the impact of a fourth dose of vaccine, 12 months af ter primary vaccination. They included 396 kidney transplant patients (278 with three doses and 118 with four doses). The fourth dose increased the antibody titers in an independent predictor titers (p=0.030 poor response to two doses of COVID-19 mRNA corticos teroids, than 1 % of patients did not respond at all and those that did respond had lower antibody titers than other popula - vaccination by at least three doses would be desirable. 3. significantly reduce the risk of morbidity and mortality-associated with COVID-19 in SOT recipients is un - clear [33]. Relevant studies a population-based cohort study [38]. A study that linked four national registries in the United Kingdom was conducted to identify outcomes within 28 days of a SARS-CoV-2 infection in unvacci - nated SOT recipients received Pfizer-BioNTech BNT162b2 or Oxford-AstraZeneca response. In another review [25], immune response after two doses of anti-SARS-CoV-2 vaccine ranged between 11% and 48%, with longer time from transplantation, first kidney trans - plant, better kidney function, and immunosuppression re - lated to more likely to seroconvert. In a meta-analysis from subset of kidney recipients, which was - ronegativity [28]. SENCOVAC is a prospective, multicentric study of four co - horts of vaccinated patients with different status of chronic kidney disease (CKD). analysis titers), 6 have of mRNA vaccine. 118 patients received a patients among who had received a third dose of vaccine (median 125 days after second dose) were catego - rized as responders vs only 53% of responders among those with only two doses (p=0.002). However, 20% of patients did not respond after a third those [29]. After dose, patients had higher anti of kidney did not respond after two doses, third those. Thus, antigenic well to vaccine [29]. Similar results were by Kamar al. (78 kidney, 12 liver, 8 lung-heart, 3 pancreas). There were 40% of SOT patients with detectable anti SARS-CoV-2 IgG before the third dose. After the third those, this percentage increased up weeks third dose humoral response after BNT162b2 vaccination. 395 and 335 second third dose respectively. SARS-CoV-2 spike IgG antibodies were detect - ed in 49.4% of patients after two doses and 77.9% after the third dose. The rate of seroconversion was 47.5% after the third for who seronegative after second terms of overall increased to be lower in this population vs general population, for both two (54%) and three (67%) doses. However, it was notably improved with the third admin - istration [38]. Take home message The level of protection vaccination from symptomatic SARS-CoV-2 disease in the general population. A primary vaccine course of two doses appears to have a limited effect on COVID-19 and its complications, in - cluding hospitalization fatal outcome. Alternative dose, high - er doses) and modulation of immunosuppression dur - ing vaccination need to be more extensively assessed in SOT recipients. 4. EFFECT OF TREATMENT WITH MONOCLONAL ANTIBODIES ON THE COURSE OF COVID-19 IN SOT RECIPIENTS SOT recipients are the use of monoclonal (mAbs) for early treatment or of special characteristics of this population, chronic to occasionally, the age of the transplant patient. For all these main reasons, SOT recipients are at higher risk of developing severe COVID-19 with the potential need of care in the hospital including ICU admission, and ultimately to die from non-hospitalized patients with laboratory-con - firmed SARS-CoV-2 infection, who are progres sion or severe disease and/or hospitalization. It is - be started as soon as possible after a positive test and within 10 days of symptom onset. Also, mAbs implications of mAbs against SARS-CoV-2 have been recently published (fig - ure 2) [47-58]. In the particular group of SOT recipients, the use of mAbs, recommended in the outpatient management of mild-moderate COVID-19, has been associated with a low - er risk of hospitalizations, emergency department (ED) visits, need for ICU care, mechanical ventilation, and fatal outcomes. Similar benefits have been reported for PEP, treatment of SOT patients with recurrent episodes of COVID-19 and possible of the risk of testing positive (incidence risk ratio with unvaccinated patients (91.8% vs. 88.8%, p = 0.002); risk adjustment (for type of organ re - ceived, time since transplant, sex, age, ethnicity, NHS region, calendar month and, analyses, vaccinat - ed patients showed a 20% reduction in the risk of death (HR 0.80, 95% CI 0.63-1.00, p = 0.05). Older age, Black ethnicity, lung transplantation, and care location were associated with a higher risk of death. A cohort study of 449 SOT patients vaccinated with one of the two approved mRNA severe course of COV - ID-19 common small number of SOT recipients (n=15) who tested positive for COVID-19 even after their full vaccina - tion (two doses of mRNA vaccine at in 9 (60%) of them. Sev - en patients had mild COVID-19, but the remaining 8 (53.3%) required hospitalization, 7 of which had severe and 2 of them died. These findings were confirmed in a review of vaccinated SOT recipients at 17 transplant breakthrough per Centers of Disease criteria 14 days after completing all recommended vaccine doses. Of these 151 cases of breakthrough infections, 87 (57.6%) re - 9.3%. Compared general population of 101 million fully vaccinated adults in the United States through April 30, 2021, SOT recipients in this study risk breakthrough of September 19, 2021, 5,281 had received two doses of ap - proved SARS-CoV-2 vaccine [37]. There were 814 (15.4%) cases of infection. Vaccine effectiveness rates were 39% (95% CI 2-58) against infection and 40% (95% CI 0-59) against hospitalization. Within 28 days of a the vaccinated general Scottish population admitted to the hospital or dying due to COVID-19 during the same period). In the multivariate analysis, predictors of breakthrough infection following pancreas). Patients were included as for Decem - ber 2020 and were followed-up until November 2021, as the vaccine program were received three doses, with remain ents who would have been qualified for therapy but did not receive the treatment, mAbs reduced the rates of hospi - talization from 32% to 15% ( p = 0.045) and death from 13% to 0% ( p < 0.04). There were no major adverse In recipi - ents diagnosed with COVID-19 from March 2020 to April 2021, 20 (21%) of which were treated with mAbs (15 bamlanivimab, 1 bamlanivimab-etesevimab, 3 mAb not known). The endpoints were hos - pitalization or ED visits [51]. Antiviral treatment with mAbs was associated with a marked decrease in hospitalization or ED visits (15% vs. 76%, < 0.001; HR 0.216, and time-dependent analysis, age, chronic kidney disease, and Hispanic ethnicity were independent factors for hospitalization or ED visits. There were no deaths in the 20 pa - tients treated with mAb whereas there were 8 (10.7%) 75 not treated with mAbs. 4.2 Sotrovimab Several groups have reported their experiences regarding the use of sotrovimab in SOT recipients. In a report of 51 SOT patients who received (during both the In this study, patients received sotrovimab on an average of 3.5 days after the onset of symptoms and 2 days after labora - tory confirmation of SARS-CoV-2 positivity. 35% of patients in this study were vaccinated with 3 doses, and 45% had an incomplete vaccination regimen (less than 3 doses) with unvaccinated. In single-center study to moderate disease, 13 (86.7%) of which had received two or events. In another single-center prospective cohort patients infected with (51 treated with sotrovimab, of which 80% were vaccinated), it was observed that vaccination 3 doses and treatment with sotrovimab are independently protective fac - tors in the progression to severe disease. Regard - ing sotrovimab treatment, number to prevent one hospitaliza - tion was 8.5 (95% CI, 4.83 to 59.1). Once again, there were no deaths in the group patients divided to prevalent VOCs and VOIs were those before Omicron (mainly Alpha, Beta Gamma, Epsilon and Delta), and sotrovimab, including patients from Septem - ber 2021 to August when the prevalent VOCs were Delta and Omicron BA.1 and BA.2 [52-58]. data referred to ret rospective case series reports of relatively emergency use in SOT recipients. In a retrospective review from the Mayo Clinic of 73 SOT pa - tients treated with mAbs, between November 2020 ICU not related to COVID-19, no deaths, or advanced respiratory and minimal adverse events were ized, mAb in those hospitalization (median days from symptom onset reinforcing the importance of early interven - tion with these treatments. The same group of authors also re - ported data of 28 SOT recipients who presented mild-to-mod - erate COVID-19 after full vaccination (defined as two doses of mRNA vaccine; except one patient who underwent vaccination with Johnson & Johnson and 4 who received a third dose), all patients received casirivimab-imdevimab, with a me - dian time of infusion of 3 days after symptoms onset. ED visits were [48]. These results are similar to those obtained in another sin - gle-center retrospective analysis of 165 SOT recipients with no records of covid vaccination, 93 of which received mAbs (76.3% bamlanivimab 15.3% the com - parator cohort, but differences after adjusting for age did not reach statistical significance (OR 0.49, 95% CI 0.18-1.32, mAbs but unknown whether they could be attributed to mAbs therapy, COVID-19, adjustments. comparator cohort and none in the mAbs-treated cohort. In a single center retrospective review of abdominal trans - plant patients between 2023;36(4): 380-391387one dose of mRNA vaccine, with 76% and 86% vaccinated with three or four doses in the sotrovimab and control group respectively. In a Spanish multicenter retrospective study sotrovimab, of which was early ( 5 days from the onset of symptoms) 46 (56.1%). Overall, more than 86.8% of patients had received three doses of vaccine before their COVID-19 di - agnosis and 42.6% had an oxygen saturation < 95% at ad - mission. Early treatment was associated with a reduced risk of progression to severe disease with need of ventila 36.1%, p < 25%, COVID-19 who received patients, 35%) and ICU admission (1 patients, 4% vs. 17 patients, 17%), and no patient died as compared patient who suffered COVID-19 progression was administered after 11 days. Overall, 92% of patients had received at least Figure 2 COVID-19 progression rates each or treatment of the studies correspond reference included in the bibliography section. The patients included in the different studies present different vaccination status. In addition, the outcomes were collected at different administration, the majority at one-month post-treatment, however, in some stu - dies it is not specified. Three of the publications included in the sotrovimab treatment block have not been included in this graph, one of them is Villanego F, et al. Clin Kidney J. 2022;15(10):1847-55 [56], which at the beginning of the study, 81.7% of the patients were hospitalized, so progression is measured 8.5%. 42% an saturation >5 2022:e13930 is not for The Immunopharmacol [58], since meta-analysis publications are included, indicating that sotrovimab treatment the of hospitalization p<0.001), ICU admission (OR 0.17, p = 0.009) and death (OR 0.15, p=0.010) compared to the control group without mAb treatment. Reduction in the risk of 380-391388able options, mAbs have been both effective and safe in this population. Treatment of COVID-19 with mAbs in SOT recipients, in particular early treatment af - ter diagnosis, is associated with a reduced likelihood of pro - gression to severe risk visits, mortality, and, very especially to take into account in this immunosuppressed population, the re - duction or avoidance of the risk of opportunistic infections by multiresistant hospital bacteria and by fungi that cause invasive fungal infection (CAPA, reduced against new circulating variants, it is known, how in vitro correlates with clinical efficacy. This is specially in the case of sotro - vimab, a mAb that has a double mechanism of action, not only neutralizing but also with effector function that is mediated by Fc region of the mAb [59]. This effector function has been shown, in animal models, to be an additional protection mechanism beyond virus neutralization, being critical for the maintenance of its activity against have shown the same effective - ness data of the antibody against Omicron BA.2 vs BA.1, being BA.1 a variant against which neutralization capac - ity is not impacted [60, some efficacy BA.5 also [62]. Same kind of not peer reviewed works, have report - ed that effector function sotrovimab is able to reduce viral load in animal models for this variant [63,64]. Although more evidence and continuous surveillance is needed, to potential impact in important especially who from other therapeutic options because of interactions with con - comitant medications. Findings of the present review are timely and informative to the transplant community. The ability to draw firm conclu - sions is limited by the retrospective nature of data collection, the absence of a control group and the limited number of participants in most studies. It is difficult to this data to estimate comparative effectiveness of mAbs therapies in SOT recipients exposed to or infected with SARS-CoV-2 and at high risk of developing severe COVID-19, however the weight of evidence is in favor of a benefit of mAb treatment. It is nec - essary to continue to explore the best approach in preventing severe COVID-19 in this vulnerable SOT patient population in the context of limited immunogenicity of vaccines possi - of variants.p 0.002), and mortality due to COVID-19 (2.2% vs. 16.7%, p = 0.02). In the multivariate analysis, early use of sotrovimab was the only protective risk factor (OR 0.026) for a composite outcome defined as the need for ventilatory support or ICU care or COVID-19-related mortality. There was a good safety profile, even in patients with multiple comorbidities or chronic stage. In who had earlier administration of (14.3% 4 p = [57]. Finally, in a meta-analysis of 6 cohort studies - ports the outcomes of SOT patients treated with sotro - vimab vs a control group between January 2021 and August 2022, it was shown that treated patients had a lower frequen - cy COVID-19 disease progression (Figure 2). Sotrovimab treatment was shown to reduce the risk of hospitalization (OR 0.29, p < 0.001), ICU admission (OR 0.17, p = 0.009) and death (OR 0.15, p = 0.010) compared to the control group without mAb treatment [58]. Take home message: Treatment with - tions provides favorable outcomes at high admissions, gression to severe mAbs is safe with a few adverse events generally mild, lished in the literature reinforces the importance of an ear - ly diagnosis of COVID-19 in SOT recipients and completion anti-SARS-CoV-2 up to 70 - 80% of transplant patients with detectable anti - bodies after 3 doses. The third dose seems to be key for this population, vaccination, a considerable percentage of this group remains at high risk and should be treated soon after COVID-19 diagnosis. Among current 380-39138910.1111/ajt.16369 10. Nimmo A, Gardiner D, Ushiro-Lumb I, Ravanan R, Forsythe JLR. The global impact of COVID-19 on solid organ Bartelt L, transplan - 2022;36(3):100710. doi: 10.1016/j.trre.2022.100710 14. Ao G, Wang Y, Qi X, Nasr B, Bao M, Gao M, Sun Y, Xie D. The asso - ciation between severe or death COVID-19 and solid trans - plantation: A, Steidle organ Anzalone AJ, Lee SB, French E, et al. COVID-19 in solid organ transplantation: Results of JS, recipients 10.3390/jcm10194533 Tartour E, de Lamballerie X, Wittkop L, Loubet P, et al. Immunological and clinical efficacy of COVID-19 vaccines in A, Tabary COVID-19 mRNA vaccines in immunocompromised patients: a Hansen Pries-Heje MM, et al. Decline in concentration 6 months after solid organ transplant ACKNOWLEDGMENTS The authors thank Grupo SANED, S.L., for logistic support and Marta Pulido, MD, PhD, for editing the manuscript and ed - D. Lorite Mingot, M. Manzano Crespo, P. P\u00e9rez Portero and R. Cuervo Pinto are employees of GSK, and hold shares in the company. REFERENCES 1. Aubert O, Yoo D, Zielinski D, Cozzi E, M, D\u00fcrr M, al. - pandemic and worldwide organ transplantation: a Lancet Public Health. 2021;6(10):e709-19. doi: 10.1016/S2468-2667(21)00200-0 2. Miller J, Wey A, Valapour M, Hart A, Musgrove D, Hirose R, et al. Impact of COVID-19 pandemic OS, Kim D, Kanwal F, Esquivel CO, Ahmed A. Early impact of COVID-19 on solid organ transplan - tation in United 10.1097/TP.0000000000003391 Danziger-Isakov L, Blumberg EA, Impact of J 2021;21(3):925-37. S, Manzia Lombardini L, Tisone G, Cardillo in organ trans 10.1016/j. puhe.2020.06.017 7. Dom\u00ednguez-Gil B, Coll E, Fern\u00e1ndez-Ruiz M, Corral E, Del R\u00edo F, Zaragoza R, et al. COVID-19 in Spain: Transplantation in the midst of the Rey JI, Fern\u00e1ndez-Vega P, Frag - iel M, Oteo D, et al. COVID-19 in donation and transplant. Rev Esp Quimioter. 2022;35(Suppl3):54-62. M, S\u00e1nchez-\u00c1lvarez JE, Mart\u00ednez-Fern\u00e1ndez JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2021;21(5):1825-37. doi: Rahamimov R, Sifri CD, Ali NM, et Lambourg E, Watters C, O'Neil M, Almond A, et al. The impact vaccination in Soc Nephrol. 2022;33(4):677-86. doi: 10.1681/ASN.2022010046 38. Naylor KL, Kim SJ, Smith McArthur E, Kwong JC, Dixon SN, et al. Effectiveness of first, second, and third COVID-19 vaccine dos - es in solid organ transplant recipients: A M, Storti S, Tiecco G, et al. Monoclonal antibodies syndrome R, Smolic M. Mini-review: The market diagnostic therapeutic doi: 10.3233/HAB-211513 43. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal antibodies for COVID-19 N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for of Lusivika-Nzin - ga C, C, al. of high-risk patients treated Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Break - through COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis B, Kanbay A, et al. 26. Swai J, Gui M, Long M, Wei Z, Hu Z, Liu S. Humoral Born A, Horn MP, Maurer B, et al. Humoral and cellular immune responses Ortiz A, Orero E, Tejedor S, et al. Humoral Re - sponse to Third Dose Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Trans - JR, Abazi R, et Response Gomes P\u00e9rez VO, et response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: Curtis SV, Whitaker H, Andrews N, et al. Real-world effectiveness of the Pfizer-Bi - oNTech BNT162b2 and vac - Esp 2023;36(4): 380-39139110.1111/tid.13779 49. Sarrell BA, Bloch K, El Chediak A, Kumm K, Tracy K, Forbes RC, et al. Monoclonal antibody for Mehta R, Emamaullee J, Kim Blodget E, et al. of anti-spike 10.1111/ajt.16843 Dhand A, Okumura K, Wolfe K, Lobo SA, Nog R, Keller M, et al. Sotrovimab for treatment of Salemi F, Galluc - F, et al. patients Marks N, Humar of Vaccination and Early Monoclonal Antibody Ther C, Sberro-Soussan R, Pavie J, et al. Early treatment with sotrovimab monoclonal anti body Cubillo B, Merino MJ, Poveda I, Saura IM, et al. Treatment with sotrovimab doi: 10.1080/08923973.2022.2160733. Pinto, YJ., Beltramello, M. Cross-neutralization of Tazare J, Curtis HJ, Fisher L, Nab L, et al. Com - parative effectiveness of sotrovimab molnupiravir Campbell J, Carr EJ, Tazare J, Nab L, et al. Comparative Lamballerie, X., Nou - gair\u00e8de A., In vivo activity of Toniutti D, Staropoli I, Porrot F, et al. Longitudinal analysis serum of 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Rev Esp Quimioter 2023;36(4): 392-399392Management of COVID-19 pandemic in hospital at home in two regional Spanish hospitals. what it meant, who we cared for, who died and how assistance has evolved over time ABSTRACT Introduction. Home Hospitalization (HH) is an alterna - tive hospitalization modality that can be very useful in times of health stress such as the COVID-19 pandemic. This paper includes the management of patients admitted with COVID-19 in HH in two county spanish hospitals for two years. Methods. A descriptive, observational and retrospective of all patients a was out. characterize the patients who died in HH or 30 days after discharge and another to compare the man - agement between the first phase of the study (2020) and the second one (2021 and part of 2022). Results. A total of 167 patients were recruited. A 52.1% moved to watch that the recovery continued compared to 40.7% in which it was done to watch that they did not worsen. The patients who died in HAD were older (mean 87.5 years), more comorbid and more likely to have do-not resucitate or - ders (DNR) in case of cardiac arrest (85%). In the second phase of the study, older patients, more comorbid patients and a greater degree orders admitted than those ad HAD a useful resource to increase the re - silience of health systems in cases of stress such as the disease caused by COVID-19. The development and growth of existing units, as well as the creation of new ones where they do not exist, could be a basic tool for the medicine of the future. Keywords: Home Care Services, Hospital-Based; COVID-19; Coronavirus; Mortality; Epidemics; Pandemics. Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempo 1Servicio de Medicina Interna, Hospital Reina Sof\u00eda de Tudela (Espa\u00f1a). 2Servicio de Neumolog\u00eda, Hospital Reina Sof\u00eda de Tudela (Espa\u00f1a). 3Servicio de Medicina Interna, Hospital Garc\u00eda Orcoyen de Estella (Espa\u00f1a). 4Servicio de Digestivo, Hospital Obispo Polanco de Teruel (Espa\u00f1a).David S\u00e1nchez Fabra1 Tina Herrero Jord\u00e1n2 Alicia Alda Published: 3 May 2023 RESUMEN Introducci\u00f3n. La Hospitalizaci\u00f3n a Domicilio (HAD) es una modalidad de ingreso alternativa que puede resultar de gran utilidad en momentos de estr\u00e9s sanitario como la pandemia de COVID-19. En el presente trabajo se recoge el manejo de los pacientes ingresados con COVID-19 en HAD en dos hospitales comarcales espa\u00f1oles durante dos a\u00f1os. M\u00e9todos. Se realiz\u00f3 un estudio descriptivo, observacional y retrospectivo de los pacientes ingresados en HAD con CO - VID-19. Posteriormente se realiz\u00f3 un an\u00e1lisis para caracterizar a los pacientes que fallecieron en HAD o a 30 d\u00edas del alta y otro para comparar el manejo entre la primera fase del estudio (2020) y la segunda (2021 y parte de 2022). Resultados. Se reclutaron 167 pacientes. Un 52,1% se trasladaron para vigilar que continuaban mejorando frente a un 40,7% en los que se hizo para vigilar que no empeoraran. Los pacientes que fallecieron en HAD resultaron m\u00e1s ancianos (87,5 a\u00f1os de media), m\u00e1s com\u00f3rbidos y con mayor probabili - dad de ser no reanimables en caso de paro cardiaco (No RCP) (85%). En la segunda fase del estudio se ingresaron pacientes m\u00e1s ancianos, m\u00e1s com\u00f3rbidos y en mayor grado No RCP que los ingresados en 2020. Conclusiones. La HAD es un recurso \u00fatil para aumentar la resiliencia de los sistemas sanitarios en casos de estr\u00e9s como supuso la enfermedad por COVID-19. El desarrollo y crecimien - to de las unidades ya existentes, as\u00ed como la creaci\u00f3n de otras nuevas all\u00e1 donde no existan, puede ser una herramienta b\u00e1si - ca para la medicina del futuro. Palabras clave: Hospitalizaci\u00f3n a Domicilio; COVID-19; Coronavirus; Mor - talidad; Epidemia; Correspondencia: San Rafael 42, 3\u00baB, Zaragoza (50017) Espa\u00f1a. E-mail: davidsanchezfabra@gmail.comManejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399393motivo de ingreso en el hospital, motivo de traslado a HAD y estado en ese momento, de uso de oxigenoterapia, de indi - caci\u00f3n de No Reanimaci\u00f3n cardiopulmonar en caso de paro card\u00edaco (No RCP) o Limitaci\u00f3n del Esfuerzo Terap\u00e9utico (LET) y de resultados (estancia, mortalidad durante el ingreso, re - ingreso en el hospital desde HAD y mortalidad o reingreso a los 30 d\u00edas del alta; todo ello para causa relacionada o no con la COVID-19). Las variables de mejor\u00eda antes del traslado se dieron como afirmativas si quedaba reflejado o impl\u00edcito en la historia cl\u00ednica o los registros inform\u00e1ticos que durante la estancia en planta se dio mejor\u00eda cl\u00ednica, gasom\u00e9trica (pO2 o SaO2), radiol\u00f3gica (radiograf\u00edas sucesivas) o de laboratorio (descenso de reactantes); y negativa si hubo empeoramien - to o, simplemente, no pudo objetivarse mejor\u00eda (el paciente se traslad\u00f3 en un estado similar al ingreso, el paciente fue directamente a domiciliaria sin pasar un solo d\u00eda en el hos - pital o no se pidieron pruebas de control antes de trasladarlo a HAD). Rellenamos las variables de No RCP o LET gracias a la interpretaci\u00f3n de la lectura comprensiva de la historia y curso evolutivo de cada paciente, dejando como datos perdi - dos aquellos en los que no fue sencillo determinarlo. Para las variables de motivo de traslado a HAD en cada paciente pudo darse m\u00e1s de una. La recopilaci\u00f3n de datos se realiz\u00f3 por va - rios investigadores m\u00e9dicos a trav\u00e9s de la lectura de historias cl\u00ednicas y registros inform\u00e1ticos. Realizamos un estudio descriptivo, observacional y re - trospectivo. Posteriormente llevamos a cabo dos an\u00e1lisis adi - cionales de inter\u00e9s cient\u00edfico. En primer lugar, comparamos las caracter\u00edsticas de los casos que hab\u00edan fallecido durante el ingreso en HAD o a los 30 d\u00edas del alta de HAD frente a los que no, en aras de intentar objetivar qu\u00e9 tipo de paciente de HAD ha fallecido en este periodo de estudio. En segundo lugar, realizamos un estudio comparativo entre la primera fase de la pandemia respecto a la segunda, tomando como punto de cor - te el 1/1/2021. Se decidi\u00f3 esta fecha en particular por ser con - siderada por los autores como un punto de inflexi\u00f3n en la pan - demia por tres motivos: la superaci\u00f3n de la primera y segunda olas, el inicio de la vacunaci\u00f3n en diciembre de 2020 y la po - sibilidad de asumir que la informaci\u00f3n cl\u00ednica y la experiencia de los facultativos a la hora de tratar la COVID-19 resultaron significativamente superiores a lo largo de 2021. Para este \u00falti - mo an\u00e1lisis excluimos al HGO por existir datos perdidos. Para el an\u00e1lisis descriptivo usamos porcentajes, medias y cuartiles. Para el contraste de hip\u00f3tesis se utilizamos Chi cua - drado para las variables cualitativas y T de student para las variables normales cuantitativas. Empleamos el programa es - tad\u00edstico SPSS\u00a9 versi\u00f3n 15. Se obtuvo autorizaci\u00f3n del Comit\u00e9 \u00c9tico de Navarra. RESULTADOS Caracter\u00edsticas de los pacientes y del curso en hospi - talizaci\u00f3n convencional. Se reclutaron 167 pacientes. El HRS aport\u00f3 el 85,6% de la muestra. Ambos hospitales se consideran comarcales y atienden un \u00e1rea rural de similares caracter\u00edsti - cas. La comorbilidad m\u00e1s frecuente fue la demencia (35,9%) y INTRODUCCI\u00d3N La Hospitalizaci\u00f3n a Domicilio (HAD) se ha definido como una modalidad de ingreso alternativa a la hospitalizaci\u00f3n con - vencional que puede producir similares o mejores resultados en cuanto a mortalidad, reingreso o estancia [1]. Su utilidad para reducir el consumo de los recursos del hospital ha sido demos - trada tambi\u00e9n en episodios de epidemia de gripe [2]. En 2020, la pandemia de COVID-19 fue un \u00abcisne negro\u00bb que puso a prueba los sistemas sanitarios mundiales, haci\u00e9ndose necesario cono - cer si la HAD pudo ser o ser\u00e1 en el futuro un elemento decisivo a la hora de afrontar tales retos. Hasta la fecha, y pese a la enorme bibliograf\u00eda existente sobre la COVID-19, son pocos los trabajos que analizaron su manejo en r\u00e9gimen de HAD. Al inicio de la pandemia ya se vio que la HAD tambi\u00e9n pod\u00eda tener utilidad y ser segura a la hora de tratar la COVID-19 [3,4]. Aunque fueron series peque\u00f1as y preliminares se pudo elaborar el primer documento de consen - so [5]. Otros estudios posteriores intentaron dirimir los factores de riesgo asociados a reingreso y la verdadera magnitud de la descarga hospitalaria que produjo [6-8]. Sin embargo, la mayor\u00eda de los trabajos analizaron solo el manejo de la HAD en etapas incipientes de la pandemia y, sobre todo, como factor de reducci\u00f3n de ingresos. Pese a la enorme potencialidad de la HAD para hacer m\u00e1s resilientes los sistemas sanitarios durante momentos de estr\u00e9s como la pandemia de COVID-19 [9], todav\u00eda se hace necesario aumentar el conoci - miento de lo que supuso la HAD durante la pandemia. En el presente trabajo exponemos los datos del manejo real de la HAD en dos hospitales comarcales que dan cobertura a la zona sur de Navarra durante un periodo que comprende tanto \u00e9pocas de estr\u00e9s como otras de menor presi\u00f3n asistencial (des - de marzo de 2020 hasta marzo de 2022). Se registraron todos los pacientes atendidos en HAD con diagn\u00f3stico de COVID-19. Los objetivos del mismo son detallar qu\u00e9 tipo de pacientes se atendieron, cu\u00e1les fueron los resultados y qu\u00e9 modelos men - tales de toma de decisiones llevaron a cabo los facultativos en dicho contexto. PACIENTES Y M\u00c9TODOS Inclu\u00edmos todos los casos mayores de 18 a\u00f1os con diag - n\u00f3stico de presunci\u00f3n de COVID-19, infecci\u00f3n por coronavi - rus o SARS-COV-2 ingresados en r\u00e9gimen de HAD entre marzo de 2020 y marzo de 2022. Excluimos aquellos pacientes en los que, finalmente, e independientemente de las pruebas, el m\u00e9 - dico cl\u00ednico decidi\u00f3 que no ten\u00edan infecci\u00f3n por coronavirus. Los criterios de ingreso en HAD fueron los mismos que se em - pleaban en la pr\u00e1ctica cl\u00ednica habitual para otras enfermeda - des. Los casos se reclutaron del Hospital Reina Sof\u00eda de Tudela (HRS) y del Hospital Garc\u00eda Orcoyen de Estella (HGO), ambas poblaciones sitas en Navarra. Registramos variables demogr\u00e1ficas, cl\u00ednicas, de comor - bilidades, de procedencia de ingreso (desde urgencias, des - de planta de hospitalizaci\u00f3n o directamente en el domicilio), Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399394Manejo en HAD . La mayor\u00eda de traslados se hicieron por patolog\u00eda respiratoria por COVID-19 (77,2%) con un tiempo medio de 10 d\u00edas desde el inicio de los s\u00edntomas. Objetivar al - g\u00fan tipo de mejor\u00eda no fue necesario para los cl\u00ednicos en un 41,3% de los casos. Un 52,1% de los pacientes se trasladaron para vigilar que continuaba la recuperaci\u00f3n frente a un 40,7% un 46,5% de los pacientes fueron claramente No RCP desde el principio del ingreso. La estancia media en el hospital fue de 5,4 d\u00edas, siendo de 7,1 en HAD. Respecto al uso de ox\u00edgeno, un 65,9% de los pacientes precisaron oxigenoterapia en HAD, la mayor\u00eda de ellos con flujos bajos. En las Tablas 1 y 2 se recoge informaci\u00f3n m\u00e1s detallada.Variable Valor Hospital; HRS n (%) 143 (85,6) Sexo mujer; n (%) 80 (47,9) Edad; media (p25/p50/p75) 75,5 (63/81/88) HAD fuera de su domicilio habitual; n (%) 8 (4,8) \u00cdndice de Charlson; media (p25/p50/p75) (n=165) 4,5 (0/5/7) Demencia; n (%) 60 (35,9) Insuficiencia card\u00edaca; n (%) 46 (27,5) Diabetes; n (%) 40 (24) Institucionalizados; n (%) 57 (34,1) Ingresa en el hospital por NAC COVID; n (%) 100 (59,9) Ingresa en el hospital por causa respiratoria asociada a COVID; n (%) 135 (80,8) Otras causas de ingreso hospitalario NAC bacteriana; n (%) 24 (14,4) Otras infecciones; n (%) 21 (12,6) Fiebre; n (%) 15 (9) Cardiol\u00f3gica; n (%) 14 (8,4) Fracaso renal agudo; n (%) 12 (7,2) Digestivas; n (%) 11 (6,6) ETEV; n (%) 5 (3) COVID nosocomial; n (%) 10 (6) COVID fue un hallazgo casual; n (%) 22 (13,2) Ingreso en UCI; n (%) 1 (0,6) Desaislado durante la estancia; n (%) 5 (3) Estancia en el hospital; media (p25/p50/p75) (n=109) 5,4 (2/5/8) Estancia en (n=137) 7,1 (4,5/6/8) Pacientes no RCP e indicaci\u00f3n de LET** Paciente claramente no RCP desde el principio; n (%) (n=159) 74 (46,5) Paciente en el que se indica LET desde el principio; n (%) (n=166) 24 (14,5) Paciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 17 (10,2) Paciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 39 (23,4)Tabla 1 Caracter\u00edsticas generales de los pacientes. Salvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. Siglas: HRS, Hospital Reina Sof\u00eda; p25/p50/p75, percentiles 25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en la Comunidad; ETEV, Enfermedad Tromboemb\u00f3li UCI, Unidad de Cuidados Intensivos; RCP, Reanimaci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico. *Para el c\u00e1lculo se excluyen exitus durante su estancia en el hospital. ** Se excluyen los casos en los que fue dif\u00edcil precisar o responder a dicha pregunta.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399395muy avanzada edad, muy com\u00f3rbido y en la mayor\u00eda de los casos considerado No RCP o LET. La inercia de manejo en la segunda parte del periodo respecto a la primera, lo que tradu - cir\u00eda un cambio de comportamiento a la hora de usar la HAD, sugiere que con el paso del tiempo la HAD se ha empleado m\u00e1s para pacientes de mayor edad, m\u00e1s com\u00f3rbidos y en fases m\u00e1s tempranas de la enfermedad, muchas veces sin haber com - probado mejor\u00eda antes de cursar el ingreso en la misma. Esto implicar\u00eda que se ha optimizado su uso para los pacientes que realmente lo necesitaban, a diferencia del principio de la pan - demia, cuando todav\u00eda no se ten\u00eda tanta experiencia sobre el manejo de la enfermedad. En comparaci\u00f3n con otros art\u00edculos similares, nuestro tra - bajo comprende un periodo mucho m\u00e1s largo que los dem\u00e1s. Los datos recogidos en dichos trabajos son muy heterog\u00e9neos aunque en algunos supuestos coinciden con los nuestros. En el trabajo de Lwin et al [3], muy precoz al inicio de la pande - mia, con una edad media similar a la de nuestra muestra, 7 de los 23 los pacientes ingresados en HAD requirieron reingreso en el hospital y solo uno falleci\u00f3. El uso de ox\u00edgeno fue ex - clusivamente hospitalario. En la serie de Peric\u00e0s et al [4], ya con 63 pacientes, solo uno recibi\u00f3 ox\u00edgeno en HAD. La edad media de la muestra fue 51 a\u00f1os, un 4,8% de los pacientes reingresaron y ninguno falleci\u00f3, lo que contrasta con nuestros datos (edad media de 75,5 a\u00f1os, 10,2% de reingresos y 24% de mortalidad). En otra serie espa\u00f1ola de gran tama\u00f1o [8] se objetiv\u00f3 la gran capacidad de HAD para aumentar la resiliencia de los sistemas sanitarios. La muestra fue de 917 casos, los re - ingresos fueron un 6,2% y solo falleci\u00f3 una paciente, aunque, nuevamente, los criterios de admisi\u00f3n de ingresos selecciona - ron pacientes m\u00e1s j\u00f3venes y menos graves que los recogidos en nuestro trabajo. En otros estudios internacionales [10] se vio asimismo pacientes m\u00e1s j\u00f3venes y con mejores resultados. Cabe rese\u00f1ar tambi\u00e9n en este punto la utilidad de los hoteles y otros edificios que se medicalizaron durante la pandemia y que resultaron de utilidad para aliviar la presi\u00f3n hospitalaria. en los que se hizo para vigilar que no empeoraran. El 10,2% de los casos tuvieron que reingresar en el hospital. La mayor\u00eda de reingresos y exitus hospitalarios fueron producidos por la COVID-19 (Tabla 3). Caracter\u00edsticas del paciente diagnosticado de CO - VID-19 que falleci\u00f3 en HAD. El paciente fallecido en HAD tuvo m\u00e1s edad, comorbilidades, demencia y probabilidad de estar institucionalizado que el que sobrevivi\u00f3. Asimismo, tuvo m\u00e1s estancia en el hospital, sin existir diferencias en cuanto a la estancia en HAD; y fue menos probable objetivar en \u00e9l alg\u00fan tipo de mejor\u00eda antes del traslado. La probabilidad de ser No RCP o iniciar LET desde el principio o durante el curso fue mu - cho mayor en los pacientes fallecidos (Tabla 4). Comparativa entre fases de la epidemia. Para el an\u00e1li - sis solo se incluyeron los casos de HRS. Los pacientes diagnos - ticados de COVID-19 e ingresados en r\u00e9gimen de HAD durante 2020 fueron m\u00e1s j\u00f3venes, menos com\u00f3rbidos, llevaban m\u00e1s d\u00edas desde el inicio de los s\u00edntomas y fue m\u00e1s probable en - contrar mejor\u00eda en ellos antes de trasladarlos a HAD respecto a los pacientes ingresados en 2021 y principios de 2022. Fue tambi\u00e9n mucho menos probable que se consideraran No RCP o se iniciaran medidas de LET al principio o durante el ingre - so, sin que se encontraran diferencias en cuanto a la estancia hospitalaria o en HAD. Aunque hubo cierta tendencia a encon - trar un mayor grado de mortalidad en los pacientes de 2021 y principios de 2022, esta no alcanz\u00f3 significaci\u00f3n estad\u00edstica (Tabla 5). DISCUSI\u00d3N En el presente trabajo encontramos datos muy rese\u00f1ables sobre la pr\u00e1ctica real de asistencia a los pacientes con CO - VID-19 en r\u00e9gimen de HAD durante un largo periodo de tiem - po, objetivando que el prototipo de paciente fallecido fue de Variable Valor OCD previa; n (%) 16 (9,6) Precis\u00f3 ox\u00edgeno en HAD; n (%) 110 (65,9) Precis\u00f3 prescripci\u00f3n de ox\u00edgeno al alta; n (%) (n=137)* 38 (27,7) D\u00edas con oxigenoterapia durante el ingreso (hospital y HAD); media (p25/p50/p75) (n=117) 10,4 (6/10/14) Necesidad de oxigenoterapia (litros por minuto) Basal <2 2 a 5 5 a 10 10 a 15 OAF Flujo m\u00e1ximo de ox\u00edgeno administrado en el hospital; n (%)(n=128) 36 (28,1) 40 (31,3) 33 (25,8) 10 (7,8) 8 (3,3) 1 (0,8) Flujo de ox\u00edgeno necesario al traslado a HAD; n (%) 86 (51,5) 44 (26,3) 29 (17,4) 6 (3,6) 1 (0,6) 0 Flujo m\u00e1ximo de ox\u00edgeno administrado en HAD; n (%) (n=156) 47 (29,9) 67 (43) 34 (21,8) 5 (3,2) 3 (1,9) 0Tabla 2 Uso de oxigenoterapia Salvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. OCD, Oxigenoterapia Cr\u00f3nica Domiciliaria; HAD, Hospitalizaci\u00f3n a Domicilio; p25/p50/p75, percentiles 25, 50 y 75. OAF, Ox\u00edgeno a Alto Flujo. *Se excluyeron pacientes fallecidos o reingreso al hospital.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399396Variable Valor Ingreso directo desde urgencias; n (%) 7 (4,2) Ingreso directo en el domicilio sin pasar por el hospital; n (%) 58 (34,7) Ingreso desde planta de hospitalizaci\u00f3n; n (%) 102 (61,1) Motivo de traslado asociado a problemas por COVID respiratorios; n (%) 129 (77,2) Motivo de traslado asociado a problemas por COVID no respiratorios; n (%) 32 (19,2) Ingreso para vigilar si hay empeoramiento en fases muy incipientes de la enfermedad o cuando no hay suficiente informaci\u00f3n del curso; n (%) 74 (44,3) Antes del traslado se objetiv\u00f3 alg\u00fan tipo de mejor\u00eda; n (%) 98 (58,7) Cl\u00ednica; n (%) 95 (56,9) De laboratorio; n (%) 70 (41,9) Gasom\u00e9trica; n (%) (n=144) 36 (25) Radiol\u00f3gica; n (%) (n=144) 36 (25) D\u00edas desde s\u00edntomas hasta ingreso en HAD; media (p25/p50/p75) (n=148) 10 (5/10/13,7) D\u00edas desde la positivizaci\u00f3n de la PCR hasta el ingreso en HAD; media (p25/p50/p75) (n=165) 8,3 (3/7/12) Motivo de traslado a HAD (un paciente puede tener varios) Vigilancia por parte de un especialista de que contin\u00faa la recuperaci\u00f3n; n (%) 87 (52,1) Vigilancia estrecha por si hay empeoramiento relacionado con la NAC o SDRA estrictamente relacionados con el COVID; n (%) 68 (40,7) Continuar tratamientos con posolog\u00eda o uso hospitalario no relacionados con el COVID, incluyendo TADE; n (%) 46 (27,6) Continuar tratamientos con posolog\u00eda o uso hospitalario relacionados con el COVID; n (%) 38 (22,8) Descompensaci\u00f3n de comorbilidades; n (%) 21 (12,6) Cuidados paliativos; n (%) 13 (7,8) Sobreinfecci\u00f3n o aparici\u00f3n de nuevas enfermedades infecciosas; n (%) 13 (7,8) Necesidad de oxigenoterapia a altos flujos; n (%) 8 (4,8) Tratamiento y control de la ETEV; n (%) 6 (3,6) Otros; n (%) 5 (3) Reingreso en el hospital desde HAD; n (%) 17 (10,2) Relacionado con el COVID; n (%) 9 (52,9) No relacionado con el COVID; n (%) 7 (41,2) Petici\u00f3n del paciente o familiares; n (%) 1 (5,9) D\u00edas hasta reingreso; media (P25/50/75) 4,4 (2/3/5,5) Exitus en el hospital o en HAD; n (%) 31 (18,6) Producido por COVID; n (%) 25 (80,6) D\u00edas desde ingreso en HAD hasta exitus en el hospital o en HAD; media (p25/p50/p75) 9,3 (3/8/15) Exitus a 30 d\u00edas del alta; n (%) (n=135) 9 (6,7) Producido por COVID; n (%) 5 (55,6) D\u00edas desde alta hasta exitus a 30 d\u00edas; media (P25/50/75) 13,25 (7,25/11,5/20,5) Reingreso a 30 d\u00edas del alta; n (%) (n=132) 10 (7,6) Producido por COVID; n (%) 5 (50) D\u00edas desde alta hasta reingreso; media (P25/50/75) 10,3 (2/10,5/14)Tabla 3 Manejo en Hospitalizaci\u00f3n a Domicilio Salvo que se especifique con contrario, la n ser\u00e1 de 167 pacientes. Siglas: HAD, Hospitalizaci\u00f3n a Domicilio; PCR, Reacci\u00f3n en Cadena de la Polimerasa; NAC, Neumon\u00eda Adquirida en la Comunidad; SDRS, S\u00edndrome p25/p50/p75, percentiles 25, 50 y 75.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 3,6 Demencia; n (%) 29 (72,5) 31 (24,4) <0,001 Institucionalizados; n (%) 28 (70) 29 (22,8) <0,001 D\u00edas desde s\u00edntomas hasta ingreso en HAD; media (n=148) (p25/p50/p75) 6,9 (1/7/12) 11 (6/11/14) 0,007 el hospital; media 8,3 (3/8/10,5) 5 (2/4/7) 0,017 Ingresa en el hospital por NAC COVID; n (%) 18 (45) 82 (64,6) <0,028 Antes del traslado se objetiv\u00f3 mejor\u00eda; n (%)* 11 (27,5) 87 (68,5) <0,001 Paciente claramente no RCP desde el principio; n (%) (n=159) 34 (85) 40 (31,5) <0,001 Paciente en el que se indica LET desde el principio; n (%) (n=166) 14 (35) 10 (7,9) <0,001 Paciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 16 (40) 1 (0,8) <0,001 Paciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 28 (70) 11 (8,1) <0,001Tabla 4 An\u00e1lisis de la mortalidad: Exitus durante el ingreso o a los 30 d\u00edas del alta de HAD. Ejemplo de lectura de tabla: la demencia se dio en 29 (72,5%) de los fallecidos respecto a 31 (24,4%) en los no fallecidos con una p <0,001. Salvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. p25/p50/p75, percentiles 25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en la Comunidad; RCP, Reanima - ci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico; No hubo diferencias en cuanto a sexo, a si el COVID fue un hallazgo casual, si el COVID fue nosocomial, a la estancia en r\u00e9gimen de HAD o a los d\u00edas desde positividad de la PCR hasta ingreso en HAD. * La significaci\u00f3n estad\u00edstica se dio para las cuatro variables de mejor\u00eda cl\u00ednica (cl\u00ednica, de laboratorio, gasom\u00e9trica o radiol\u00f3gica). Nosotros tuvimos un 4,8% de la muestra en dicha situaci\u00f3n (teniendo en cuenta que solo un peque\u00f1o porcentaje de nues - tros pacientes derivados a los hoteles estaban cubiertos por un ingreso de HAD), pero existe tambi\u00e9n una serie espa\u00f1ola con 516 pacientes con dicho r\u00e9gimen de ingreso de los cuales solo un 5,4% reingresaron [11]. Sobre el manejo de la oxigenoterapia, con un 65,9% de prescripci\u00f3n durante el ingreso en HAD en nuestro trabajo des - tacamos haber hecho un amplio uso de la misma, muy superior al de las otras series publicadas [3,4,6,8]. Respecto al an\u00e1lisis de las caracter\u00edsticas asociadas a los traslados a HAD, creemos haber aportado datos no recogidos en la bibliograf\u00eda consultada y que son de gran utilidad para comprender lo que ha significado dicha modalidad de ingreso durante este periodo en nuestro medio. Resulta rese\u00f1able que solo se objetiv\u00f3 mejor\u00eda en un 58,7% de los casos antes del traslado, y que la mejor\u00eda gasom\u00e9trica o radiol\u00f3gica solo fue necesaria un 25% de las ocasiones para los facultativos. No en vano, respecto a los dos principales motivos de traslado a HAD, frente a un 52,1% de los casos en los que se hizo para vigilar que continuaba la recuperaci\u00f3n, en un 44,3% pareci\u00f3 hacerse sabiendo que el paciente pod\u00eda empeorar pero prefi - riendo tenerlo en HAD pese a ello respecto a la hospitalizaci\u00f3n convencional o al manejo ambulatorio (alta), lo que pudo tener gran importancia a la hora de aliviar la presi\u00f3n asistencial. En relaci\u00f3n con las variables de reingreso y exitus durante la es - tancia o a 30 d\u00edas, aunque son superiores a los de otras series, creemos que son unos resultados esperables asumiendo las caracter\u00edsticas de la poblaci\u00f3n atendida (edad avanzada, co - morbilidad...). En el caso de la mortalidad, y enlazando con la Tabla 4, encontramos que los pacientes que fallecieron en HAD fueron aquellos de los que cabr\u00eda esperar un exitus en caso de contraer la COVID-19, ya no solo por tener una media de edad y de \u00cdndice de Charlson de 87,5 a\u00f1os y 7,1 puntos, respecti - vamente, sino por el hecho tambi\u00e9n de que un 85% fueron claramente No RCP desde el inicio y en un 70% de los casos se indic\u00f3 LET durante alg\u00fan momento del curso evolutivo. Estos datos son, a nuestro parecer, novedosos y de gran relevancia, ya que este tipo de variables no suelen recogerse en los traba - jos observacionales de cualquier enfermedad que estudian la mortalidad y, sin ellas, ser\u00eda imposible evaluar adecuadamente \u00abqui\u00e9n se est\u00e1 muriendo realmente\u00bb en cada supuesto. En este caso, por ejemplo, los datos parecen orientar a que los resul - tados adversos del ingreso en HAD (reingreso o mortalidad), estuvieron controlados o asumidos por las decisiones cl\u00ednicas que se tomaron al respecto, primando, quiz\u00e1, el confort perso - nal y familiar o la salvaguarda del \u00edndice de ocupaci\u00f3n hospita - lario sobre otra serie de medidas que, seg\u00fan se interpreten, po - dr\u00edan considerarse desde f\u00fatiles hasta obstinaci\u00f3n terap\u00e9utica. Por \u00faltimo, en lo tocante a las diferencias entre ambos periodos (2020 o 2021 en adelante), creemos haber detecta - do las diferencias de manejo de la COVID-19 en r\u00e9gimen de HAD secundarias a los factores que fueron diferentes entre un momento y otro, a saber, el conocimiento recabado, la inmu -Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399398Periodos de estudio 2020 2021 y 2022 p N\u00famero de pacientes, n (%) 74 (51,7) 69 (48,3) - Edad; media (p25/p50/p75) n (%) 11 (14,9) 25 (36,2) 0,003 D\u00edas desde s\u00edntomas hasta ingreso en HAD; media (n=148) (p25/p50/p75) 11,8 (9/12/14) 8,4 (1,5/6/12) 0,003 Ingresa en el hospital por NAC COVID; n (%) 58 (78,4) 37 (53,6) 0,002 Antes del traslado se objetiv\u00f3 mejor\u00eda; n (%) 55 (74,3) 37 (53,6) 0,01 Cl\u00ednica; n (%) 55 (74,3) 34 (49,3) 0,002 De laboratorio; n (%) 40 (54,1) 24 (34,8) 0,021 n (%) (n=122)* 30 (44,1) 2 (3,7) <0,001 Radiol\u00f3gica; n (%) (n=122) * 25 (36,8) 8 (14,8) 0,007 Paciente claramente no RCP desde el principio; n (%) (n=143) 20 (27) 35 (50,7) <0,001 Paciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 2 (2,7) 14 (20,7) 0,001 Paciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 5 (6,8) 14 (20,3) 0,017 Exitus en el hospital o en HAD; n (%) 8 (10,8) 14 (20,3) 0,116 Exitus a los 30 d\u00edas del alta; n (%) 2 (3) 6 (10,9) 0,082Tabla 5 Comparativa entre periodos, 2020 (1/3/20 - 31/12/20) frente 2021 y 2022 (1/1/21 - 31/3/22). Salvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. p25/p50/p75, percentiles 25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en la Comunidad; RCP, Reanimaci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico. No hubo diferencias en cuanto a sexo, que el COVID fuera un hallazgo casual, COVID nosocomial, inicio de LET desde el principio, traslado a HAD con oxigenoterapia, reingreso al hospital desde HAD, reingreso a 30 d\u00edas del alta, estancia hospitalaria o en HAD, d\u00edas de oxigenoterapia o d\u00edas hasta exitus extrahospitalario y reingreso. *Se excluyeron los casos en los que las pruebas gasom\u00e9tricas o radiol\u00f3gicas no fueron relevantes para evaluar el curso de la enfermedad. nidad adquirida por la poblaci\u00f3n (natural o tras la vacunaci\u00f3n), la presi\u00f3n asistencial o la posible atenuaci\u00f3n de la virulencia del virus. A este respecto, es necesario destacar que pese a que hubo una tendencia no significativa a encontrar mayor mor - talidad en la segunda fase del periodo de estudio, tambi\u00e9n es - tos pacientes fueron m\u00e1s mayores, m\u00e1s com\u00f3rbidos o tuvieron mayor indicaci\u00f3n de No RCP o LET, todo esto \u00faltimo siendo estad\u00edsticamente significativo. La interpretaci\u00f3n que hacemos de estos datos ser\u00eda que durante 2020 la HAD se emple\u00f3 para pacientes con menores probabilidades basales de fallecer, que estaban menos graves, llevaban m\u00e1s d\u00edas de evoluci\u00f3n o en los que se hab\u00eda constatado con mayor frecuencia mejor\u00eda cl\u00ednica durante el periodo de hospitalizaci\u00f3n. Por el contrario, en el periodo de 2021 y principios de 2022 la HAD tuvo mayor uti - lidad para atender a pacientes m\u00e1s fr\u00e1giles en los que poder indicar LET o asistencia al final de la vida. Al tratarse de un es - tudio observacional de todos los casos atendidos en el hospital HRS, creemos que en esta tabla se recoge con fidelidad c\u00f3mo se adapt\u00f3 la HAD a las necesidades del hospital en cada fase de la pandemia. Nuestro trabajo tiene algunas limitaciones. Adem\u00e1s de todas las asumibles a la naturaleza de los estudios observa -cionales, el hecho de haber incluido solo los datos de dos hos - pitales comarcales, perdiendo incluso los pacientes de uno de ellos para el an\u00e1lisis de la Tabla 5, no recoge los usos que se hayan podido hacer en otros lugares de Espa\u00f1a. Sin embargo, el trabajo tiene algunas fortalezas como el disponer de un ta - ma\u00f1o muestral importante, el haber recogido todos los casos durante un largo periodo de tiempo, el examen del prototipo de paciente que falleci\u00f3 a trav\u00e9s de la lupa de las \u00f3rdenes de No RCP o LET, elemento que se echa en falta en la mayor\u00eda de estudios observacionales, especialmente en relaci\u00f3n con esta pandemia, o la gran cantidad de datos aportados, pese a que algunos sean interpretativos, sobre lo que ha supuesto este manejo hol\u00edstico de la COVID-19 en r\u00e9gimen de HAD. A modo de conclusi\u00f3n, la HAD supuso en nuestro medio un elemento crucial a la hora de luchar contra la pandemia de COVID-19, tanto en sus momentos m\u00e1s crudos como en las fases posteriores, en las que la enfermedad ha sido integrada como \u00abuna m\u00e1s\u00bb dentro de nuestra pr\u00e1ctica cl\u00ednica habitual. Compartimos los pensamientos de otros autores que han de - finido la HAD como un recurso indispensable de cara al futuro por su capacidad de aumentar la resiliencia de los sistemas sa - nitarios, su seguridad, su versatilidad, su r\u00e1pida escalabilidad y Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al. Rev Esp Quimioter 2023;36(4): 392-399399su mayor coste-efectividad [9,12]. Integrar los enormes ade - lantos tecnol\u00f3gicos en cuanto a telemedicina podr\u00eda potenciar todav\u00eda m\u00e1s la mejora los resultados de la atenci\u00f3n de pacien - tes en HAD [13]. Consideramos que el desarrollo y crecimiento tanto de las unidades ya existentes de HAD como la creaci\u00f3n de otras nuevas en las \u00e1reas de salud donde no existen pue - de resultar de vital importancia a la hora de hacer a nuestro sistema sanitario m\u00e1s robusto, especialmente en los tiempos venideros en lo referente tanto a la aparici\u00f3n de nuevos retos de salud como a la probable necesidad de practicar la medicina en un contexto econ\u00f3mico y social de menor flujo de recursos. FINANCIACI\u00d3N Los autores declaran que no han recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses BIBLIOGRAF\u00cdA 1. Leong MQ, Lim CW, Lai 2. Salmer\u00f3n R\u00edos S, Lozoya Moreno S, Sol\u00eds Garc\u00eda Del Pozo J, Salme - r\u00f3n R\u00edos R, Plaza Carmona L, Abizanda Soler P. Unidad domiciliaria de atenci\u00f3n integral: Reducci\u00f3n de recursos hospitalarios durante brotes de gripe [Comprehensive Care Home Unit: reduction of hos - pital resources during influenza outbreaks]. Rev Esp Salud Publica. 2018 Nov 2;92:e201811080. PMID: 30394367. 3. Lwin N, Burgess J, Johnston C, Johnson N, Chung S. Hospital-in- the-Home experience of first 23 COVID-19 patients at a regional NSW hospital. Intern J, Serra - lab\u00f3s J, Alv\u00e9s, et al. Hospital at home for the management of CO - VID-19: preliminary experience with 63 patients. Infection. 2021 Apr;49(2):327-332. 5. Bryant Bowen AC, Pollard J; Hospital-in- the-Home Society Australasia. Planning and clinical role of acu - te medical home care services for COVID-19: consensus position statement by the Hospital-in-the-Home Society 2020 Oct;50(10):1267-1271. doi: 10.1111/imj.15011. 6. Chou SH, McWilliams A, Murphy S, Sitammagari K, Liu TL, Hole C, et al. Factors Associated With Risk for Care Escalation Among Pa - tients With COVID-19 Aug;174(8):1188-1191. doi: 10.7326/M21-0409.. 7. Llorens P, Moreno-P\u00e9rez O, Espinosa B, Garc\u00eda T, Pay\u00e1 AB, Sola S, et al. J. An integrated emergency department/hospital at home model in mild COVID-19 pneumonia: feasibility and outcomes after dis F, Castells X, D\u00edez-P\u00e9rez A, Sabat\u00e9 RA, Petit I, et al. Hospital-at-Home Expands Hospital Capacity During COVID-19 2021 doi: 10.1016/j.jamda.2021.01.077. 9. Nicol\u00e1s D, JM. Alternatives conventional hos - pitalisation S, Kowalkowski M, Chou SH, Sullivan M, Taylor S, et al. Insights From Rapid Deployment of a \"Virtual Hospi - tal\" as Standard Cube - do M, Cucchiari D, Calvo J, et al. Medicalized Hotel as an Alternati - ve to Hospital Care for Management of Noncritical COVID-19. Ann Intern Med. 2021 Sep;174(9):1338-1340. doi: 10.7326/M21-1873. 12. Coloma E, Nicol\u00e1s D. Hospital at Home units in the post-COVID 19 era. Eur J Clin / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Rev Esp Quimioter 2023;36(4): 400-407400Influencia de factores epidemiol\u00f3gicos y cl\u00ednicos en la reactogenicidad a la vacuna Comirnaty\u00ae en trabajadores sanitarios de un hospital universitario espa\u00f1ol (estudio COVIVAC) RESUMEN Introducci\u00f3n. Comirnaty\u00ae es una vacuna de ARNm con - tra el COVID-19 que se ha administrado a millones de personas desde finales de 2020. Nuestro objetivo fue estudiar los facto - res epidemiol\u00f3gicos y cl\u00ednicos que influyen en la reactogeni - cidad y la limitaci\u00f3n funcional asociadas tras las dos primeras dosis de la vacuna en trabajadores de la salud. Metodolog\u00eda. Estudio de cohorte prospectivo post-auto - rizaci\u00f3n para evaluar la seguridad y eficacia de la vacuna. Resultados . Los efectos secundarios locales fueron leves y se presentaron tanto con la primera como con la segunda dosis de Comirnaty. Los efectos secundarios sist\u00e9micos fueron m\u00e1s frecuentes despu\u00e9s de la segunda dosis. No obstante, la infecci\u00f3n previa por SARS-CoV-2 se asoci\u00f3 con efectos sist\u00e9 - micos tras la primera dosis de la vacuna (OR de 2 a 6). No se informaron efectos adversos graves. El an\u00e1lisis multivariante demostr\u00f3 que el grado de limitaci\u00f3n funcional tras la primera dosis aument\u00f3 con la edad, el sexo femenino, contacto previo con COVID-19, la infecci\u00f3n previa por SARS CoV-2 y el \u00edndi - ce de comorbilidad de Charlson (ICC). Tras la segunda dosis, el grado de limitaci\u00f3n funcional observado fue menor en aque - llos con infecci\u00f3n previa por SARS-CoV-2, y se asoci\u00f3 positi - vamente al grado de limitaci\u00f3n funcional tras la primera dosis. Conclusi\u00f3n. Los efectos adversos sist\u00e9micos fueron m\u00e1s frecuentes despu\u00e9s de la segunda dosis de Comirnaty. La infec - ci\u00f3n previa por SARS-CoV-2 se asoci\u00f3 con efectos sist\u00e9micos despu\u00e9s de la primera dosis. La edad, el sexo femenino, infec - ci\u00f3n por COVID-19 previa, el aislamiento previo por contacto de COVID-19 y el ICC se mostraron como predictores inde -Influence factors to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study) 1Internal Medicine Departmente Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain. 2Queen Mary University, London, United Kingdom 3Medical Assistant Direction. Complejo Asistencial de \u00c1vila, \u00c1vila, Spain. 4Internal Medicine Deparment, Hospital Universitario HM Montepr\u00edncipe, HM Hospitales, Madrid, Spain. 5Intensive Care Service, HM Sanchinarro University Hospital. Hospitales Madrid. Madrid, Spain. Carlos Risco-Risco1 Diego Mart\u00ednez-Urbistondo1 Rafael Su\u00e1rez del Villar1 Luis Ayerbe Garc\u00eda-Monz\u00f3n2 Alberto P\u00e9rez-Rubio3 Jos\u00e9 Barber\u00e1n-L\u00f3pez4 David Comirnaty\u00ae is an mRNA vaccine against COV - ID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs). Material and methods. Prospective post-authorization co - hort study to monitor safety and effectiveness of the vaccine. Results. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic systemic the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were the first dose Comorbidity dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the limitation after dose. Conclusion. SARS-CoV-2 in - fection was first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comir - the 2nd dose, the degree of functional limitation was lower in Spain. davidandaluz78@yahoo.esInfluence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC exposure work, previous COVID-19 infection, or previous isolation due to COVID-19 contact), age, sex, eth - nicity, blood group, date of administration of the study (informed consent) at the time of receiving the second dose of vaccine. The study was approved by the Ethics Advisory Board of HM hospitals. Quantitative data were presented with mean and stand - ard deviation, or median and interquartile range in case of Qualitative were presented with proportions and percentages. Association was studied with Pearson coefficient for normal quantitative data, and chi square test in case of parametric qualitative data. In non-para - the different secondary effects to previous COVID-19 infection (multi - variate) was used to study the association of clinical and ep - idemiological factors to the degree of functional limitation with each dose of the vaccine. Data analysis was performed with STATA software version 16.1. RESULTS Up 193 female). The mean age was 39.34 years in men, and 36.31 years in women (p<0.05). The complete description of the character - istics of participants is presented in Table 1. pa - tients without adequate protection in the laboral environment, around 15% at home, and around 15% had been isolated be - fore the vaccination due to COVID-19 contact. 19 per cent of them reported previous SARS-CoV-2 infection The list of symptoms in those with previous COVID-19, as well as oth - er more concrete data about previous exposure to COVID-19 might was local pain, signif - icantly common after first dose (83 vs 78%, p<0.05). On the other dose More concrete details might be consulted in Table post-vaccine lim - itation was significatively higher after the second dose of the vaccine (Figure 1). Previous COVID-19 was significantly associated with high - er incidence of low-grade fever (OR 2.96), tation, after the first dose of Comirnaty\u00ae. On the other hand, after the second dose of Comirnaty\u00ae, previous COVID-19 was pendientes del grado de limitaci\u00f3n funcional tras la 1\u00aa dosis de Comirnaty\u00ae. Despu\u00e9s de la 2.\u00aa dosis, el grado de limitaci\u00f3n funcional fue menor en los que previamente ten\u00edan infecci\u00f3n por SARS-CoV-2. Palabras clave: COVID-19, Vacunas, Comirnaty, reactogenicidad INTRODUCTION Since December 2019 more than 295 million COVID-19 cases and almost 5.5 million deaths have been reported world - wide [1]. The magnitude of the health problem has driven the focus of public health efforts to the development of effective and - ONTech, has been one of the first vaccines in being approved by EMA (European Medicines Agency) and FDA (USA Food and Drug Administration) [3,4]. This vaccine showed to be reason - safe, and evidenced a high efficacy in preventing sympto - matic (over 90%) and severe COVID-19 %) in clinical trials conducted in adults, younger people (from 12-15 years old) and lately, in children (from 5 to 11 years) [5-8]. In differ - ent post-authorization studies conducted in Israel, vaccine showed an effectiveness over 95% in preventing symptomat - ic COVID-19, and even higher in preventing or death [9,10] In clinical trials conducted (adult people, ad - olescents, children), the safety profile of the vaccine showed such as myocarditis, and pericar - ditis, more common in young male people, have been report - ed [11,12]. Other possible frequent studies are order to more precisely define the safety profile of these new vaccines [13]. The COVIVAC-1 is a cohort investigation on the safety and effectiveness of Comirnaty\u00ae vaccine in health care workers of a university teaching Spanish hospital who re - ceived two doses of the vaccine, taking into account epidemi - ological and clinical comorbidities, previous COVID-19 or previous METHODS COVIVAC-1 is a cohort study about mRNA BNT162b2 This investigation was health workers (HCW) of the HM Sanchinarro, a university teaching hospital in Madrid (Spain), who had received two doses of the vaccine. The first phase of the study, concerning safety, was carried out after reception of both doses of the vaccine. In this phase, which was focused on safety issues of the vaccine, the health care Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)C. capacity of different factors and covariables in the degree of self-reported (from 0 to 5) functional limitation after each dose of the vaccine. Neither ethnicity, mass index revealed cough (OR 0.16), and, as with the first dose, with greater incidence of asthenia (OR 2.48). The rest of adverse effects show significative association with previous COVID-19 (Table 4).Sex n (%) Men 85 (30.58) (IC (89.41) Asian 0 (0) Latin 9 (10.59) Black 0 (0) Other 0 (0)Caucasian 166 (86.01) Asian 2 (1.04) Latin 23 (11.92) Black 1 (0.52) Other 1 (0.52) p=0.749 Blood (0) 4 (2.07) 0 (0) 0 (0) 4 (2.07) 0 (0) 0 (0) 0 (0) 0 (0) 4 (2.07) 0 (0) 0 (0) 3 (1.55) 0 (0) 0 (0) 0 (0) 0 (0)14 (7.25) 0 (0) 0 (0) 2 (1.18) 0 (0) 0 (0) 0 (0) 2 (2.35) 2 (2.35) 0 (0) 0 (0) 2 (2.35) 0 (0) 0 (0) 1 (1.18) 0 (0) 0 (0) 0 (0) 0 (0)p=0.234 p=0.606 p=0.182 p=0.0325 p=0.0325 p=0.883 375 (88.24) 8 (9.41) 2 (2.35) 0 (0)167 and clinical factors the reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al. Rev Esp Quimioter 2023;36(4): 400-407403Comirnaty \u00ae, around 90% did experience at least one side ef - fect. Most of the self-reported side effects were to mod - erate. The main adverse effect observed after the first and sec - ond dose of Comirnaty \u00ae was local pain. In general, systemic side effects were significatively more intense after the second dose of the vaccine. The degree of self-reported functional limitation (from 0 to 5) after vaccination was also significantly higher after the second dose of the vaccine (p<0.05). This echoes the results of the clinical trial conducted Polack [5], and the cohort study by Chapin-Bardales [14], with over three and half million participants, using the V-safe Ac - tive Surveillance System, in USA. On the contrary, another evidence from our study was that in those with previous SARS-CoV-2 infection, systemic side effects Comirnaty\u00ae. These findings were in with those reported by Me -tors of functional limitation after the first or second dose of Comirnaty\u00ae. After the first dose of Comirnaty\u00ae, in the mul - tivariate model, we found a positive independent association between degree of functional limitation and age fe - male sex, previous previous Index Punctuation. By contrast, after the second dose of the vaccine, in the multivariate model, the degree of functional limitation was positively associated with the degree of functional lim - itation (0 to 5) after the first dose of vaccine (p<0.001), and it was significatively lower in people with previous COVID-19 (Table 5) DISCUSSION In our group of health care workers fully vaccinated with COVID-19 Laboral contact n (%) 167 (60.07) COVID-19 Cohabiting Contact n (%) 40 (14.39) Isolation due to COVID-19 contact n (%) 42 (15.11) N. isolations due to COVID-19 contact 1 isolation n (%) 2 isolations n (%) 3 isolations n (%)29 (70.73) 9 (21.95) 3 (7.32) Previous COVID-19 diagnose n (%) PCR n (%) Ag test n (%) Serology n (%)53 (19.06) 31 (11.15) 3 (1.08) 19 (6.83) Hospitalization due to COVID-19 1 (0.36) ICU admission due to COVID-19 1 (0.36) Symptoms in previous COVID-19 cases in vaccinated health factors reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)C. No deaths or other serious adverse events were reported in our study. A strength of our study is the attention paid to different epidemiological and clinical factors and their influence in the reactogenicity to Comirnaty \u00ae. In this way, in the multivari - ate linear regression analysis we found that effect Dose 27(9.71) 6 (34.17) Urgent need 0 (0) 0 4 (1.44) 16 (5.76) 0.003 mRNA BNT162b2 vaccine (n =278) ni [15] in the British Symptom Study and D'Arminio [16] HCW attributed to mRNA vaccines (Pfizer and Moderna) has the development of myocar - ditis and/or pericarditis, mainly in the first week after the sec - ond dose, as reported by Kim [17], Montgomery [18], Marshall [19] Boehmer No events pericarditis or myocarditis post-vaccination with Comirnaty \u00ae were reported in our epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC effects did not show significant (OR) with previous nor with 1st dose, with 2nd dose. Figure 1 Degree limitation (0 to 5) in HCWs after 1st dose of ComirnatyInfluence clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, dose of Comirnaty\u00ae independent predictors of a higher degree of functional limitation after the first dose of Comirnaty \u00ae. After the second dose, previous COVID-19 was associated with a lower func - tional limitation, and only the degree of functional limitation after the first dose revealed itself as an independent predic - tor of greater impairment. Other evidences from our analyses not published in functional limitation post-vaccination observed accord - ing to body mass index, ethnicity, or blood group. A limitation of our study was the limited number of participants, though this could be counterbalanced with the higher degree of precision in the answer to the questionnaire due to the fact that all of them were HCW. Although this lim - itation, we obtained results in congruence with much great - studies, [14,15]. CONCLUSION In conclusion, the same way as other studies, global - ly we found a higher incidence of systemic side effects with the second dose of Comirnaty \u00ae than with the first SARS-CoV-2 were No events of myocarditis neither pericarditis were reported HCW or major events were The degree of functional limitation after the first dose was independently associated with sex, of functional limitation after the dose showed to be an pendent predictor of higher degree second dose, while SARS-CoV-2 infection was associated with second dose. Further post-emergency use authorization stud - ies are still needed in order to define more precisely the safety profile of these new vaccines against COVID-19. FUNDING None to declare. CONFLICT declare no have conflict of interest REFERENCES 1. WHO, COVID-19 Dashboard, 4 th January 2022, https://cov - id19.who.int/ . Last access 5 th february 2022 2. Our World in Data. ''Coronavirus (COVID-19) from https://ourworldindata.org/covid-vaccinations . last factors to Comirnaty\u00ae vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, al. Rev Esp 400-4074074. full approval in people of sixteen or older for Comir January 2022 Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vac - cine. N Engl J Dec 31; vaccine had 95% effica - cy against COVID-19 7 days after the 2nd dose. Ann Intern Med. 2021 et al; Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-250. doi: 10.1056/NEJMoa2107456. C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386(1):35-46. doi: 10.1056/ NEJMoa2116298. 9. Haas and effectiveness of COVID-19 following wide study 2021 May 15;397(10287):1819- 1829. doi:: 10.1016/S0140-6736(21)00947-8. 10. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, New England Journal of Medicine 2021;384(15):1412-1423. doi: 11. EMA update on safety profile from th January 2022 12. Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a systematic review of published case reports and S et al. Evaluation of post-in - troduction COVID-19 vaccine effectiveness: Summary of inter - im guidance of the World Health Organization. Vaccine, S0264- 410X(21)00707-6. doi: 14. Chapin-Bardales C., Klaser, K., A., al (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COV - ID Symptom Study app in the UK: a with SARS mRNA Myocarditis following im - munization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021;6(10):1202-1206 19. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in sev - en adolescents 20. Boehmer TK, Kompaniyets L, Lavery AM, et al. Be tween COVID-19 and Myocarditis Using Hospital-Based Adminis Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista 408-415408Agust\u00edn Juli\u00e1n-Jim\u00e9nez1* Itziar Huarte Sanz3 Carmen Navarro Bustos4 Francisco Javier Candel5 Pedro \u00c1ngel de Santos6 Ra\u00fal Alonso Avil\u00e9s6 en nombre ABSTRACT Objectives. evaluate 18 years or older attended in 71 Spanish ED from October 1, 2019, to March 31, 2020. Each model's predictive power was analyz - ed with the area under the receiver operating characteristic curve (AUC), patients with a age of 18 years studied; 2648 (59.7%) were men and 459 (10.3%) died days. For 30-day mortality, the AUC- COR obtained with the qSOFA = 1 model plus 2 mmol/l lac - tate was 0.66 (95% CI, 0.63-0.69) with Se: 68%, Es: 70% while 1 pre - senting to the ED due to an episode of infection, the qSOFA =1 + qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgencias 1Servicio de Urgencias, Complejo Hospitalario Universitario de Toledo, Universidad de Castilla La Mancha, Toledo, Espa\u00f1a. 2Servicio de Urgencias, Hospital Universitario Cl\u00ednico San Carlos, IDISSC, Madrid, Espa\u00f1a. 3Servicio de Urgencias, Hospital Universitario de Donosti, Espa\u00f1a. 4Servicio de Urgencias, Hospital Universitario Virgen de la Macarena, Sevilla, Espa\u00f1a. 5Servicio de Microbiolog\u00eda Cl\u00ednica, Hospital Universitario Cl\u00ednico San Carlos, IDISSC, Madrid, Espa\u00f1a 6Servicio de Urgencias, Hospital Cl\u00ednico Universitario de Valladolid, Espa\u00f1a.Original breve Article history Published: 8 May 2023 RESUMEN Objetivo. Evaluar y comparar la capacidad del lactato y del quick Sepsis-related Organ Failure Assessment (qSOFA) para predecir mortalidad a 30 d\u00edas en los pacientes que acuden al servicio de urgencias (SU) por un episodio de sospecha de infecci\u00f3n. M\u00e9todo. Estudio observacional de cohortes, multic\u00e9ntrico, prospectivo. Se incluy\u00f3 por oportunidad a pacientes 18 a\u00f1os atendidos por sospecha de infecci\u00f3n en 71 SU espa\u00f1oles del 01/10/2019 al 31/03/2020. Se analiz\u00f3 la capacidad predictiva con el \u00e1rea bajo la curva (ABC) de la caracter\u00edstica operativa del receptor (COR) y los valores de sensibilidad (Se), especificidad (Es), valor predictivo positivo (VPP) y negativo (VPN). Resultados. Se incluyeron 4.439 pacientes con edad me - dia de 67 (DE:18) a\u00f1os, 2.648 (59,7%) fueron hombres y fa - llecieron a los 30 d\u00edas 459 (10,3%). Para la mortalidad a 30 d\u00edas el ABC-COR obtenida con el modelo qSOFA=1 m\u00e1s lacta - to 2 mmol/l fue de 95%: con y 9%: 0,49-0,55) con una Se:42%, Es:64% y VPN:90%. Conclusiones. Para predecir mortalidad a los 30 d\u00edas en los pacientes que acuden al SU por un episodio de infecci\u00f3n, el modelo qSOFA=1 + lactato 2 mmol/L mejora significativa - mente el poder predictivo conseguido de forma individual por qSOFA1 y llega a ser muy similiar al de qSOFA 2. Palabras clave: Sepsis, Lactato, Pron\u00f3stico, Mortalidad, qSOFA, Servicio de Urgencias, Correspondencia: Dr. Agust\u00edn Juli\u00e1n-Jim\u00e9nez Servicio de Urgencias-Coordinador de Docencia, Formaci\u00f3n, Investigaci\u00f3n y Calidad. Complejo Hospitalario Universitario de Toledo, Toledo, Espa\u00f1a. Avda. R\u00edo Guadiana s/n. C.P: 45.071. Toledo. Espa\u00f1a. E-mail: agustinj@sescam.jccm.es *Ambos autores han contribuido de igual forma a la preparaci\u00f3n de este manuscritoCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415409SEMES(Grupo de Infecciones de la Sociedad Espa\u00f1ola de Medicina de Urgencias y Emergencias)(ver adenda) a los que se realiz\u00f3 un seguimiento durante 30 d\u00edas. Del 01/10/2019 al 31/03/2020 se incluyeron con un muestreo por oportunidad a pacientes 18 a\u00f1os diagnosticados de un proceso infec - cioso y en los que, por sus caracter\u00edsticas epidemiol\u00f3gicas y presentaci\u00f3n cl\u00ednica, los m\u00e9dicos responsables indicaron la obtenci\u00f3n de muestras anal\u00edticas con determinaci\u00f3n de biomarcadores (lactato) y cultivos microbiol\u00f3gicos. Se ex - cluyeron las pacientes de obstetricia-ginecolog\u00eda (ver crite - rio inclusi\u00f3n y exclusi\u00f3n completos en publicaciones previas) [9,19]. Como variable dependiente se consider\u00f3 la mortalidad cru - da a los 30 d\u00edas. Como variables independientes aquellas que se consideraron cl\u00ednicamente relevantes, las que pudieran influir en el pron\u00f3stico y evoluci\u00f3n, sociodemogr\u00e1ficas, de comorbi - lidad y anal\u00edticas (se asumieron y adoptaron las definiciones, t\u00e9cnicas, m\u00e9todos establecidos para la recogida de muestras, valores de referencia y variables estudiadas del estudio primi - genio) [9,19]. Se aplicaron los criterios de selecci\u00f3n de pron\u00f3stico de pacientes en las definiciones del qSOFA y las variables que la constituyen seg\u00fan la tercera conferencia de consenso de sepsis (Sepsis-3) [7]. Para el an\u00e1lisis estad\u00edstico se utilizaron medias y sus des - viaciones est\u00e1ndar (DE) para variables cuantitativas y n\u00fameros absolutos y porcentajes para las cualitativas. Las comparacio - nes se realizaron con la pruebas de ji cuadrado o exacta de Fisher, la t de Student y la U de Mann-Whitney, seg\u00fan el tipo de variable. Se consider\u00f3 significativo un valor de p<0,05. Los contrastes fueron bilaterales. La eficacia para la predicci\u00f3n de mortalidad a los 30 d\u00edas se estudi\u00f3 mediante el an\u00e1lisis del \u00e1rea bajo la curva (ABC) de la caracter\u00edstica operativa del receptor (COR) con el intervalo de confianza al 95(IC 95%) y se compar\u00f3 frente al valor neutro (0,5). Se calcul\u00f3 el rendimiento pron\u00f3s - tico de estas y de los nuevos modelos elegidos con los c\u00e1lculos de sensibilidad (Se), la especificidad (Es), el valor predictivo po - sitivo (VPP) y el valor predictivo negativo (VPN), as\u00ed como sus IC 95% por m\u00e9todos binomiales exactos. Los errores est\u00e1ndar de las ABC se calcularon por m\u00e9todos no param\u00e9tricos. La comparativa entre ABC-COR de las variables y nuevos modelos combinados predictivos se realiz\u00f3 por la prueba de ji cuadra - do para comparar ABC-COR respecto a ABC-COR de referencia elegidas. Por su parte, las proporciones se compararon con el test de McNemar para muestras independientes (accesible en la calculadora: http://home.ubalt.edu/ntsbarsh/business-stat/ otherapplets/pairedprop.htm). El an\u00e1lisis estad\u00edstico se realiz\u00f3 con los programas IBM-SPSS Statistics 22 para Windows y STA - TA/MP 16.0. El estudio ha seguido la Declaraci\u00f3n de Helsinki y fue aprobado por el Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica (CEIC) del Complejo Hospitalario Universitario de Toledo (398/2109), as\u00ed como por los CEIC/CEIm de referencia de los centros par - ticipantes. INTRODUCCI\u00d3N La atenci\u00f3n a pacientes con sospecha de infecci\u00f3n en los servicios de urgencias (SU) se increment\u00f3 significativamente antes de la pandemia COVID-19 hasta un 15-20% de las aten - ciones diarias en 2019 [1]. Adem\u00e1s, en 2020-2021 por el im - pacto del SARS-CoV-2, estas cifras han podido elevarse hasta el 50-80% [2]. Asimismo, la gravedad cl\u00ednica (pacientes con sep - sis, comorbilidad, neutrop\u00e9nicos, ancianos, sospecha de bacte - riemia, etc.) y la mortalidad a corto plazo (30 d\u00edas) tambi\u00e9n han sufrido un incremento en la \u00faltima d\u00e9cada [2,3]. En este contexto, la sepsis representa uno de los mayores problemas de salud p\u00fablica en todo el mundo, por su incidencia y mortalidad a 30 d\u00edas (24,4% para la sepsis y 34,7% para el shock s\u00e9ptico) [2,3]. Hoy en d\u00eda, el SU representa un eslab\u00f3n clave ya que es donde se realiza la sospecha de sepsis, su reconocimiento, la toma de muestras microbiol\u00f3gicas y se debe comenzar un tra - tamiento precoz y adecuado, lo que determinar\u00e1 la evoluci\u00f3n cl\u00ednica del enfermo [2,4-6]. En 2016, los criterios de Sepsis-3 recomendaron el em - pleo del quick Sepsis-related Organ Failure Assessment (qSO - FA) en pacientes no ingresados en medicina intensiva [7]. Inmediatamente se suscit\u00f3 una gran controversia ya que q- SOFA mostraba una pobre sensibilidad para detectar pacien - tes con posible mala evoluci\u00f3n, lo que impuls\u00f3 que m\u00faltiples estudios compararan el rendimiento del qSOFA con otras es - calas y algunos biomarcadores [8-12]. Por este motivo, se ha recomendado la utilizaci\u00f3n conjunta de escalas y biomarca - dores para determinar el diagn\u00f3stico de infecci\u00f3n bacteria - na, sepsis y el pron\u00f3stico de mortalidad [9,10-13]. Se con - sidera al lactato como el mejor marcador de hipoperfusi\u00f3n e hipoxia tisular y valores 2 mmol/L constituyen un factor independiente de mortalidad, incluso sin hipotensi\u00f3n [11-13]. Sin embargo, durante el desarrollo de los estudios de cara a establecer los criterios de Sepsis-3, el lactato no cumpli\u00f3 con los umbrales estad\u00edsticos para su inclusi\u00f3n en la construcci\u00f3n del modelo de qSOFA, lo que podr\u00eda justificarse por la gran cantidad de valores ausentes en el registro [7,14]. Fruto de estas consideraciones, la \u00faltima actualizaci\u00f3n de la Campa\u00f1a Sobrevivir a la Sepsis no recomend\u00f3 como screening de sepsis el empleo de q-SOFA de manera aislada, comparado con otras escalas [5]. Algunos autores han propuesto a\u00f1adir el lactato a q-SOFA (qSOFA-lactato), ya que se consigue un mayor rendi - miento diagn\u00f3stico, sobre todo para los pacientes de te\u00f3rico bajo riesgo inicial (qSOFA1) [9,14,18]. El objetivo de este estudio fue evaluar la capacidad del lactato para mejorar el rendimiento predictivo de mortalidad a corto plazo en pacientes de riesgo bajo (qSOFA=1) del SU con sospecha de infecci\u00f3n. M\u00c9TODOS An\u00e1lisis secundario del registro MPB-INFURG-SEMES [9,19], que es un estudio observacional, multic\u00e9ntrico, pros - pectivo, descriptivo y anal\u00edtico de pacientes atendidos por sospecha de infecci\u00f3n en 71 SU de la Red del Grupo INFURG-Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415410DATOS Valores perdidos Supervivientes a n=3.980 (89,7%)Fallecidos a 30 d\u00edas n= 459 (10,3%)Valor p Edad (a\u00f1os), media (DE) 67 (18) 0 (0,0) 66 (19) 77 (14) <0,001 Edad >65 a\u00f1os n (%) 2.661 (59,9) 0 (0,0) 2.293 (57,6) 368 (80,2) <0,001 G\u00e9nero masculino n (%) 2.648 (59,7) 0 (0,0) 2.370 (59,5) 278 (60,6) 0,356 Institucionalizado n (%) 382 (8,6) 0 (0,0) 274 (6,9) 108 (23,5) <0,001 COMORBILIDADES Neoplasia s\u00f3lida, n (%) 523 (11,8) 0 (0,0) 459 (11,5) 64 (13,9) 0,077 Leucemia/Linfoma, n (%) 199 (4,5) 104 (2,3) 174 (4,4) 25 (5,4) 0,183 Enfermedad hep\u00e1tica, n (%) 119 (2,7) 0 (0,0) 111 (2,8) 8 (1,7) 0,119 Enfermedad cardiaca cr\u00f3nica, n (%) 502 (11,3) 0 (0,0) 384 (9,6) 118 (25,7) <0,001 HTA 2.001 (45,1) 0 (0,0) 1753 (44,0) 248 (54,0) <0,010 Enfermedad renal cr\u00f3nica, n (%) 431 (9,7) 0 (0,0) 358 (9,0) 73 (15,9) <0,001 Enfermedad cerebrovascular, n (%) 447 (10,1) 0 (0,0) 371 (9,3) 76 (16,6) <0,001 Demencia, n (%) 490 (11,0) 0 (0,0) 368 (9,2) 122 (26,6) <0,001 EPOC, n (%) 724 (16,3) 0 (0,0) 634 (15,9) 90 (19,6) 0,027 Diabetes Mellitus, n (%) 867 (19,5) 0 (0,0) 720 (18,1) 147 (32,0) <0,001 \u00cdndice de Charlson [media (DE)] 2,8 (2,6) 0 (0,0) 2,6 (2,5) 4,2 (2,8) <0,001 \u00cdndice de Charlson 3 2.039 (45,9) 0 (0,0) 317 (69,1) <0,001 \u00cdndice de Barthel [media (DE)] 83 (30) 148 (3,3) 86 (28) 58 (40) <0,001 \u00cdndice de Barthel 60, n (%) 813 (18,9) 148 (3,3) 601 (15,1) 212 (46,2) <0,001 DATOS CL\u00cdNICOS Y DE GRAVEDAD Temperatura en grados cent\u00edgrados [media (DE)] 37,4 (7,9) 14 (0,3) 37,4 (7,9) 37,3 (6,5) 0,704 Temperatura > 38,3\u00b0C, n (%) 1.505 (34,0) 14 0,120 FC en lpm [media (20,6) 67 FC > 90 (6,9) 1.355 (34,0) 285 (62,1) <0,001 Alteraci\u00f3n de la consciencia ECG 14, n (%) 832 (19,1) 91 (2,1) 589 (14,8) 243 (52,9) <0,001 PAS en mmHg [media <0,001 PAS 100 mmHg, n (%) 1.005 (22,8) 30 (0,7) 805 (20,2) 200 (43,6) <0,001 Criterios de sepsis-2 (SRIS 2), n (7,2) 2.579 (76,0) <0,001 0, n (%) (40,07) 386 (8,7) 1.594 (40,1) 29 (6,3) <0,001 qSOFA = 1, n (%) 1.606 (39,65) 386 (8,7) 1.410 (35,4) 196 (42,7) <0,001 qSOFA = 2, n (%) 646 (15,95) 386 (8,7) 504 (12,7) 142 (30,9) <0,001 qSOFA = 3, n (%) 178 (4,39) 386 (8,7) 86 (2,2) 92 (20,0) <0,001 Criterios de sepsis-3: qSOFA 2, n (%) 824 (20,34) 386 (8,7) 590 (14,8) 234 (51,0) <0,001 Criterios Shock s\u00e9ptico (Sepsis-3), n (%) 405 (10,0) 389 (8,8) 282 (7,1) 123 (26,8) <0,001Tabla 1 Caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas, de evoluci\u00f3n, anal\u00edticas y de destino la muestra global y estudio univariable en funci\u00f3n de la existencia o no de fallecimiento del paciente a 30 d\u00edasCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415411DATOS DE EVOLUCI\u00d3N Y DESTINOTotal n=4.439 Valores perdidos Supervivientes a 30 d\u00edas n=3.980 (89,7%)Fallecidos a 30 d\u00edas n= 459 (10,3%)Valor p Destino inicial de los pacientes, n (%) 0 (0,0) <0,001 Alta 748 (16,9) 0 (0,0) 730 (18,3) 18 (3,9) Observaci\u00f3n y unidad corta estancia 335 (7,6) 0 (0,0) 327 (8,2) 8 (1,7) Planta de hospitalizaci\u00f3n convencional 2.722 (61,3) 0 (0,0) 2404 (60,4) 318 (69,3) Unidad de Cuidados Intensivos 284 (6,4) 0 (0,0) 226 (5,7) 58 (12,6) Fallecimiento en urgencias 38 (0,9) 0 (0,0) 0 (0,0) 38 (8,3) Mortalidad a los 30 d\u00edas 459 (10,3) 0 (0,0) 0 (0,0) 459 (100,0) HALLAZGOS ANAL\u00cdTICOS Y MICROBIOL\u00d3GICOS Bacteriemia verdadera n (%) 899 (20,5) 0 (0,0) 753 (18,9) 146 (31,8) <0,001 Creatinina 2 mg/dl n (%) 588 (13,3) 26 (0,6) 444 (11,2) 144 (31,4) <0,001 Leucocitos <0,001 Cayados (bandas) > 10%, n(%) 238 (7,4) 1.225 (27,6) 199 (5,0) 39 (8,5) 0,001 n (32,5) 270 (58,8) <0,001 Procalcitonina de evoluci\u00f3n, anal\u00edticas y de destino la muestra global y estudio univariable en funci\u00f3n de la existencia o no de fallecimiento del paciente a 30 d\u00edas de arterial s\u00edndrome quick Sepsis-related; Criterios de sepsis (SRIS\u00b3 2) seg\u00fan conferencia de Consenso de 2001 (Sepsis-2) (Descritos en referencia 1); Criterios de sepsis (qSOFA \u00b3 2) seg\u00fan la tercera conferencia de consenso (Sepsis-3) (Descritos en referencia 7) RESULTADOS De los 4.923 pacientes seleccionados, finalmente se inclu - yeron 4.439 (se excluyeron 484 por perder su seguimiento o cambiar a otro diagn\u00f3stico en los 30 d\u00edas tras visitar urgencias), con una edad media de 67 (DE 18) a\u00f1os, rango 18-103 a\u00f1os. El 59,9% (2.661) ten\u00edan m\u00e1s de 65 a\u00f1os y 2.648 (59,6%) eran varones. En la primera evaluaci\u00f3n, seg\u00fan la puntuaci\u00f3n de la escala qSOFA, se clasificaron 1.623 pacientes (40,07%) como qSO - FA=0, 1.606 (39,65%) con qSOFA=1 y en (15,95%) qSOFA=2 y 178 (4,39%) qSOFA=3], consider\u00e1ndose 386 (8,7%) como valores perdidos al no estar registrado uno de sus tres criterios. En el seguimiento de los 4.439 pacientes durante 30 d\u00edas fallecieron 459 (10,3%), de estos 38 (0,9%) durante su estancia en urgencias y seg\u00fan puntuaci\u00f3n de la qSOFA: 29 (1,8%) con puntuaci\u00f3n qSOFA=0; 196 (12,2%) con qSOFA=1; 142 (21,98%) con qSOFA=2 y 234 (28,4%) con un qSOFA 2. En la tabla 1 se muestran las caracter\u00edsticas sociodemogr\u00e1ficas, epidemiol\u00f3gicas, comorbilidades, funciona - les, cl\u00ednicas, de gravedad, de evoluci\u00f3n y destino de los pacien - tes, as\u00ed como los resultados de las determinaciones anal\u00edticas y de microbiolog\u00eda de la muestra global del estudio con los datos del estudio comparativo de los casos de los pacientes que falle - cieron o no a los 30 d\u00edas. En la figura 1 se muestra la capacidad predictiva de mor - talidad a los 30 d\u00edas en pacientes atendidos en el servicio de urgencias por sospecha de infecci\u00f3n, as\u00ed como los par\u00e1metros de rendimiento pron\u00f3stico (Se, Es, VPP y VPN) de qSOFA=1, Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415412 Mortalidad a corto plazo (30 d\u00edas)ABC-COR (IC 95%) Valor pSe % (IC 95%)Es % (IC 95%)VPP % (IC 95%)VPN % (IC para predicci\u00f3n de mortalidad de los criterios definitorios de sepsis 2 (SRIS 2) y qSOFA=1 y su comparativa con los nuevos modelos combinados al a\u00f1adir el lactato ABC-COR: \u00e1rea bajo la curva de la caracter\u00edstica operativa del receptor; IC 95%: intervalo de confianza al Failure Assessment) seg\u00fan la tercera conferencia de consenso (Sepsis-3) (referencia 7). *Nota: la comparativa de proporciones se realiz\u00f3 con el test de McNemar. Los valores p reflejados en la columna \"comparativa de proporciones*\" se refiere a las diferencias encontradas entre los modelos combinados y los valores de qSOFA: (qSOFA 2 + lactato 2 mmol/L con qSOFA 2 y por otro lado qSOFA=1 + lactato 2 mmol/L con qSOFA =1)Figura 1 Rendimiento para la predicci\u00f3n de mortalidad de los criterios definitorios de sepsis 2 (SRIS 2) y qSOFA=1 y su comparativa con los nuevos modelos combinados al a\u00f1adir el lactatoCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415413qSOFA 2 y los nuevos modelos combinados con lactacidemia 2 mmol/L. DISCUSI\u00d3N Los resultados del presente estudio nos permiten confir - mar la mejora del rendimiento predictivo de riesgo de mor - talidad a 30 d\u00edas que ofrece el lactato en pacientes con qSO - FA=1, para los pacientes atendidos en los SU con sospecha de un proceso infeccioso. Este hecho ya hab\u00eda sido se\u00f1alado por otros autores, as\u00ed como para los mayores de 75 a\u00f1os [9,11- 15,17,18], aunque, en la mayor\u00eda de las ocasiones en pacientes con qSOFA 2, es decir, los clasificados como de alto riesgo de mala evoluci\u00f3n y en los que se activa el \"c\u00f3digo sepsis\" y se indica su ingreso [1,9,12-14] . Todo ello, en la nueva l\u00ednea re - comendada de no utilizar como screening de sepsis el q-SOFA de manera aislada, comparado con otras escalas, por su baja Se [5,16] . En nuestro estudio, qSOFA muestra una insuficiente Se (51% y 42% para qSOFA 2 y qSOFA=1, respectivamente) y mejor Es (85% y 64%), similar a los resultados en distintos me - tan\u00e1lisis (Se: 45-55% y Es 85-88%) [8,20] . Asimismo, el nuevo modelo (qSOFA 2 + lactato 2 mmol/L) consigue un mayor rendimiento predictivo de mortalidad a 30 d\u00edas (ABC de 0,74 y Es de 91%) que qSOFA 2 aislado (0,69 y 85%). Y, por su parte, (qSOFA =1 + lactato 2 mmol/L) consigue tambi\u00e9n un mejor resultado (ABC de 0,66 y Es de 70%) que qSOFA=1 aisla - do (0,52 y 64%), pero tambi\u00e9n mejora significativamente la Se (68% vs. 42%) y el VPN (92% vs. 90%), siendo el responsable de ello la incorporaci\u00f3n del lactato. En este sentido, Seymour et al [14], en el mismo art\u00edculo que valid\u00f3 el qSOFA, publicaron que la mortalidad hospitalaria de los pacientes q-SOFA=1 con niveles de lactato s\u00e9rico 2 mmol/L era similar a los pacientes con q-SOFA 2. El estudio de Churpek et al [15], propuso bajar el umbral de positividad a q-SOFA 1 (q-SOFA1), ya que estos pacientes ten\u00edan un comportamiento similar a los SIRS 2. Y De Santos Castro PA, et al [17] encuentran que la baja Se del qSOFA1 de 42% aumentaba al 78% con una Es de 70% al a\u00f1a - dir el lactato (qSOFA-lactato). Por lo tanto, el qSOFA-lactato puede representar una \u00fatil herramienta de ayuda a la hora de reclasificar aquellos pacientes con qSOFA=1, para as\u00ed optimizar las decisiones inmediatas que se deben tomar en los SU: indi - caci\u00f3n de extracci\u00f3n de hemocultivos, administrar una terapia antimicrobiana adecuada y precoz y el ingreso hospitalario o el alta domiciliaria, entre otras [1,4,5,16] . Nuestro estudio tiene distintas limitaciones. En primer lugar, el reclutamiento de casos fue por oportunidad (cuan - do los investigadores estaban de guardia), con el componente de sesgo de inclusi\u00f3n introducido. En segundo lugar hubo da - tos perdidos (lactato en el 16,8% y alguno de los criterios de qSOFA en el 8,7%). Adem\u00e1s, el 9,8% de los pacientes incluidos inicialmente fueron excluidos en los 30 d\u00edas de seguimiento. En tercer lugar, el momento y el tipo de tratamiento no se eva - luaron, y estos aspectos pueden condicionar el desenlace de la enfermedad. A pesar de estas limitaciones, creemos que el estudio es un reflejo de la realidad cl\u00ednica de nuestros SU. Como conclusi\u00f3n de este estudio podemos se\u00f1alar que para predecir mortalidad a los 30 d\u00edas en los pacientes que acu - den al SU por un episodio de infecci\u00f3n, el modelo qSOFA=1 + lactato2 mmol/L mejora significativamente el poder predictivo conseguido de forma individual por qSOFA1 y llega a ser muy similiar al de qSOFA 2. Aunque, futuros estudios multic\u00e9ntricos de validaci\u00f3n externa del modelo son necesarios. AGRADECIMIENTOS **Otros miembros del grupo INFURG-SEMES (Grupo de Infecciones de la Sociedad Espa\u00f1ola de Medicina de Urgencias y Emergencias) participantes en el estudio: Jo- sep Mar\u00eda Guardiola Tey (Hospital de Sant Pau de Barcelona), Marta \u00c1lvarez Alonso (Hospital Universitario de Fuenlabrada), Bego\u00f1a Mora Ordo\u00f1ez (Hospital Virgen de la Victoria de M\u00e1 - laga), Oscar \u00c1lvarez L\u00f3pez (Hospital Universitario de M\u00f3stoles), Ferr\u00e1n Llopis-Roca (Hospital Universitario de Bellvitge), Mar Ortega Romero (Hospital Cl\u00ednic de Barcelona), Esperanza Puga Montalvo (Hospital Campus de la Salud de Granada), Ram\u00f3n Perales Pardo (Complejo Hospitalario Universitario de Albace - te), Mikel Mart\u00ednez-Ortiz de Zarate (Hospital Universitario de Basurto), Mar\u00eda Jos\u00e9 Marchena Gonz\u00e1lez (Hospital Juan Ram\u00f3n Jim\u00e9nez de Huelva), Mar\u00eda del Mar Sousa Reviriego (Hospital Nuestra Se\u00f1ora del Prado de Talavera), Jos\u00e9 Mar\u00eda Ferreras Amez (Hospital Cl\u00ednico Universitario Lozano Blesa de Zarago - za), Henrique Villena Garc\u00eda del Real (Complejo Hospitalario Universitario de Santiago de Compostela), Bel\u00e9n Arribas En - trala (Hospital Universitario Miguel Servet de Zaragoza), Marta Honrado Fern\u00e1ndez de Valderrama (Hospital Santiago Ap\u00f3stol de Miranda de Ebro), Eva Quero Motto (Hospital Virgen de la Arrixaca de Murcia), Agust\u00edn Ar\u00e9valo Velasco (Complejo Asis - tencial Universitario de Salamanca), Manel R. Chanovas-Borr\u00e0s (Hospital Verge de la Cinta de Tortosa), Mar\u00eda B\u00f3veda Garc\u00eda (Hospital La Fe de Valencia), Pascual Pi\u00f1era Salmer\u00f3n (Hospi - tal Universitario Re\u00edna Sof\u00eda de Murcia), \u00c1ngel Estella Garc\u00eda (Hospital Universitario de Jerez), Octavio Jos\u00e9 Salmer\u00f3n B\u00e9liz (Hospital Universitario Fundaci\u00f3n de Alcorc\u00f3n), Guillermo Bu - rillo Putze (Hospital Universitario de Canarias), Ester Moncl\u00fas Cols (Hospital Sant Jaume de Calella de Barcelona), Marta Bala - guer Catal\u00e1n (Hospital Universitario Doctor Peset de Valencia), Manuel Gil Mosquera (Hospital Universitario 12 de octubre de Madrid), F\u00e9lix Gonz\u00e1lez Mart\u00ednez (Hospital Virgen de la Luz de Cuenca), Ainhoa Urraca Gamaury (Complejo Asistencial de Za - mora), Jes\u00fas \u00c1lvarez-Manzanares (Hospital Universitario R\u00edo Hortega de Valladolid), Luis Quero Reboul (Hospital Virgen de la Merced de Osuna), Agurtzane Auzmendi Aguirre (Hospital de Mendaro de Gipuzkoa), Federico Melgosa Latorre (Hospital de Alto Deba de Arrasate), Francisco Jos\u00e9 Ezponda Inchauspe (Hospital de Zum\u00e1rraga), Pilar Jim\u00e9nez (Hospital de Antequera), Josefina Monedero La Orden (Hospital de Almansa), Ariel Ruben Lindo Noriega (Hospital de Villarrobledo), Marta Iglesias Vela (Complejo Asistencial Universitario de Le\u00f3n), Inmaculada Ad\u00e1n Valero (Hospital de Valdepe\u00f1as), Julio Javier Gamazo-Del Rio (Hospital Universitario de Galdakao-Usansolo), Bel\u00e9n Rodr\u00edguez (Hospital Universitario Rey Juan Carlos), Francisco J Arambu -Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415414ru (Complejo Hospitalario Universitario de Ourense), B\u00e1rbara D\u00edaz Garc\u00eda (Hospital de Barbanza), Virginia \u00c1lvarez Rodr\u00edguez (Hospital Universitario de Getafe), \u00c1ngel Jos\u00e9 Mac\u00edas L\u00f3pez (Complejo Asistencial de \u00c1vila), Mar\u00eda Deb\u00e1n Fern\u00e1ndez (Hos - pital Central de Asturias), Fernando Rodr\u00edguez P\u00e9rez-Reverte (Hospital Universitario Santa Luc\u00eda de Cartagena en Murcia), Neus Robert (Hospital de Can Ruti), Silvia Flores Quesada (Hos - pital San Pau i Santa Tecla de Tarragona), Rosa Garc\u00eda Garc\u00eda (Hospital Virgen de las Nieves de Granada), Raquel Rodr\u00edguez Calveiro (Hospital \u00c1lvaro Cunqueiro de Vigo), Manuel Garc\u00eda Novio (Hospital Universitario Lucus Augusti de Lugo), Laura Gonz\u00e1lez Gonz\u00e1lez (Hospital del Salnes de Vilagarc\u00eda de Arou - sa), Elena Carrasco Fern\u00e1ndez (Hospital Virgen de Altagracia de Manzanares), Mar\u00eda Pilar Lozano Garc\u00eda (Hospital Universitario de Guadalajara), Rigoberto Del Rio Navarro (Hospital de Torre - vieja), Elizabeth Ortiz Garc\u00eda (Hospital Santa B\u00e1rbara de Soria), Leopoldo S\u00e1nchez Santos (Hospital Universitario de Burgos), Rosario Peinado (Hospital Infanta Cristina de Badajoz), Beatriz Valle Borrego (Hospital Severo Ochoa de Legan\u00e9s), Pablo Javier Marchena Yglesias (Parc Sanitari Sant Joan de D\u00e9u de Sant Boi de Llobregat), Cristina Herranz Mart\u00ednez (Hospital de Viladecans de Barcelona), N\u00faria Pomares (Fundaci\u00f3 Hospital de Mollet). FINANCIACI\u00d3N Los autores declaran que no han recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses BIBLIOGRAF\u00cdA 1. Juli\u00e1n-Jim\u00e9nez A, Supino M, L\u00f3pez Tapia JD, Ulloa Gonz\u00e1lez C, Vargas T\u00e9llez LE, Gonz\u00e1lez del Castillo J, et al. Puntos clave y con - troversias sobre la sepsis en los servicios de urgencias: propues - tas de mejora para Latinoam\u00e9rica. Emergencias 2019;31:123-135. PMID: 30963741 2. Juli\u00e1n-Jim\u00e9nez A, Garc\u00eda DE, Gonz\u00e1lez del Castillo J, Guimaraes HP, Garc\u00eda-Lamberechts EJ, Men\u00e9ndez E, et al, en nombre del Grupo de Trabajo Latinoamericano para la mejora de la atenci\u00f3n del pacien - te con Infecci\u00f3n en Urgencias (GT-LATINFURG). Puntos clave sobre la COVID-19 en los servicios de urgencias: propuestas de mejora para su atenci\u00f3n en Latinoam\u00e9rica. Emergencias. 2021;33:42-58. PMID: 33496399 3. Bauer M, Gerlach H, Vogelmann Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019 -results from a systematic re - view and 2020;24:239. doi: 10.1186/ s13054-020-02950-2. 4. Candel FJ, Borges Sa M, Belda S, Bou G, Del Pozo JL, Estrada O, et al. Current aspects in sepsis things around. Rev PMID: Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international for management Crit Care Med. 2021;49:e1063-e1143. doi: 10.1097/CCM.0000000000005337. 6. Ar\u00e9valo P, Morales I, Olivares E, Guler I, Rodr\u00edguez MA, L\u00f3pez PJ. Capacidad predictiva de las escalas de alerta temprana en los ser - vicios de urgencias hospitalarios: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis. Emergencias. 2021;33:374-81. CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis Del Castillo J, Garc\u00eda- Lamberechts EJ, Huarte Sanz I, Navarro Bustos C, et al. Capacidad del lactato, procalcitonina y de los criterios definitorios de sepsis para predecir mortalidad a 30 d\u00edas, bacteriemia o infecci\u00f3n con - firmada microbiol\u00f3gicamente en los pacientes atendidos por sos - pecha de infecci\u00f3n en urgencias. Emergencias. 2022;34:181-9. PMID: 35736522 10. Llopis-Roca F, L\u00f3pez Izquierdo R, Miro O, Garc\u00eda-Lamberechts JE, Juli\u00e1n Jim\u00e9nez A, Gonz\u00e1lez Del Castillo J. Mapa de la situaci\u00f3n actual de la atenci\u00f3n a la sepsis en los servicios de urgencias es - pa\u00f1oles. Rev Quimioter. 2022;35:192-203. doi: 10.37201/ req/150.2021. J, Salido-Mota M, Mora-Ord\u00f3\u00f1ez B, Arranz-Nieto MJ, et al. Poder pron\u00f3stico de mortalidad a corto plazo de los biomarcadores en los ancianos atendidos en Urgencias por infecci\u00f3n. Enferm Infecc Microbiol Clin. 2019;37:11-8. doi: 10.1016/j.eimc.2017.11.017. Fuentes Ferrer M, Juli\u00e1n-Jim\u00e9nez A, Pi\u00f1era P, Llopis F, et al. Comparaci\u00f3n de distintas estrategias para la predicci\u00f3n de muerte a corto plazo en el paciente anciano infecta - do. Rev Esp Quimioter. 2019;32:156-64. PMID: 30808154 13. Juli\u00e1n-Jim\u00e9nez A, Candel-Gonz\u00e1lez FJ, Gonz\u00e1lez del Castillo J. Uti - lidad de los biomarcadores de inflamaci\u00f3n e infecci\u00f3n en los ser - vicios de urgencias. Enferm Infecc Criteria The MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, et al. 2017;7:906-11. doi: 10.1164/ rccm.201604-0854OC 16. Juli\u00e1n-Jim\u00e9nez A, Garc\u00eda DE, Gonz\u00e1lez Del Castillo J, L\u00f3pez Tapia Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n en urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al. Rev Esp Quimioter 2023;36(4): 408-415415JD. De la gu\u00edas internacionales \"Campa\u00f1a para sobrevivir a la sepsis 2021\" a las gu\u00edas para \"Detectar, prevenir la progresi\u00f3n y atender a los pacientes con infecci\u00f3n grave en urgencias\" elaboradas por urgenci\u00f3logos. Emergencias. 2022;34:471-73. PMID: 36625699 17. De Santos Castro PA, Alonso Avil\u00e9s R, Arranz D\u00edez B, Mayo Garc\u00eda V, Gonz\u00e1lez Hurtado E, Mat\u00edas Rodr\u00edguez S. \u00bfPodemos rescatar el q-SOFA?. Rev Esp Urg Emeg. 2022;1:69-74 18. De Santos Castro PA, Alonso Avil\u00e9s R. Sobre la capacidad de lac - tato, procalcitonina y los criterios definitorios de sepsis para pre - decir mortalidad a 30 d\u00edas, bacteriemia o infecci\u00f3n confirmada microbiol\u00f3gicamente en los pacientes atendidos por sospecha de infecci\u00f3n en urgencias. Emergencias 2022;34:406 PMDI:36217940 19. Juli\u00e1n-Jim\u00e9nez A, Gonz\u00e1lez Del Castillo J, Garc\u00eda-Lamberechts EJ, Huarte Sanz I, Navarro Bustos C, Rubio D\u00edaz R, et al. A bacteraemia risk prediction model: development and validation in Infection. Rochwerg B, Seely al. Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista quinolones) justifies a genetic study of mutations to improve cure rates. Material and methods. A total of 8,508 2018 to July 2022 TM cases 23S rRNA V and detected were checked to assess their medical to demographic and treatment information. Results. Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative. Conclusions. High rate of resistance in our environment evidences the therapy genotypic study of macrolide resistance, supported by in parC and gyrA to predict quinolones susceptibility and the y fluoroquinolonas en Mycoplasma genitalium en el \u00e1rea sur de Tenerife Servicio de Microbiolog\u00eda y Parasitolog\u00eda Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Tenerife, SpainCristian Mateo Le\u00f3n Diego Garc\u00eda Mart\u00ednez de Artola Berta 8 May 2023 RESUMEN Introducci\u00f3n. Mycoplasma genitalium (MG) es un re - conocido pat\u00f3geno de transmisi\u00f3n sexual. El aumento de las resistencias asociadas a las principales l\u00edneas de tratamiento (macr\u00f3lidos y quinolonas) justifican un estudio gen\u00e9tico de mutaciones para mejorar las tasas de curaci\u00f3n. Material y m\u00e9todos. Un total de 8.508 muestras fueron analizadas entre abril de 2018 y julio de 2022 para la detec - ci\u00f3n de MG mediante la t\u00e9cnica de PCR multiplex Allplex TM STI Essential Assay.En los casos positivos para MG se estudi\u00f3 el dominio V del gen 23S rRNA y los genes gyrA y parC . Se evalu\u00f3 la importancia cl\u00ednica de las mutaciones y se revisaron las historias cl\u00ednicas para obtener informaci\u00f3n demogr\u00e1fica y de tratamiento. Resultados. Se realiz\u00f3 estudio de resistencias a 92 muestras (65 hombres y 27 mujeres). En lo relativo al estudio genot\u00edpico, 28 pacientes presentaban mutaciones a macr\u00f3lidos (30,43%). La m\u00e1s habitual fue A2059G (18.48%). Para las quinolonas, 5 pa - cientes (5,43%) presentaron mutaciones cl\u00ednicamente relevantes en el gen parC. Destaca un paciente con la mutaci\u00f3n G295 en gyrA asociada a G248T en parC. Treinta individuos se sometieron al test de cura (TOC). La azitromicina fue el r\u00e9gimen emp\u00edrico m\u00e1s com\u00fan y el moxifloxacino la principal alternativa. Conclusiones. La elevada tasa de resistencias en nuestro entorno evidencia la necesidad de realizar una terapia dirigida por el estudio genot\u00edpico de resistencias a macr\u00f3lidos, apoy\u00e1n - donos en la detecci\u00f3n de mutaciones en parC y gyrA para pre - decir la susceptibilidad a quinolonas y en el uso del TOC para evaluar la respuesta al tratamiento. Palabras clave: Mycoplasma genitalium , macr\u00f3lidos, fluoroquinolonas. Correspondence: Cristian Mateo Le\u00f3n. Servicio de Microbiolog\u00eda y Parasitolog\u00eda Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Tenerife, Spain. E-mail: cristianmateoleon@gmail.com.Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium en el \u00e1rea sur de TenerifeC. Mateo Le\u00f3n, et al. Rev Esp Quimioter 2023;36(4): 416-420417durante 7 d\u00edas. En este contexto, el tratamiento dirigido basado en la de - tecci\u00f3n por reacci\u00f3n en cadena de la polimerasa (PCR) de las principales mutaciones que confieren resistencias a macr\u00f3lidos, permite comenzar de forma precoz con el tratamiento de se - gunda l\u00ednea, mejorando el porcentaje de curaci\u00f3n inicial de un 60 a un 90 % aproximadamente [5]. Para evaluar la eficacia del tratamiento, la IUSTI recomien - da la realizaci\u00f3n de un test de cura (TOC) a partir de la tercera semana de la finalizaci\u00f3n del tratamiento [6]. El objetivo de este estudio se centra en conocer la epide - miolog\u00eda y las resistencias asociadas a MG en el \u00e1rea sur de Te - nerife, haciendo hincapi\u00e9 en el impacto que estas mutaciones tienen en el tratamiento. MATERIAL Y M\u00c9TODOS Un total de 8.508 muestras fueron analizadas en el per\u00edodo de abril de 2018 a julio de 2022 para la detecci\u00f3n de MG me - diante la t\u00e9cnica de PCR multiplex en tiempo real AllplexTM STI Essential Assay (Seegene). Se excluyeron las muestras positivas de pacientes a los que se le realiz\u00f3 estudio de resistencias dentro de los 3 meses an - teriores. Adem\u00e1s, una carga bacteriana baja (Ct>30) supuso un importante h\u00e1ndicap para la amplificaci\u00f3n y posterior detec - ci\u00f3n de resistencias.INTRODUCCI\u00d3N Mycoplasma genitalium (MG) es un microorganismo de transmisi\u00f3n sexual reconocido como un grave problema de sa - lud a nivel global debido a su alta tasa de resistencia a antimi - crobianos. Se asocia a cervicitis, enfermedad p\u00e9lvica inflamato - ria e infertilidad en mujeres, aunque destaca como causante de uretritis no gonoc\u00f3cica en varones, en porcentajes que oscilan entre el 10-30% [1]. Hist\u00f3ricamente, la presencia de requerimientos especiales en el cultivo y su lento crecimiento dificultan su identificaci\u00f3n y la realizaci\u00f3n del antibiograma. En la actualidad, las t\u00e9cnicas de amplificaci\u00f3n de \u00e1cidos nucleicos han supuesto una revolu - ci\u00f3n en el diagn\u00f3stico de este pat\u00f3geno [2]. En relaci\u00f3n al tratamiento, la ausencia de pared celular li - mita las opciones terap\u00e9uticas. Las \u00faltimas recomendaciones de The International Union against Sexually Transmitted Infec - tions (IUSTI) proponen como tratamiento de elecci\u00f3n azitromi - cina 500 mg/d\u00eda 1 d\u00eda, seguido de 250 mg/ d\u00eda durante 4 d\u00edas. No obstante, en los \u00faltimos a\u00f1os, diferentes metaan\u00e1lisis han notificado un importante incremento de las resistencias aso - ciadas a macr\u00f3lidos; del 10 % en estudios anteriores a 2010, a alrededor del 50 % en estudios publicados en 2016 y 2017 [3]. La principal alternativa terap\u00e9utica son las fluoroquinolo - nas, con un porcentaje de resistencias mucho menor (7-10%) [4], siendo la pauta m\u00e1s aceptada moxifloxacino 400 mg/d\u00eda Figura 1 Diagrama de flujo del procesamiento de las muestras.8508 muestras 225 positivos 133 pacientes excluidos 121 pacientes con Ct>30 2 pacientes positivos en los 3 meses anteriores 1O pacientes con problemas relacionados con la muestra y/o secuenciaci\u00f3n 55 pacientes sin mutaciones 28 pacientes mutaciones en 23 S 15 pacientes mutaciones en gyrA/parC15 pacientes TOC92 muestras con estudio de resistencias 65 hombres 27 mujeresElevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium en el \u00e1rea sur de TenerifeC. Mateo Le\u00f3n, et al. Rev Esp Quimioter 2023;36(4): 416-420418el estudio de resistencias a 92 muestras (40.88%), de las cu\u00e1les 65 (70.65%) correspond\u00edan a hombres y 27 (29,34%) a mujeres (Figura 1). En las mujeres la muestra de elecci\u00f3n fue el exudado en - docervical (92.6%), mientras que en los hombres fue el exuda - do uretral (83,07%) y el rectal (9,23%). Tambi\u00e9n se detectaron 4 casos en orina y 5 en otras localizaciones. En lo relativo al estudio genot\u00edpico, 28 pacientes pre - sentaban mutaciones que confieren resistencias a macr\u00f3lidos (30,43%). Las m\u00e1s habituales fueron A2059G (18.48%). Para las quinolonas, en el gen parC fueron detectadas mu - taciones en 15 pacientes. Sin embargo, s\u00f3lo 5 de ellos (5,43%), presentaban resistencias con demostrada relevancia cl\u00ednica. As\u00ed, encontramos 1 mutaci\u00f3n G248T(S83I) (1.09%),1 G248A (S83N) (1.09%) y 3 relaci\u00f3n a las mutaciones en gyrA, cabe destacar a un paciente que presentaba la muta - ci\u00f3n G295A (D99N) asociada a G248T(S83I) en parC. El resto de polimorfismos \u00fanicos de nucle\u00f3tido (SNP) no descritos en la bibliograf\u00eda o sin demostrado significado cl\u00ednico aparecen recogidos en la Tabla 1. Con respecto a la antibioterapia, se realiz\u00f3 TOC a 30 pa - cientes (32.6%), de los cuales 11 presentan resistencias \u00fanica - mente a macr\u00f3lidos y 4 a macr\u00f3lidos y quinolonas.El estudio de resistencias se bas\u00f3 en analizar el dominio V del gen 23S rRNA (283pb) [7] para determinar la resistencia frente a macr\u00f3lidos y la regi\u00f3n determinante de resistencia a quinolonas (QRDR) de los genes gyrA y parC, causantes de re - sistencia a fluoroquinolonas [8]. Los amplicones fueron secuenciados mediante tecnolog\u00eda Sanger BigDye Terminator v3.1 Cycle Sequence Kit (Applied Biosystems, Foster City, CA) en un secuenciador ABI 3500 (Applied Biosystems). Las mutaciones detectadas frente a la cepa de referencia Mycoplasma genitalium G37 (NC_000908.2) fueron registradas para estudiar si supon\u00edan un cambio aminoac\u00eddico relacionado con las resistencias descritas en las diferentes bases de datos. Las historias cl\u00ednicas de los pacientes fueron revisadas re - copilando datos demogr\u00e1ficos, tratamiento antibi\u00f3tico utiliza - do, realizaci\u00f3n de test de cura, nueva consulta en el centro o persistencia de los s\u00edntomas. RESULTADOS Durante el periodo estudiado, 225 muestras fueron posi - tivas para MG (2,64%), con una prevalencia mayor en hombres (3,59%) que en mujeres (1,68%). La mediana de edad fue 38,5 a\u00f1os (rango 14-68). Despu\u00e9s de aplicar los criterios de exclusi\u00f3n se les realiz\u00f3 Macr\u00f3lidos: dominio V 23S rRNA N\u00ba 23s) y quinolonas ( gyrA y parC). aDatos sobre poblaci\u00f3n total a la que se le han realizado resistencias. bCaracter\u00edsticas similares a C284T (S83I). cAsociado a mutaciones en parC. dAsociada a la mutaci\u00f3n G248T(S83I) en parC.Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium en el \u00e1rea sur de TenerifeC. Mateo Le\u00f3n, et al. Rev Esp Quimioter 2023;36(4): 416-420419[9,10]. En las muestras que presentaron mutaciones, en cuatro pacientes se observ\u00f3 tratamiento previo con 1,5 gramos de azi - tromicina; esta pauta se ha relacionado con un aumento de las resistencias a macr\u00f3lidos [3]. Para las fluoroquinolonas, la ausencia de la mutaci\u00f3n S83I en parC es altamente predictiva de curaci\u00f3n con moxifloxaci - no [11,12]. Otros SNP con relevancia cl\u00ednica son S83N, D87N y D87Y, aunque su papel est\u00e1 menos establecido y es nece - sario profundizar en su importancia en el futuro. El papel del gen parC ha sido escasamente descrito en estudios nacionales, como el de De Salazar et al [13]. Solamente 5 de nuestros pacientes presentaban mutacio - nes relevantes cl\u00ednicamente. La mutaci\u00f3n D87Y se encontr\u00f3 en 3 pacientes. En dos de ellos no se realiz\u00f3 test de cura, por lo que no podemos asegurar que se solventara el cuadro, y en el otro individuo el cuadro se resolvi\u00f3 con moxifloxacino. Un paciente presentaba la mutaci\u00f3n S83N, del cual no se pudo obtener da - tos en relaci\u00f3n a la antibioterapia ni a la resoluci\u00f3n del caso y el \u00faltimo presentaba la mutaci\u00f3n G248T(S83I) en parC asociada a G295A (D99N) en gyrA. Este paciente presentaba persistencia en los s\u00edntomas y finalmente fue tratado con minociclina. Aun -En la tabla 2 se describen los tratamientos emp\u00edricos y el tratamiento dirigido post test de cura de los pacientes con al - guna mutaci\u00f3n. Por otro lado, 13 pacientes a los que se les detect\u00f3 resis - tencias (13/28) no acudieron a consulta o no realizaron test de cura. Se obtuvo informaci\u00f3n acerca del tratamiento en 5 de ellos; dos pacientes resolvieron el cuadro cl\u00ednico con tra - tamiento emp\u00edrico con doxiciclina y al resto se les modific\u00f3 el tratamiento emp\u00edrico por persistencia de s\u00edntomas (en una ocasi\u00f3n se cambi\u00f3 a eritromicina y en los otros 2 se utiliz\u00f3 moxifloxacino). DISCUSI\u00d3N Los resultados de nuestro estudio evidencian una preva - lencia y una tasa de resistencias a los principales antibi\u00f3ticos implicados en el tratamiento de MG semejantes a lo descrito en la bibliograf\u00eda [3]. Con respecto a las mutaciones asociadas a la resistencia a macr\u00f3lidos, los resultados son similares a los publicados en otras regiones del pa\u00eds, siendo la mayoritaria la A2059G (17/28). Paciente Tratamiento previo Mutaci\u00f3n 23 s Mutaci\u00f3n parC/gyrA Test de cura Tratamiento dirigido Resoluci\u00f3n del cuadro 1* Azitromicina + Doxiciclina A2059G - 3* Peniciclina - + ND G259T + Moxifloxacino s\u00edTabla 2 Tratamiento emp\u00edrico, tratamiento de segunda l\u00ednea y evoluci\u00f3n de los pacientes con mutaciones detectadas que realizaron test de cura. -: Negativo; a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium en el \u00e1rea sur de TenerifeC. Mateo Le\u00f3n, et al. Rev Esp Quimioter 2023;36(4): 416-420420que en nuestro estudio es un caso aislado, algunas mutaciones en gyrA se relacionan con fracaso terap\u00e9utico, tal y como su - gieren las \u00faltimas revisiones al respecto [11,14]. En la poblaci\u00f3n estudiada la mayor\u00eda de los casos son hombres (65/92) y adem\u00e1s suponen pr\u00e1cticamente la totalidad de los positivos con mutaciones (27/28 para macr\u00f3lidos y 5/5 en las mutaciones cl\u00ednicamente relevantes para fluoroquino - lonas). Entre ellos destacan los episodios de uretritis, siendo el exudado uretral la muestra m\u00e1s frecuente (83% de los casos). Entre las limitaciones de este estudio se encuentran la dif\u00edcil amplificaci\u00f3n de los genes propuestos cuando la carga bacteria - na obtenida en la PCR era insuficiente (Ct >30) y la imposibilidad de obtener un antibiograma para correlacionar los resultados fe - not\u00edpicos con las mutaciones detectadas. Tambi\u00e9n creemos que ser\u00eda necesario acortar el tiempo de respuesta incorporando una PCR dirigida a SNP concretos, ya que las resistencias a macr\u00f3li - dos est\u00e1n bien descritas y podr\u00edamos obtener informaci\u00f3n r\u00e1pida. Adem\u00e1s, aunque el tratamiento de segunda l\u00ednea con fluo - roquinolonas en los pacientes con resistencia a macr\u00f3lidos supu - so la resoluci\u00f3n del cuadro en la mayor\u00eda de nuestros pacientes, la falta de informaci\u00f3n desde atenci\u00f3n primaria en relaci\u00f3n al tratamiento y la no realizaci\u00f3n del test de cura (30/92 secuencia - dos) impiden tener unos datos concluyentes sobre la efectividad de los tratamientos. A pesar de estas limitaciones, los resultados de este estudio son de un valor importante, debido a la gran cantidad de casos secuenciados, el acceso a la informaci\u00f3n de la mayor\u00eda de los tratamientos junto a la evoluci\u00f3n cl\u00ednica de los pacientes, y la adici\u00f3n del estudio del gen gyrA. En conclusi\u00f3n, la elevada tasa de resistencias en nuestro entorno evidencia la necesidad de realizar una terapia dirigida por el estudio genot\u00edpico de resistencias a macr\u00f3lidos, apoy\u00e1n - donos en la detecci\u00f3n de mutaciones en parC (especialmente S83I) y gyrA para predecir la susceptibilidad a quinolonas y en el uso del test de cura para evaluar la respuesta al tratamiento. FINANCIACI\u00d3N Los autores declaran no haber recibido financiaci\u00f3n para la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores no presentan ning\u00fan conflicto de intereses. BIBLIOGRAF\u00cdA 1. Jensen JS, Cusini M, Gomberg genitalium infections. J 9;30(10):1650-6. DOI: 10.1111/jdv.13849 . 2. Getman Resistant Mycoplasma genitalium in Urogenital Tract a US Clinical Cohort. Clin Infect Mycoplasma JS, Unemo M, Murray G, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium : a systematic re - view J, European guideline on the M, strains of Mycoplasma genitalium Santa A, Aramburu Arnuelos J, S\u00e1nchez A, Bell\u00e9s Be - ll\u00e9s A. Mycoplasma genitalium : Analysis of mutations associated DA, Danielewski J, Plummer et al. parC Variants in Mycoplasma genitalium : Trends over Time and Zou H, Zhang K, Y, Ke W. Can ParC status A, Barrientos-Dur\u00e1n Espadafor B, Fuentes-L\u00f3pez A, Chueca N, Garcia F. Macrolide and fluoroquinolone resistance Mycoplasma genitalium in Machalek Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola and confirmed lower 28-day all-cause mortality compared with usual care or received oxygen or invasive mechani - cal have cases [5] main clinical presentations of CNS (only) 9 %, cutaneous or lymphocutaneous (8 %) and sin - gle site extrapulmonary (egg, eyes, bone) 12 %. The onset of pulmonary nocardiosis may be acute, subacute, or chronic and is not distinguished by any specific signs or case of a patient initially and treated for review showed only other five reports of these asso - ciations. Data regarding these cases are shown [6-10]. An 86-year-old man infected with SARS-CoV-2 was ad - mitted to the hospital for productive cough and dyspnea on minimal exertion. He was already suffering multiple health conditions, including type 2 diabetes hyper - tension, treated with cyclophospha - mide because infection: case report and literature review 1Infectious Diseases Unit. Hospital Cl\u00ednico San Juan de Alicante. Spain. 2University Miguel Hern\u00e1ndez of Alicante. Spain. Infectious Diseases Unit. Hospital Cl\u00ednico San Juan de Alicante. Spain. 3Microbiology Department. Hospital Cl\u00ednico San Juan de Alicante. Spain.Jos\u00e9 Ortiz1 Francisco Jover2 Victoria Ortiz de la Tabla3 Elisabet Other associated viral, pro helminth, and bacterial infections. Regarding these last prospective cohort study in England, Scotland, and Wales an - alyzed data from COVID-19 inpatients showing that the N. asteroides and often been identified as the predominant immunocom - study alleviate University Miguel Hern\u00e1ndez of Alicante. Spain. Infectious Diseases Unit. Hospital Cl\u00ednico San Juan de Alicante. Spain. E-mail: fjoverdiaz@gmail.comPulmonary nocardiosis after covid-19 infection: case report and literature review F. Jover, et al. Rev Esp Quimioter 2023;36(4): 421-424422Figure 1 Multifocal and bilateral and distal bronchial thickening. Author (year) [reference] Sex region in hypertension, HF10 days DyspneaRight upper lobe 3.3 x 3.2 cm mass and a left upper lobe 1.9 x 1.5 pattern infection: case report and literature review F. Jover, et al. Rev Esp Quimioter 2023;36(4): 421-424423While corticosteroids shown to have varying effects on T lymphocytes, high doses can cause a rapid de - pletion of circulating T cells by redistribution of circulating cells to other body compartments. In addition, they cause inhibition of interleukin T-cells. They of T-lymphocytes, which fur ther depletes of result in promotes the opportunistic infec - tions. It has been previously demonstrated that the of various immune is suppressed early during COVID-19 [11]. There is now a growing body of evidence that supports that COVID infection can lead to significant been deterioration outcomes. We identified only five published case reports (6 overall including our case) of adult patients with a mean age of 59 years (16-86). Main factors Well-known risk factors were present in all six patients (type 2 diabetes as the main factor). Nocardia infection was diagnosed at a median of 13 days af - ter diagnosis of Covid 19 (5-32 of Nocardia COVID-19 coinfected pa - weeks of intravenous therapy, patients can be switched to system and use of steroids in COVID 19 can favor Nocardia as an opportunistic infection. We believe that these cases should serve as an example of potential threats this patient population. We would like also out early to opportunistic infections in tem - porarily stopped. The patient had been in his usual state of health until 5 days before this new admission (11 days after he was dis - charged), when fever developed. He noted shortness of breath at rest and dyspnea exertion. He was brought to the emer - gency department of our hospital for further evaluation. On examination, the temperature was 36.7\u00b0C, mm ratory to 95% with the administration of supplemental oxygen through a nasal cannula at a rate of four liters per minute. Inspiratory crackles could be heard at the lung bases. The heart sounds were regular, with tachycardia but no murmur. There was no tenderness on palpation of the abdomen and no pitting edema were present in the legs. Laboratory lobes. Both SARS antigen and rT-PCR in nasopharyngeal sweep were positive (Ct = or < 30 expressing high viral patient was started and intravenous imipenem for 4 weeks. We ruled out the use of cotrimoxazole or linezolid due to the foreseeable toxicity at the kidney and bone marrow level in this specific patient. The patient was discharged home on oral minocycline 100 mg every 12 hours for 6 months.Pulmonary nocardiosis after covid-19 infection: case report and literature review F. Jover, et al. Rev Esp Quimioter 2023;36(4): 421-424424FUNDING None conflict of interest. REFERENCES 1. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG et Co-infections, secondary and antimicrobial hospitalized first L, P et al. infection over 5 years (2011-2015) in an Italian tertiary hospital. New Microbiol. 2018 Apr;41(2):136-140 3. Margalit I, Goldberg E, Ben Ari Y, Ben-Zvi H, Shostak Y, Krause I et al. Clinical correlates of nocardiosis. Sci Rep. 2020 Aug 31;10(1):14272. doi: 10.1038/s41598-020-71214-4. 4. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Colaneri M, Lupi M, Sachs M, Ludovisi S, Di Matteo A, Pagnucco L et al. A challenging case of SARS-CoV-2- 7. Laplace Flamand T, Ion C, Gravier S, Zadeh MM, Debriel D et al. Pulmonary Nocardiosis as an Opportunistic Infection in COVID-19. Eur J Case Rep Intern Med. 2022 Aug 22;9(8):003477. doi: 10.12890/2022_003477. 8. Atemnkeng J, K. Diagnosing Dis - seminated Nocardiosis in a Patient FJ. COVID-19 infection and nocardiosis causing the death of an - fibrosis. Pediatr Pulmonol. 2022 Jul;57(7):1823- 1825. doi: 10.1002/ppul.25954. 11. Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. Immuno - suppression in the early stage of COVID-19 disease. Nat Commun. 11:5859. by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista - amphotericin B (0.50 mg/L), itraconazole (0.12 mg/L), voriconazole (0.03 mg/L), and posaconazole (0.03 mg/L) against the patho - genic strain were found to be low. However, MIC of flu - conazole (8 mg/L), micafungin (>8 mg/L), caspofungin (>8 mg/L) these results, drops for two months and oral voriconazole three weeks were administered with good clinical evolution. Reviewing the literature, we have only found a few cases of eye infection by E. dermatitidis others. Regarding susceptibility, there are no defined break - points for any species in the genus. Our strain had high MIC to fluconazole and echinocandins. These data are in line with other reported cases [1, 4]. It is necessary to study large number of cases in order to obtain represent - ative data of the antifungal susceptibility species. The case presented here confirm the ability of E. der - matitidis as an opportunistic pathogen especially in pa - tients disease or None Arnau de Vilanova Lleida. Institut de Recerca Biom\u00e8dica (IRB) Lleida. Universitat de Lleida (UdL). SpainSaray Mormeneo Bayo Alba Bell\u00e9s Bell\u00e9s Iv\u00e1n Prats S\u00e1nchez Eric L\u00f3pez Gonz\u00e1lez Jes\u00fas Aramburu Arnuelos Albert Bernet S\u00e1nchez Merc\u00e8 Garc\u00eda Gonz\u00e1lezLetter to black yeast. It is widely distributed in the natural environment and it has the capacity to grow in extreme conditions. Although human infections caused by E. dermatitidis are subcutaneous and infections. Factors biofilm and melanin, which forms part of the cell wall of black yeasts [1,2]. Here, we present a case of corneal infection by E. dermatitidis . A 68-year-old woman was admitted to the Emergency Department for pain and red eye of one week of evolution. She had undergone a protected penetrating our laboratory. The patient was initially with moxifloxacin eye drops and the treatment was changed to vancomycin and ceztazi - dime eye drops and oral doxycycline. The sample obtained was incubated in blood, choco - late and Saboureaud agar and thioglycolate broth. There was growth of dark colonies after 48 hours of incubation at 37\u00b0C in the three media and in the reseed of thiogly - colate (Figure 1A). The Saray Mormeneo Bayo. Unidad de by Sekiguchi R, Urabe N, TT, Yang JF. Exophiala dermatitidis meningoencephalitis in an immunocompetent host: A review. J Infect Chemother. 2021 Oct;27(10):1520-1524. doi:10.1016/j.jiac.2021.06.014. 10. Lang R, Minion H, Hotta F, al. of triamcinolone acetonide: a case report and a of literature related to Exophiala eye infections. BMC Infect Dis. T, Hotchi Y, Usami K, Shimozawa S, Tokun - aga S, et al. dermatitidis. J Cases. Revathi - dran V, et al. Exophiala dermatitidis Endophthalmitis: Case Report and Literature Review. Mycopathologia. 4. Clamp MF, Jumper JM, Ku CW, McDonald der matitidis keratitis Central stream Infection in a Child with Ewing's Sarcoma: Case Literature Review on Paediatric 2022;187(5-6):595-602. doi:10.1007/s11046-022-00658-1.Figure 1 E. dermatitidis in Sabouraud agar. A BISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Quimioterapia doi:10.37201/req/136.2022 Rev Esp Quimioter 2023;36(4): 427-4284272022); 20 positivas para SARS CoV-2, 20 positivas para gripe y 20 positivas para virus respiratorio sincitial. No hay ning\u00fan caso de infecci\u00f3n mixta por estos virus. Tambi\u00e9n hemos proce - sado las primeras 20 muestras negativas para los tres virus. En este periodo, la variante circulante m\u00e1s prevalente en nuestro medio es Omicron (Linaje BA.5) y todos los casos de gripe son causados por influenza A [3]. Ambas t\u00e9cnicas tienen formato individual y la prueba eva - luada es f\u00e1cil y r\u00e1pida de realizar (mezclar 10\u00b5l de Magnetic Beads y 200\u00b5l de muestra al cartucho de PCR que viene in - cluido en el kit y cargar en el aparato) por lo que el tiempo t\u00e9cnico de ambas t\u00e9cnicas es similar (menor de 5 minutos por muestra). Como desventaja frente a la t\u00e9cnica de referencia, no permite diferenciar entre influenza A y B, el tiempo de pro - cesamiento de la t\u00e9cnica es m\u00e1s largo (84 versus 36 minutos) y se trata de una t\u00e9cnica cualitativa. El an\u00e1lisis de concordancia muestra un elevado \u00edndice kappa (98% para SARS CoV-2 y 95% para gripe y virus respi - ratorio sincitial) ya que la \u00fanica discrepancia detectada es la existencia de 1 falso negativo para el primer virus y 2 falsos negativos para los otros dos virus estudiados. Considerando como patr\u00f3n de referencia los datos aportados por el Genex - pert /Cepheid) la sensibilidad de la prueba es: SARS CoV-2 95%, Gripe 90% y VRS 90% con una especificidad del 100% en todas ellas. Todas estas muestras discrepantes ten\u00edan baja carga viral (Ct superiores a 35) por el sistema de referencia y por tanto, con baja capacidad de transmisi\u00f3n del proceso; es - ta disminuci\u00f3n de la sensibilidad tambi\u00e9n se produce en otras t\u00e9cnicas como las basadas en RT-LAMP (reverse-transcription loop-mediated isothermal amplification) [4]. La disponibilidad de varios m\u00e9todos diagn\u00f3sticos que ofrezcan resultados en menos de 90 min basados en la de - tecci\u00f3n del genoma de los tres virus de forma simult\u00e1nea, aporta importantes ventajas para el manejo de estos pacien - tes en relaci\u00f3n con la detecci\u00f3n de ant\u00edgenos virales, t\u00e9cnicas que muestran una menor sensibilidad especialmente frente a Concordancia entre el GeneXpert y el Life Real Detection Kit en el diagn\u00f3stico de las infecciones respiratorias agudas 1Departamento Microbiolog\u00eda, Hospital General Universitario Doctor Balmis, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1a 2Departamento de Enfermedades Infecciosas, Hospital General Universitario Doctor Balmis, Instituto de Investiga - ci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1aCelia Garc\u00eda-Rivera1 Isabel Escribano1 Esperanza Merino2 Juan May 2023 Estimado Editor: Los nuevos protocolos de manejo cl\u00ednico de los pacien - tes con infecci\u00f3n respiratoria aguda necesitan el diagn\u00f3stico r\u00e1pido de las infecciones por SARS CoV-2, gripe y virus respi - ratorio sincitial por lo que los Laboratorios de Microbiolog\u00eda deben disponer de los medios adecuados para dar respuesta a esta demanda durante las 24 horas de los 7 d\u00edas de la se - mana. Desde el punto de vista cl\u00ednico, la detecci\u00f3n r\u00e1pida de las infecciones respiratorias agudas producidas por SARS CoV- 2 y gripe ayuda a seleccionar el tratamiento antiviral en los pacientes vulnerables o con indicaci\u00f3n del mismo y dado que dicho tratamiento es m\u00e1s efectivo en funci\u00f3n de la precocidad de la administraci\u00f3n, la rapidez del diagn\u00f3stico contribuir\u00e1 a un tratamiento m\u00e1s eficaz, en la elecci\u00f3n del antiviral correc - to y su administraci\u00f3n precoz. En cuanto al VRS, en poblaci\u00f3n muy seleccionada, contribuir\u00e1 a la indicaci\u00f3n del tratamiento, y en poblaci\u00f3n no susceptible de tratamiento, a evitar trata - mientos antibi\u00f3ticos en cuadros de infecci\u00f3n respiratoria de v\u00edas altas. Adem\u00e1s, de la importancia del diagn\u00f3stico r\u00e1pido en el manejo de los pacientes, es importante a la hora de aplicar medidas de prevenci\u00f3n y control de infecciones de forma r\u00e1pi - da, como la r\u00e1pida gesti\u00f3n de aislamientos y camas en funci\u00f3n del virus identificado [1,2]. En este marco, hemos evaluado la concordancia de uno de los sistemas de diagn\u00f3stico r\u00e1pido m\u00e1s utilizados en la pr\u00e1c - tica cl\u00ednica asistencial (Genexpert\u00ae Xpert Xpress CoV-2/Flu/ RSV plus, Cepheid) con un nuevo sistema que acaba de llegar al mercado (Life Real (2019-nCoV/Influenza/RSV Nucleic Acid (RNA) Detection Kit, HangZhou Lifereal Biotechnology). Hemos analizado en paralelo las primeras 80 muestras re - cibidas durante el periodo estudiado (octubre y noviembre de Correspondencia: Celia Garc\u00eda-Rivera Departamento Microbiolog\u00eda, Hospital General Universitario Doctor Balmis, Instituto de Inves - tigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1a E-mail: garcia_celriv@gva.esConcordancia entre el GeneXpert y el Life Real Detection Kit en el diagn\u00f3stico de las infecciones respiratorias agudasC. Garc\u00eda-Rivera, et al. Rev Esp Quimioter Erdo an A, Kl\u00e7 S, et al. Considerations for the selection of tests for SARS-CoV-2 mole - cular diagnostics. Mol Biol Rep. 2022 Oct;49(10):9725-9735. 10.1007/s11033-022-07455-5.algunas variantes virales (hasta el 50%) y que habitualmen - te ofrecen informaci\u00f3n exclusivamente sobre la presencia de SARS CoV-2, lo que limita su utilidad en la pr\u00e1ctica cl\u00ednica asis - tencial en los pr\u00f3ximos meses de convivencia de los tres virus en nuestro entorno [5-8]. Aunque hemos realizado una evaluaci\u00f3n preliminar, nues - tros datos muestran que la t\u00e9cnica evaluada puede ser una alternativa v\u00e1lida como complemento de las herramientas ya disponibles en el mercado teniendo en cuenta que es reco - mendable disponer de varios m\u00e9todos diagn\u00f3sticos de estos procesos que puedan paliar posibles roturas de stocks, proble - mas t\u00e9cnicos de los equipos, etc [9]. FINANCIACI\u00d3N Este estudio no ha recibido financiaci\u00f3n pero la casa co - mercial suministr\u00f3 los materiales necesarios para llevar a cabo el trabajo. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses BIBLIOGRAF\u00cdA 1. Christensen BB, Azar MM, Turbett SE. Laboratory Diagno - sis Infection. Infect Clin 2022 PK. Rapid Diagnostic Testing for Engl J Med. Taib N, Moustafa Abo D et al. COVID-19 and their impact on SARS-CoV-2 doi: 10.1080/07853890.2022.2031274. 4. Pu R, Liu S, Ren X, Shi D, Ba Y, Huo Y, et al. The screening value of RT-LAMP and RT-PCR in the Nyaaba N, Domen J, et Rapid, diagnosis SS, Mihaila AA, Pop LA. Influen - za A, Influenza B, and SARS-CoV-2 Similarities and Differences - A Focus on Diagnosis. Front Microbiol. 2022 Jun 20;13:908525. doi: 10.3389/fmicb.2022.908525. 7. Kim J, Sung H, Lee H, Kim JS, Shin S, Jeong S, et al. Clinical Perfor - of Point-of-Care Variants of Concern: A Living Viruses. 2022 Jul \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola more prevalent spontaneously without treatment. NSAIDs or paracetamol are first line of treatment for symptomatic control. Despite the overall prognosis is satisfactory, symptoms can up a known etiological agent of cervical types vaccination campaign is established for certain three marketed that differ in the number bivalent (HPV2), and 18; the tetravalent vaccine (HPV4), which protects against types 16, 18, 6, and 11; the 9-valent vaccine (HPV9), which protects against types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is already widely HPV vacci - nation only been reported in the literature once [14]. Recently, there have been reports of KFD - nation, mainly to to this growing increase, immunomodulatory mechanism of vaccination and the underdiagnosis of KFD, a literature and adverse events databases search has been conducted to assess re - lation between HPV vaccines and KFD. A search in the Spanish adverse database (FEDRA) and the European adverse events database (Eudravigilance) was carried out. To criteria necrotising lymphadenitis\" for any drug. To know the cases with any other lymphadenopathy a new search with Kikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human papillomavirus vaccines 1Pharmacovigilance Division, Department of Pharmacy, Directorate General of Health Policy and Planning, Regional Ministry of Health of the Principality of Asturias, Spain 2Department of Pharmacy, Hospital Universitario Central de Asturias, SpainAdri\u00e1n Rodr\u00edguez-Ferreras1 R\u00edo1 Casares-L\u00f3pez1 females are equally affected, and different cases have been re - ported all over the world [1,2]. KFD is usually presented as painful cervical nodes and is frequently associated with fever, headache, night sweats, nau - sea, and sore throat. of postulated: infections and Numer Directorate General of Health Policy and Planning, Regional Ministry of Health of the Principality of Asturias, Spain. E-mail: adrianrf7@gmail.comKikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human papillomavirus 2023;36(4): 429-431430of lymphadenopathy as well. Eight of them were and seven required hospitalization. KFD is a rare entity, which real incidence is unknown. Due to its self-limited course and its common symptoms, it is often mistaken other lymphadenopathies, and is un [6]. The current incidence of lymphadenopathy with HPV vac cines is not Sheets bi described \"rare\". Underreporting and the fact that the data may are a clear to a relationship. In the Spanish national database, 25 events categorized under the MedDRA term tetra and 9-valent vaccines. This means that some of these cases could have been KFD and might have not been properly diagnosed. According to table 1, 3 of 5 cases correspond to female of Asian origin, which fits the data available. The literature re - view shows that KFD frequently presents concomitantly with other lymphadenopathies [1], and ment of KFD [1]. In three of five cases, negative microbiological test were available. Taking into account the infectious KFD mechanisms, plausible causal relationship may be reinforced, although more research is re - quired. Symptoms -the criteria \" was conducted. According tothe Diction All adverse events registered as September 18 th 2022 were included. The study was conducted in accordance with the ethical standards established in the Declaration of Helsinki. Since FE - DRA and Eudravigilance are anonymized, no informed other tozinameran KFD asso - ciated to HPV vaccines was found. On the other hand, Eudra - vigilance included a total of 62 KFD cases, of which 5 were associated to HPV vaccines (table I) and 19 to other vaccines. Regarding HPV vaccines associated reports, 3 after [one case also suspected drug, Encevac\u00ae, Median age was 13 (range 12-26). Out of the 5 cases, four required hospitalization and in all five cases other lymphadenopathy was also notified. In case 2, screening for influenza A and B viruses was negative. In case 3, the both cases 2 and 3, Quantiferon test was al - so negative. In case 4, serologies for VEB, VIH, VHB, VHC Concerning \" lymphadenopathy and linphadenitis \", 7 cas - es for Cervarix\u00ae and 16 for Gardasil\u00ae were found in FEDRA. Whereas 108 and 547 cases were found for Cervarix\u00ae and Gar - dasil\u00ae, respectively, in Eudravigilance. In relation to other vaccines, 15 of KFD related to case of KFD related the flu vaccine was reported, and other one with bacilli Calmette-Guerin. Median age was 30 (range 10-52). Six of these cases had another type Case Sex Country Vaccine Other immune disorders* Outcome** Seriousness 1 F notificationKikuchi-Fujimoto rare type of and its plausible relationship with human papillomavirus vaccinesA. Altshuler M, Stonehouse A. Devel - opment of cervical papilloma virus vaccination. Pharmacotherapy. doi:10.1592/phco.28.9.1194 13. MP, lymphad Kikuchi-Fujimoto disease following vaccination human papilloma encephalitis. Eur J Pediatr. 2012;171(9):1409- 1411. doi:10.1007/s00431-012-1729-1 See KC. Kikuchi-Fujimoto Disease Post COVID-19 Vaccination: Case Report and Review of Literature. Vac - cines (Basel). 2021;9(11):1251. doi:10.3390/vaccines9111251search is needed to understand the origin of the disease. Re - porting of suspected adverse events is essential to assess the real incidence and to optimize patient management present - ing with of subacute or with have conflict of interest. REFERENCES 1. Perry AM, Choi SM. Kikuchi-Fujimoto A Review. Arch Pathol Lab Med. 2018;142(11):1341-1346. Ahmed Hakobyan Kannan A, Ojinnaka U et al. Kikuchi-Fujimoto Disease: of Cervical Lymphad - enopathy. doi:10.7759/cureus.17021 3. Surg Pathol. 1999;23(9):1040-1047. doi:10.1097/00000478-199909000-00006 4. Pepe F, Disma S, Teodoro C, Pepe P, Magro G. Kikuchi-Fujimoto disease: a clinicopathologic of Kikuchi M, Sasazuki T. DNA typing of HLA class II (HLA-DR, M. Take a second look: it's Kikuchi's disease! A report and review doi:10.4081/cp.2018.1095 9. Bosch J Rare Dis. 2006;1:18. Published 2006 May 23. doi:10.1186/1750-1172- 1-18 10. Rezai K, Kuchipudi S, Chundi V, Ariga Loew J, Sha BE. Costa APF, Cobucci RNO, Costa Lima PH, Giral -ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Quimioterapia doi:10.37201/req/141.2022 Rev 2023;36(4): 432-433432subcultivos en agar sangre y Schaedler, incub\u00e1ndose el prime - ro en atm\u00f3sfera enriquecida con CO 2 y el segundo en anae - robiosis. A las 72 horas se observaron unas colonias gris\u00e1ceas de peque\u00f1o tama\u00f1o (aproximadamente 0,5mm de di\u00e1metro) \u00fanicamente en las placas incubadas en anaerobiosis. La espec - trometr\u00eda de masas (MALDI-TOF MS [Bruker, Billerica, USA]) realizada a partir de las colonias identific\u00f3 el microorganismo como S. moorei (score 2,33). La concentraci\u00f3n m\u00ednima inhibitoria (CMI) obtenida diante tiras de gradiente (Liofilchem, Roseto degli Abruzzi, Ita - lia) de penicilina, amoxicilina-clavul\u00e1nico y metronidazol fue de 0,19, 0,094 y 0,094 mg/L respectivamente. El aislado era sensible a todos ellos seg\u00fan los puntos de corte de CLSI (M100 ED32:2022) y EUCAST Redondo Farias2 Mar\u00eda Jos\u00e9 Lopez de Goikoetxea1Carta Director Article Solobacterium moorei es un bacilo Gram-positivo anaerobio estricto que forma parte de la micro - biota oral y fecal y juega un papel en la halitosis [1]. Sin em - bargo, tambi\u00e9n puede ser un pat\u00f3geno oportunista, causando bacteriemia, infecciones de herida u otros cuadros [2]. Presen - tamos un caso de bacteriemia por S. moorei , con foco probable en una sinusitis. Una mujer de 19 a\u00f1os acudi\u00f3 al Servicio de Urgencias por dolor en zona maxilar izquierda de 24 horas de evoluci\u00f3n, acompa\u00f1ado de fiebre, edema y eritema palpebral en hemicara izquierda. A su llegada la paciente estaba febril (39,6\u00baC), ta - quic\u00e1rdica (144 lpm) e hipotensa (97/55 mmHg). Se realiz\u00f3 TC, donde se observaron hallazgos compatibles con sinusitis agu - da con ocupaci\u00f3n de la totalidad del seno maxilar y celdillas etmoidales izquierdas. Se extrajeron hemocultivos e ingres\u00f3 a cargo del Servicio de Otorrinolaringolog\u00eda con pauta de amoxi - cilina-clavul\u00e1nico (1g/8h iv), metronidazol (500mg/100ml/12h iv) y corticoide (20mg/8h iv). Un TC realizado el cuarto d\u00eda de ingreso (Figura 1) mos - traba una sinusitis izquierda con patr\u00f3n de obstrucci\u00f3n de unidad osteomeatal complicada con absceso subperi\u00f3stico que improntaba a la grasa extraconal orbitaria. Debido a la ma - la evoluci\u00f3n, se realiz\u00f3 abordaje quir\u00fargico mediante cirug\u00eda endosc\u00f3pica nasosinusal, logrando drenar el seno maxilar, las celdillas, etmoidales y el absceso subperi\u00f3stico adyacente. Se tomaron muestras del material purulento para cultivo. Los hemocultivos recogidos en el Servicio de Urgencias se remitieron al Servicio de Microbiolog\u00eda en frascos aerobios y anaerobios y fueron incubados en el equipo BD Bactec Fx (Becton Dickinson, Franklin Lakes, USA). Tras 64 horas de in - cubaci\u00f3n se detect\u00f3 crecimiento en un frasco anaerobio, cuya tinci\u00f3n de Gram mostr\u00f3 bacilos Gram-positivos. Se realizaron Correspondencia: Izaskun Alejo-Cancho Servicio de 46 A, 48960, Galdakao (Spain) E-mail: i.alejo.cancho@gmail.comFigura 1 TC en el que se aprecia ocupaci\u00f3n de los senos izquierdos. Bacteriemia por Solobacterium moorei en paciente con sinusitis S Ben, Domenjod C, En - ault C, et al. A new look at the genus solobacterium: A retrospecti - ve analysis of twenty-seven cases of infection involving S. moorei and a review of sequence - nisms R, Rowlinson MC, Fine - and characterization S, Pet Z, T, et al. Six cases of Solobacterium moorei isolated alone or in mixed cul - ture in Hungary and comparison with previously published cases. Anaerobe 2020 1;65. doi: 10.1016/j.anaerobe.2020.102241 6. Lee J, Lee S, Park DH, Kim MN, Jung J. First case report of Solobac - terium moorei bacteremia due MA, Gomez Gal - don M, Zaarour A, et al. First case of Campylobacter Veloo ACM, Jean-Pierre H, Justesen US, Morris T, Urban E, Wybo I, et al. of muestras de pus creci\u00f3 abundante microbiota mixta aerobia y anaerobia, entre la cual se hallaba S. moorei . El cuadro cl\u00ednico mejor\u00f3 tras el drenaje quir\u00fargico y la pa - ciente fue dada de alta tras 11 d\u00edas de ingreso, manteniendo el tratamiento con amoxicilina-clavul\u00e1nico 875/125mg/8h du - rante 7 d\u00edas m\u00e1s. S. moorei forma parte de la microbiota oral y fecal, pero la muestra cl\u00ednica en la que m\u00e1s frecuentemente ha sido aislado es la sangre [2,3]. Esto podr\u00eda deberse, entre otras causas, a un mayor esfuerzo por parte de los microbi\u00f3logos para alcan - zar la identificaci\u00f3n a nivel de especie en este tipo de muestra. Adem\u00e1s, es frecuente que S. moorei forme parte de infecciones polimicrobianas [2,4,5], lo cual dificulta establecer cual es real - mente su papel pat\u00f3geno en esas ocasiones. El caso que describimos se present\u00f3 como un cuadro s\u00e9p - tico derivado de una sinusitis, en el que se pudo identificar S. moorei como \u00fanico microorganismo presente en la sangre de la paciente, aisl\u00e1ndose tambi\u00e9n junto a abundante flora mixta en las muestras del pus drenadas de la sinusitis, lo que sugiere que pudiera ser el origen de la bacteriemia. Es el primer caso de bacteriemia por S. moorei publicado cuyo foco probable fue una sinusitis. Otros estudios mencionan como posible foco infeccio - nes bucales, colangitis o translocaci\u00f3n de flora intestinal [2,6]. Hasta el momento, los casos descritos de bacteriemia por S.moorei se hab\u00edan descrito en pacientes con patolog\u00eda de base, enfermedad hematol\u00f3gica u oncol\u00f3gica [2,3,5], siendo este el pri - mero publicado en una paciente joven sin enfermedades de base. S. moorei es un pat\u00f3geno oportunista poco frecuente, de crecimiento lento y de dif\u00edcil identificaci\u00f3n. La identificaci\u00f3n mediante secuenciaci\u00f3n del gen 16S rRNA es lenta, costosa y no est\u00e1 disponible en todos los laboratorios. En nuestro caso, la identificaci\u00f3n se realiz\u00f3 gracias a la espectrometr\u00eda de masas, una herramienta ampliamente empleada hoy en d\u00eda en los la - boratorios de Microbiolog\u00eda que permite identificar pat\u00f3genos de manera r\u00e1pida y fiable [2,5,7,8]. Las mejoras en las bases de datos han aumentado el n\u00famero de microorganismos que pueden ser identificados, como es el caso de los anaerobios [9]. El empleo de estas t\u00e9cnicas podr\u00eda explicar el mayor n\u00famero de infecciones por S. moorei observadas en los \u00faltimos a\u00f1os, cuyo papel como pat\u00f3geno a\u00fan est\u00e1 por determinar. FINANCIACI\u00d3N Los autores no han recibido financiaci\u00f3n para la realiza - ci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de inter\u00e9s. BIBLIOGRAF\u00cdA 1. Barrak I, St\u00e1jer A, Gajd\u00e1cs M, Urb\u00e1n E. - 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Rev 2023;36(4): 434-435434Case 2 A 77-year-old man brain injury with a subdural 2 months later cranioplasty with bone patient developed a subdur - al was of cerebritis. Surgical for 4 weeks. CT scan then showed resolution of the collection. These two cases show the usefulness of ceftaroline for complicated infection of ventriculoperitoneal shunt by MSSA with second - ary bacteriemia. While waiting for susceptibility test, daptomy - cin was inappropriate as first-line therapy because of its low penetration in CSF, as it was linezolid for its bacte - riostatic effect in bacteriemia. The case linezolid out of resistance. Available literature in this is scarce. A large ret - rospective study conducted by Britt et al. evaluated ceftaroline in 764 patients, 2% of which had meningitis. Mortality was low (6%), but microbiological etiology or causes of death were not provided [2]. al with Streptococcus -Use of ceftaroline in complex central nervous system infections Complejo Hospitalario Universitario A Coru\u00f1a, SpainAlicia Alonso \u00c1lvarez Efr\u00e9n S\u00e1nchez Vidal Luc\u00eda Ramos Merino Dolores Sousa Regueiro Joaqu\u00edn Serrano Areba Enrique M\u00edguez Rey Pedro Llinares Mod\u00e9jarLetter to is fifth-generation cephalosporin approved for skin and soft tissue infections and pneumonia, but its use in out-off-label indications is increasing, as we have previously reported in journal [1]. It is resistant may be restricted because of adverse effects or low efficacy. Few data are available about its use in central nervous system (CNS) infections. In the last 5 years, we have recorded 5 CNS infections treated with ceftaroline [1]. We here present two of them which were evaluable. Case 1 A 67-year-old woman was admitted due to fever and gait instability. She was carrying a ventriculoperitoneal shunt device aureus (MSSA) grew 23 later in 2 of 2 sets. MIC to vancomycin was 2 mg/L using microdilution and 1.5 mg/L by E-test. A sample of (CSF) was then confirmed device was removed. While waiting for definite antibiotic susceptibility testing blood cultures, ceftaro - line (600mg every 8 hours) was employed for the first 7 days and then switched to cloxacillin plus linezolid. After 2 weeks of antibiotic treatment, CSF culture was negative, ventricu - loperitoneal week afterwards. Correspondence: Alicia Alonso Alvarez Complexo Hospitalario Universitario A Coru\u00f1a, Spain E-mail: aliciaaloalv@gmail.comUse of ceftaroline in complex central nervous system infections A. Alonso \u00c1lvarez, et al. Rev Esp Quimioter 2023;36(4): 434-4354353. Mart\u00edn-Cerezuela M, Padr\u00f3s Jun;46(6):348-350. doi: 10.1016/j.medi - ne.2021.05.007. 4. ceftaroline the treatment of MRSA meningitis secondary to an V. of in the treatment of Streptococcus pneumoniae meningitis S, Sipahi OR. Ceftaroline versus in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in an Cottagnoud F, A. Efficacy of cef - fosamil against penicillin-susceptible -resistant Strep - tococcus tically ceftaroline despite of being more severe cases [3]. Most experience comes from case series, including some regarding ceftaroline use in described 5 patients with gram positive bacterial meningitis (4 due to S. pneumoniae, of which one was penicillin-resistant, and 1 MSSA). Four of them treated with 600mg of ceftaroline fosamil every 8 hours were successful whilst the other one with 600mg very 12 hours failed [7]. Both cases reported here were treated with 600mg every 8 hours. Little is known about CSF penetration of ceftaroline. Chauzy et al reported a mean of 9% in a series of 11 patients with external ventricular drain, showed by Helfer et alt [9]. In fact, animal models of meningitis show variable rates from 15 to 51%. Ceftaroline was no-inferior to vancomycin in an animal study of meningitis by SARM and was superior to ceftriaxone in meningitis by penicillin-susceptible S. pneumoniae and to option in CNS infections. Al - though there is little experience in meningitis by penicillin-re - sistant S. pneumoniae or MRSA, its penetration in CSF is like other third-generation cephalosporins and better to vancomy - cin, which together with its higher in vitro activity makes epidermidis - an problem with taxes of 17% in our center- ceftaroline could be the best choice, as it was in our second case. FUNDING None to declare CONFLICTS OF INTEREST Authors declare no conflict of interest REFERENCES 1. Alonso \u00c1lvarez A, Ramos Merino L, Castelo Corral LM, Pad\u00edn Trigo A, Sousa Regueiro D, M\u00edguez Rey E, S\u00e1nchez Vidal E. Ceftaroline fosamil: clinical experience after 23-month prescription in KR, Sorensen KM, Jones X, Bollinger M, Frei CR. Early Use of Ceftaroline Fosamil in the United States Veterans 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Rev Esp 2023;36(4): 436-438436persistencia de Cp indetectable en el d\u00eda +40 se suspendi\u00f3 la rifampicina y se asoci\u00f3 fosfomicina (4.000 mg c/8h). A partir de este momento, se realizaron controles peri\u00f3dicos de linezolid en los que la Cp continu\u00f3 indetectable pese a los incrementos de dosis y la interrupci\u00f3n de la rifampicina (Figura 1). En el d\u00eda +49 con una dosis de 1.800 mg c/24h en PC se detect\u00f3 por primera vez presencia del f\u00e1rmaco (1,77 mg/L). Posteriormente, el d\u00eda +57 se alcanz\u00f3 valores terap\u00e9uticos (3,56 mg/L) junto con la disminuci\u00f3n de un 90,9% de la prote\u00edna C reactiva (PCR) respecto del valor inicial al comenzar la TDM (Figura 2). Du - rante el seguimiento, no se observaron reacciones adversas al linezolid y tanto la creatinina s\u00e9rica como la bilirrubina, ambos factores predictivos de eliminaci\u00f3n para linezolid [3], se man - tuvieron constantes (Figura 2). Finalmente, en el d\u00eda +64 fue dada de alta. La Cp indetectable se puede atribuir a una interacci\u00f3n en - tre linezolid y rifampicina ya que no se identific\u00f3 otra posible interacci\u00f3n con el tratamiento instaurado. La disminuci\u00f3n de la Cp de linezolid por la rifampicina es conocida [4], pero los me - canismos subyacentes no est\u00e1n del todo definidos. El linezolid se metaboliza mediante reacciones de oxidaci\u00f3n del anillo de morfolina. Las enzimas implicadas eran desconocidas, por este motivo se denomin\u00f3 como \"metabolismo oxidativo no enzim\u00e1 - tico\". Sin embargo, un estudio reciente demuestra la partici - paci\u00f3n del sistema microsomal (CYP450) mediante las CYP4F2 y CYP1B1 [5]. El metabolismo se iniciar\u00eda con formaci\u00f3n de 2-hidroxilinezolid y finalizar\u00eda con desetilenli - nezolid, aunque se forman tambi\u00e9n otros metabolitos. De estos citocromos, el CYP2J2 es el que mayor importancia tiene en el metabolismo, tanto en la reacci\u00f3n inicial como en las sucesi - vas. Est\u00e1 presente en el h\u00edgado, pero predomina en el miocar - dio, donde representa la mayor parte de los CYP450 de este tejido [6]. Adem\u00e1s, el miocardio dispone de una v\u00eda de s\u00edntesis de \u00e1cidos epoxieicosatrienoicos (AEET) [6] con actividad antiin - flamatoria en la que el CYP2J2 es una enzima implicada en la s\u00edntesis de dichos mediadores. En presencia de estr\u00e9s oxidativo, el CYP2J2 est\u00e1 sobreexpresado en el tejido mioc\u00e1rdico por Ajuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en endocarditis infecciosa 1Farmacia Hospitalaria, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, Espa\u00f1a 2Medicina Interna, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, Espa\u00f1aAaron Pupl\u00e0 Bartoll1 Editor: Presentamos el caso de una mujer de 60 a\u00f1os con ante - cedentes de hipertensi\u00f3n arterial, espondilitis anquilosante, meningiomatosis m\u00faltiple y s\u00edndrome de seno cavernoso. Acu - di\u00f3 a urgencias por imposibilidad para movilizar los miembros inferiores y desorientaci\u00f3n. Ingres\u00f3 en UCI por shock s\u00e9ptico, d\u00f3nde se inici\u00f3 tratamiento emp\u00edrico con meropenem (2g c/8h) en perfusi\u00f3n extendida tras aureus sensible a meticilina (SASM) y se realiz\u00f3 que confirm\u00f3 endocarditis infecciosa sobre v\u00e1lvula nativa (EIVN) tric\u00faspidea, por lo que se modifi - c\u00f3 el tratamiento a daptomicina (750 mg c/24h) y cloxacilina (2000 mg c/4h) [1]. En el d\u00eda +7 de ingreso, es trasladada a medicina inter - na manteniendo episodio febril por lo que se asoci\u00f3 linezolid (600 mg c/12h) para ampliar la cobertura debido a la aparici\u00f3n de \u00e9mbolos s\u00e9pticos pulmonares, as\u00ed como por persistencia de SAMS en hemocultivos seriados. En el d\u00eda +10 estaba afebril y negativiz\u00f3 los hemocultivos. Transcurridos siete d\u00edas se retir\u00f3 la daptomicina y se mantuvo la asociaci\u00f3n de linezolid/cloxa - cilina. Pese a que la asociaci\u00f3n de rifampicina s\u00f3lo est\u00e1 reco - mendada en endocarditis infecciosa sobre v\u00e1lvula prot\u00e9sica [2], debido a la progresi\u00f3n de las lesiones card\u00edacas observadas mediante PET-TAC el d\u00eda +30 y a la presencia de clips quir\u00fargi - cos por una reciente meningioblastectom\u00eda, se decidi\u00f3 asociar rifampicina (600 mg c/24h). En el d\u00eda +36 se realiz\u00f3 monitorizaci\u00f3n farmacocin\u00e9tica (TDM) del linezolid debido a la potencial interacci\u00f3n con ri - fampicina, obteni\u00e9ndose una concentraci\u00f3n plasm\u00e1tica (Cp) indetectable, por lo que se decidi\u00f3 administrar el linezolid en perfusi\u00f3n cont\u00ednua (PC) con dosis de 1200 mg c/24h. Ante Correspondencia: Aaron Pupl\u00e0 Bartoll Farmacia Hospitalaria, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, Espa\u00f1a E-mail: pupla_aar@gva.esAjuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en Pupl\u00e0 Bartoll, et al. Rev Esp Quimioter 2023;36(4): 436-438437longarse hasta dos semanas tras la suspensi\u00f3n del tratamiento [7]. Este efecto explicar\u00eda la ausencia de linezolid pese a Cp de rifampicina indetectables en el d\u00eda +48 (Figura 1D). La interacci\u00f3n entre linezolid y rifampicina es relevante y requiere de TDM. Adem\u00e1s, debido a la importancia del CYP2J2 en el metabolismo y la poca evidencia disponible actualmente, parece l\u00f3gico pensar que en cualquier endocarditis tratada con linezolid deber\u00eda realizarse TDM independientemente del trata - miento concomitante con rifampicina, ya que su metabolismo podr\u00eda estar aumentado por la sobreactivaci\u00f3n de la v\u00eda de los AEET. lo que es razonable pensar que tambi\u00e9n podr\u00eda estarlo en el caso de endocarditis. Por otro lado, la rifampicina posee una gran capacidad inductora del metabolismo oxidativo, aunque parece que no afecta significativamente al CYP2J2 [6]. El 80% de la rifam - picina se elimina en forma desacetilada en la bilis por lo que la persistencia de la interacci\u00f3n pese a la suspensi\u00f3n de la ri - fampicina se puede explicar por una eliminaci\u00f3n disminuida de \u00e9sta (Figura 1C) ya que la paciente present\u00f3 un patr\u00f3n colest\u00e1 - sico objetivado por valores de GGT elevados (Figura 2). Hay que considerar que el efecto inductor del metabolismo puede pro -Figura 1 Concentraci\u00f3n plasm\u00e1tica de linezolid (mg/L) medida a lo largo del seguimiento. Las dosis de linezolid se muestran adjuntas sobre cada monitorizaci\u00f3n (l\u00ednea azul). El gradiente morado intenta representar de forma te\u00f3rica el efecto inductor de la rifampicina, donde se consideran cuatro escenarios: (A) efecto inductor total; (B) semivida de la rifampicina (3-4h); (C) posible tiempo de acumulaci\u00f3n por colestasis; (D) posible tiempo de inducci\u00f3n diferida una vez eliminada la rifampicina. La l\u00ednea roja en 2 mg/L representa el l\u00edmite inferior del intervalo terap\u00e9utico para linezolid. En amarillo se indican los d\u00edas tras el ingreso. Ajuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en endocarditis infecciosa Pupl\u00e0 Bartoll, et al. Rev Esp Quimioter 2023;36(4): 436-438438Figura 2 Representaci\u00f3n de la evoluci\u00f3n de diferentes valores bioqu\u00edmicos durante el seguimiento. Para facilitar la interpretaci\u00f3n, se ha anotado sobre cada determinaci\u00f3n el valor obtenido, ya que son de magnitudes diferentes. FINANCIACI\u00d3N Los autores declaran que no han recibido financiaci\u00f3n pa - ra la realizaci\u00f3n de este estudio. CONFLICTO DE INTERESES Los autores declaran no tener conflicto de intereses. BIBLIOGRAF \u00cdA 1. Garc\u00eda de la M\u00e0ria C, Garc\u00eda-Gonz\u00e1lez J, Villamonte M, Almela M, Ambrosioni J, Quintana E, et al. Eficacia de daptomicina y cloxa - cilina en el tratamiento de la endocarditis experimental por Sta- phylococcus aureus sensible MG, Casalta JP, del Zotti F, et al. Gu\u00eda ESC 2015 sobre el tratamiento de la endocarditis infecciosa. Rev Esp safety of linezo Opinion Tsuji Y, Seto Y, Ogami C, Yamamoto Y, To H. Effects of mg c\u00e1psulas duras. Centro de infor - maci\u00f3n online de medicamentos de la AEMPS - CIMA [internet]. Consultado el 15/05/2022ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista The second sequence registered in GenBank with acces - sion number OP601405. After switching to IV 1 g/8 h cefotax mg/6 patient 1C). Case 2 A Glanzmann's thrombasthenia and in the showed a C-reactive admitted with IV antibiotic treatment with 2 g/6 h of ampicillin. The patient had daily febrile fever for 5 days until reaching a fever of 39\u00baC, at which time lung ultrasound was performed (Figure 2B) and the laboratory for micro - biological studies and cultures. The treatment was changed to IV 2 g/8 h of cefotaxime, 1 g/8 h of vancomycin and 500 mg/8 h fluid 0 mg/dL. In microbiological cultures there was no growth after 5 days, being performed sequencing of the 16S rRNA gene with P. oris a homology percentage of 98.94%. The sequence was registered in GenBank with acces - sion number OP601436. After 5 more days of treatment the patient was discharged with good evolution (Figure 2C). The occurrence of oral commensals as - monary infections is invariably related to aspiration of or other secretions, which together with dental procedures constitute the most likely cause of these infections. Bilbao (Biscay). Spain. 2Biocruces Bizkaia Health Research Institute. Biscay. Spain. 3Radiodiagnosis service of Cruces University Hospital. Bilbao (Biscay). Spain.Domingo Fern\u00e1ndez Vecilla1,2 Mary Paz Ugalde Z\u00e1rraga1,2 Miren Josebe Unzaga Bara\u00f1ano1,2 Jos\u00e9 Luis D\u00edaz de Tuesta del Arco1,2Letter to the Editor Article history May 2023 genus Prevotella is a group of obligate anaerobic Gram-negative bacteria that includes more than 50 species, many of them associated with the human microbiota, where they are commensals of the upper respiratory tract and the genitourinary system. Prevotella oris was isolated for the first time in 1982 a patient with periodontitis being named [1]. In this manuscript, we describe two cases of pleuropulmonary infections, a with a history of sickle cell anemia presented with fever up to 39\u00baC associated with cough and pu - rulent expectoration of 19 days of evolution. At the beginning of the clinical picture, the patient was diagnosed as a respira - tory viriasis due to Influenza A virus by PCR. On examination, no alarm signs were observed and the blood analysis showed 20,680 leukocytes with 81% neutrophils and a C-reactive tein of 210 mg/L. A Pulmonary ultrasound showed condensa - tion in the right upper lobe (Figure 1A) and the patient was admitted for study and IV antibiotic treatment with the GeneXpert MTB/RIF panel (Cepheid, California, USA). After two days of hospitalization, a computed tomogra - phy Correspondence: Domingo Fern\u00e1ndez Vecilla, Clinical microbiology Service, Basurto University Hospital. Montevideo Avenue, 18, Gurtubay pavilion, 3rd floor. Postal code: 48013, Bilbao causing serious Esp Quimioter 2023;36(4): 439-441440discrepancies. This idea is stated in both the articles by Wy - bo I et al. and G\u00fcrsoy M et al., in which they collect statistics concerning the percentage of strains identified by species level of Prevotella spp. [9, 10]. In the first article, out of 102 isolates, the genus was identified in 73.5% and the species in 62.7%, while in the second one, out of 123 isolates, the genus was identified in 100% and the species in 88%. Although MALDI-TOF MS is of great help, by stated the articles of Wybo I et al and G\u00fcrsoy M et al. Furthermore, in our experience, we believe that confirmation is necessary in order to avoid misidentifications of some species of Prevotella. In fact, in case, our MALDI-TOF identified isolate as abscesses both adult and pediatric populations [2,5-8]. Both the article by Viswanath LS et al. and Cobo F et al. describe cases in which P. oris are an unequivocal cause of pleural pathology. These cases and the ones presented here show that P. oris should be taken of pleuropulmonary infections after bronchoaspiration or when there is a history previous birth procedures with con diagnosis, the MALDI-TOF mass spectrometer is a rapid tool of great help for the identification of numerous species, however, in the case of Prevotella there be Figure 2 Chest X-ray (A) a showed presence of empyema (asterisk), which was drained with a trocar (arrow). The control radiograph (C) shows the placement of the drainage catheter (arrow) complete X-ray in the lobe (arrow). Contrast-enhanced CT (B) shows the condensation (arrow) with the presence of an air level suggestive of cavitary pneumonia (asterisk). The control radiograph (C) shows complete resolution of the picture. Two cases of Prevotella oris causing serious pleuropulmonary infections 439-441441with a homology percentage greater than 99% refer - ence strain studied through complete genomic sequence). In terms of treatment, control of the focus by draining the collections associated with antibiotics to penicillin, but an increasing rate of resistance been lately doc - umented [11-13]. Prevotella spp. are generally susceptible beta-lactams inhibitor, met - ronidazole, tigecycline or re - sistant to clindamycin, tetracyclines or moxifloxacin as can be seen, for example, in the multicenter study by Ulger Toprak N et al [13]. On the other hand, metronidazole has been reported as resistant in a case of caused spp. or metronidazole be used. In our cases, it was not possible to study the susceptibility of the strains as they were identified only by sequencing of the 16S rRNA gene. This may be due to the fact that the patients had received in - travenous antibiotics in the days prior to sampling. FUNDING None to declare. CONFLICT OF INTEREST abscess and meningitis due to Prevotella treptococcus micros after Care Med 2004, 30, Jousimies-Somer Marina M, Borenstein L, Shah H, Fi - negold SM. A retrospective review of cases of anaerobic empye - ma and Jamir I, S B, S A, K A, Biswas R. E, P\u00e9rez-Carras - co V, Garc\u00eda-Salcedo JA, Navarro-Mar\u00ed JM. Two rare cases of pleu - A, K\u00f6n\u00f6nen E. Performance of MALDI-TOF MS of 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). Revista Espa\u00f1ola de Quimioterapia 2023;36(4): 442-443442VM, correspondiendo 10 a HSV-1 (62,5%) y HSV-2 (37,5%). Los tres casos de enterovirus correspond\u00edan a ni\u00f1os con diag - n\u00f3stico del s\u00edndrome mano-pie-boca, que tambi\u00e9n presenta lesiones plantares. El resto de virus y su \u00e1mbito de detecci\u00f3n se presentan en la Tabla 1. A pesar de las caracter\u00edsticas dermatol\u00f3gicas espec\u00edfica, aunque no siempre, existen otros virus causantes de manifes - taciones cut\u00e1neas y lesiones muy parecidas a alguna de las fa - ses evolutivas presentes en la VM [3,4]. La principal es el virus varicela-z\u00f3ster, que en su forma de varicela del adulto puede confundirse como sospecha de la VM. De este modo, hemos confirmado como de las alternativas virol\u00f3gicas a la VM, el vi - rus varicela-z\u00f3ster ha sido el responsable del 50% de los casos, seguidos del herpes simple tipo 1 (26,3%), herpes simple tipo 2 (15,7%) y los enterovirus (7,8%). Las infecciones por el VVZ en el adulto son mas severas que en la infancia y asociadas en ocasiones a complicaciones neurol\u00f3gicas. Un estudio realizado en la Rep\u00fablica Democr\u00e1ti - ca del Congo [5] mostr\u00f3 que en 730 pacientes diagnosticados cl\u00ednicamente de varicela-z\u00f3ster, el virus de la VM era el respon - sable del 3,3% de estas lesiones (confirmaci\u00f3n de laboratorio) y otro 7,3% se diagnosticaron de z\u00f3ster at\u00edpico (sin confirma - ci\u00f3n etiol\u00f3gica); por ello se recomienda la toma muestras y su estudio etiol\u00f3gico viral tanto en \u00c1frica como fuera de es - te continente. La epidemia de 2022 represent\u00f3 un nuevo reto diagn\u00f3stico, aunque sin la endemicidad africana, la sospecha de VM se estableci\u00f3 de una forma prioritaria, mientras que las otras etiolog\u00edas virales se realizaron de forma secundaria. En el estudio de Hughes et al.[3] realizado en la Rep\u00fa - blica Democr\u00e1tica del Congo en 2021, observan que de 991 muestras cut\u00e1neas analizadas en adultos 400 (40,4%) estaban causadas por el VM, 457 (46,1%) por el virus varicela-z\u00f3ster y 134 (13,5%) eran infecciones mixtas entre ambos virus. Se en - contraron diferencias en la gravedad y los s\u00edntomas en aque - llos con coinfecciones en comparaci\u00f3n con aquellos con VM o varicela-z\u00f3ster solos. Los casos de coinfecci\u00f3n presentaban Diagn\u00f3stico v\u00edrico alternativo en las sospechas de viruela del mono Unidad de Virolog\u00eda, Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases. Facultad de Medicina de la Uni - versitat Illes Balears. Palma de Mallorca.Jordi Reina Elisa Gonz\u00e1lez de HerreroCarta al Director Article 10 January 2023; February Editor: Las caracter\u00edsticas dermatol\u00f3gicas de las lesiones cut\u00e1neas asociadas a la infecci\u00f3n por la viruela del mono (VM) son bas - tante espec\u00edficas, aunque var\u00edan en su proceso evolutivo [1]. Su localizaci\u00f3n en las palmas y plantas es muy sugerente, pero en la epidemia de 2022 un porcentaje elevado de las lesiones se presentaban adem\u00e1s en las zonas genitales. Las lesiones cut\u00e1 - neas junto al comportamiento sexual de las personas afectadas y el contexto epidemiol\u00f3gico, se constituyeron como el princi - pal indicio de sospecha de VM [2]. Durante el per\u00edodo epid\u00e9mico situado entre el 1 de junio y el 30 de noviembre de 2022 se analizaron 367 muestras cu - t\u00e1neas con sospecha cl\u00ednica de VM. La detecci\u00f3n del virus de la VM se realiz\u00f3 mediante una RT-PCR comercial en tiempo real basada en la prote\u00edna de fusi\u00f3n 14-kDA del g\u00e9nero Orthopox - virus (LightMix Modular Orthopox virus; Roche). Las muestras negativas al VM se analizaron mediante una RT-PCR comercial (Meningitis V1/V2 Assay; Seegen) que detecta todos los her - pesvirus y enterovirus. De las 367 muestras analizadas muestras analizadas 293 (79,8%) correspond\u00edan al \u00e1mbito hospitalario y 74 (20,2%) a atenci\u00f3n primaria. De las 141 muestras consideradas como positivas a VM (78,7%), 133 (94,3%) lo fueron en el \u00e1mbito hospitalario y 8 (5,7%) de primaria. El virus de la VM se detect\u00f3 en 133 muestras/159 positivas (83,6%) hospitalarias y en 8/20 positivas (40%) de primaria. De los 38 (21,2%) diagn\u00f3sticos etiol\u00f3gicos alternativos, el virus varicela-z\u00f3ster represent\u00f3 el 50% (19 casos). El diagn\u00f3stico alternativo v\u00edrico m\u00e1s frecuente fue el de VZV, detect\u00e1ndose 12 casos (7,5%) en hospitales y 7 (35%) en primaria. Los virus no-VM representaron el 16,5% en hospitales frente al 60% en primaria. De las lesiones ge - nitales 16 (8,9%) fueron diagnosticadas como alternativa a la Correspondencia: Jordi Reina Unidad de Virolog\u00eda, Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases. Facultad de Medicina de la Universitat Illes Balears. Carretera Valldemossa 79. 07120 Palma de Mallorca. E-mail: jorge.reina@ssib.esDiagn\u00f3stico v\u00edrico alternativo en las sospechas de viruela del mono J. Reina , et al. Rev Esp Quimioter 2023;36(4): 442-4434432. Ponencia de alertas y planes de preparaci\u00f3n y respuesta. Protocolo para la detecci\u00f3n precoz y manejo de casos ante la alerta de vi - ruela de los monos (monkeypox) en Espa\u00f1a. Ministerio de Sanidad. 5 de agosto de 2022. Disponible en: https://www.sanidad.gob.es/ profesionales/saludPublica/ccayes/alertasActual/alertaMonkeypox/ Astindari R, Anggraeni S 4. Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B et al. A tale of two viruses: coinfections of monkeypox and var - icela-zoster virus in the Democratic Republic of Congo. Am J Trop Med Hyg 2021; 104:604-11. Acta 1988; 45:297- 307. PMID: 2907258. 6. Lewis A, Josiowicz A, Maris S, Riade H, Tous M, Palacios G et al. Introduction and differential diagnosis of monkeypox doi:10.3201/ eid2810.221075 .m\u00e1s s\u00edntomas asociados con la VM y ten\u00edan mayor n\u00famero de lesiones que los casos con varicela-z\u00f3ster solo. Es posible que la coinfecci\u00f3n entre estos dos virus pueda modular no s\u00f3lo la expresi\u00f3n dermatol\u00f3gica de las lesiones sino incluso la grave - dad o complicaciones de la misma [3,4]. En nuestro estudio las muestras positivas a la VM no fueron sometidas a la detecci\u00f3n de otros virus cut\u00e1neos, con lo que no tenemos datos de las posibles coinfecciones entre ambos virus. Es destacable el mayor porcentaje de detecci\u00f3n de casos de VM en las urgencias hospitalarias frente a atenci\u00f3n prima - ria. Probablemente la existencia de dermat\u00f3logos en el hos - pital haya facilitado esta sospecha. Adem\u00e1s es posible que en atenci\u00f3n primaria no tengan muchas oportunidades de obser - var casos de varicela del adulto, que ha sido la primera causa alternativa (35% frente al 7,5% hospitalaria). Los tres casos de enterovirus correspond\u00edan a ni\u00f1os con diagn\u00f3stico del s\u00edndrome mano-pie-boca, que tambi\u00e9n pre - senta lesiones plantares. En un estudio realizado en Argentina sobre 9 casos de sospecha de VM, s\u00f3lo 3 (33,3%) fueron VM y 4 (44,4%) correspond\u00edan a enterovirus [6]. La r\u00e1pida incorporaci\u00f3n de la detecci\u00f3n molecular espec\u00ed - fica frente a la VM ha permitido no s\u00f3lo establecer un diagn\u00f3s - tico r\u00e1pido y espec\u00edfico de la infecci\u00f3n, sino que ha permitido la adopci\u00f3n de medidas preventivas para contener la epidemia. FINANCIACI\u00d3N No se ha recibido ninguna financiaci\u00f3n para la realizaci\u00f3n de este trabajo. CONFLICTO DE INTERESES Los autores declaran no tener ning\u00fan conflicto de inte - reses. BIBLIOGRAF\u00cdA 1. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014; 58:260-7. doi:10.1093/cid/cit703 .N\u00famero de muestras Hospitales Atenci\u00f3n primaria Total (293) (74) (367) Viruela del mono 133 8 141 Varicela-Z\u00f3ster 12 7 19 HSV-1 7 3 10 HSV-2 5 1 6 Enterovirus 2 1 3 Total 159 20 179Tabla 1 Principales virus detectados en los casos de sospecha de viruela del mono. "}